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The proliferation of massively parallel nucleotide sequencing and increases in the 
throughput of mass spectrometry has produced an unprecedented volume of highly specific, 
highly accurate data elucidating the transcriptome and proteome. This data explosion has 
facilitated a tremendous number of novel discoveries in both disease and basic biology. It has 
also presented a number of challenges due to the characteristics of these cutting-edge 
technologies.  Across these studies, we focus on the context of human cancer where these 
technologies are increasingly being used to characterize and target molecular aberrations for 
treatment tailored to individuals’ cancer biology. 
First, we evaluate the emerging technology of single-molecule sequencing (SMS), which 
may provide a clearer picture of the biological activity in the cell by avoiding the sample 
amplification steps that may introduce biases in the data. We compare transcriptome data from 
both SMS and a method employing amplification, noting the effects that the differences in 
sample preparation may have on the resulting data in terms of dynamic range and coverage 
bias. In particular, we find that SMS has greater dynamic range, providing more resolution for 
low abundance transcripts while avoiding coverage peaks which may result from the 
amplification process.  
We then turn to the challenge of integrating NGS-derived transcriptome data with tandem 
mass spectrometry data quantifying the proteome. The relationship between the transcriptome 
and the proteome is broadly defined by the central dogma of molecular biology. However, 
previous attempts at integrating data from the transcriptome and the proteome have seen 
large variation in the correlation between transcript and protein. To address this, we developed 
xix 
 
a framework for integrating data from these two realms using a novel common reference 
employing corresponding transcript and protein sequences. We apply this framework to 
integrate data derived from the RWPE and VCaP prostate cell lines and show how a number of 
methodological factors and sources of error can impact the correlation between transcript and 
protein.  
Finally, we analyze the results of our data integration pipeline with a focus on the 
transcript-protein relationship. We classify the genes in our dataset into broad categories, and 
show how their biological roles as well as experimental characteristics impact the relationship 
we observe between transcript and protein. To compare the cell lines in terms of their genes’ 
transcript-protein relationship with the goal of uncovering the uncoupling of this relationship in 
prostate cancer, we apply a novel concordance and discordance index to the genes in the 
dataset. Using these indices, we show how variations in protein abundance drive many of the 
differences between the cell lines and how stability has substantial impacts on the transcript-
protein relationship.  
The results and methods derived from this work can be used by researchers in the future to 
better understand the characteristics of emerging NGS technologies and integrate this data 




Chapter 1: Introduction 
 
The advent of massively parallel “next-generation” sequencing (NGS) technologies has 
made for an unprecedented explosion in both the volume and depth of data derived from 
biological experiments. While opening new avenues of research and enabling the most precise 
view of the cell’s molecular machinery to date, the massive volume and characteristics of NGS 
has created many new questions in the analysis, interpretation, and integration of the 
experimental results. This research focuses on its impact in characterizing the transcriptome, 
the most frequently assessed metric of molecular activity in cells, and extending those results 
by coupling them with results from tandem mass spectrometry to gain a multi-scale picture of 
cellular activity in a cancer context. First, we characterize one of the emerging single-molecule 
sequencing technologies. Without using an amplification step in sample preparation, we assess 
the advantages and disadvantages of these methods in assessing the abundance distribution 
and aberrations in the transcriptome. This is contextualized by our study of the biological 
characteristics and topological structure of biological networks, subsets of which are often seen 
dysregulated in human disease. Then, we turn our attention to the proteome, and the 
particular technical challenge of integrating the rapidly increasing yield of tandem mass 
spectrometry experiments with the tremendous output of massively parallel mRNA sequencing, 
or RNA-Seq. Finally, we focus on the results from our computational framework to analyze the 
transcript-protein relationship and how it is dysregulated in our VCaP prostate cancer model. 
We pay particular attention to the effect these derangements have on important pathways and 






NGS and RNA-seq for interrogating the transcriptome 
Next generation sequencing is typically used to describe the massively parallel methods for 
sequencing nucleic acids that do not employ the Sanger sequencing chemistry that the first 
generation of sequencing machinery relied upon. The 454 pyrosequencing methodology was 
the first of the NGS technologies, making its debut in 2005 [1]. Unlike the Sanger chemistry-
based sequencing method which produces reads up to 800bp in length, most of the NGS 
approaches produce short reads of  ranging from 50-150bp.  
The chemistry underlying each of the methods is highly varied; most methods use a 
sequencing-by-synthesis approach, such as those from Illumina  [2], Ion Torrent [3], and Pacific 
Biosciences  [4, 5], although more exotic approaches, such as the ABI SOLiD sequencing-by-
ligation approach exist. Most methods generally involve the construction of a library involving 
the attachment of adapter molecules to the ends of sheared DNA or RNA and an amplification 
step [6]. A subset of these sequencing methods are considered “single-molecule” approaches, 
which do not involve amplification steps that may affect sensitivity and bias sequencing results, 
ultimately producing a clearer picture of the experimental sample.  
In this work, I focus on the use of NGS methods to sequence mRNA, an application 
commonly called RNA-seq. This is an application where DNA microarrays had previously been 
the standard for global transcriptome characterization, followed by more exotic methods such 
as the Serial Analysis of Gene Expression (SAGE) [7] and Massively Parallel Signature Sequencing 
(MPSS) [8], which were much more rarely used. RNA-seq offered a number of clear advantages 
over microarrays; not requiring a priori knowledge of the transcripts under study (observing 
only the transcripts for which there is a probe), the production of sequence information about 
the transcripts under study (due to the direct sequencing of the transcripts in the sample), a 
much lower background signal, and much higher potential dynamic range [9-11]. Compared to 
SAGE and MPSS, it has the advantage of higher sensitivity as a result of higher throughput. 
The characteristics and possible advantages of the single-molecule approach (in comparison 
to competitive approaches utilizing an amplification step) had not been well characterized in a 
transcriptome context, and are the first topic of study. The characteristics of single-molecule 
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based methods are discussed in Chapter 2 using data from the Helicos Heliscope. While the 
technology had been proven in sequencing the human genome [12], its application to sequence 
the transcriptome had not yet been explored in depth. 
To date, NGS technology has yielded an unprecedented amount of data – never has so 
much data been produced. The simultaneous factors of constantly plummeting costs, improving 
quality, and increases in experimental yield guarantee that these technologies will become 
widespread in the future, thus making the characterization of experimental results and 
development of methods to leverage their data invaluable.  
Disease and the dysregulation of biological networks 
High-throughput techniques for determining molecular interactions have opened the door 
to genome scale evaluation of the molecular interactome of many species due to the quickly 
growing pool of data. A number of databases have been developed in order to integrate protein 
interaction data from high throughput experiments such as DIP, BIND, HPRD, and several 
others. Studies looking at this data across a number of organisms have indicated that these 
networks are organized into functional biomodules that function at multiple scales [13-15]. 
Analysis of disease gene knowledge coupled with data from large-scale protein interaction 
networks to form a phenome-interactome network have revealed that a significant portion of 
disease-associated genes form small sub-networks. The networks formed by the interactions of 
known disease genes have been used to relate phenotypically similar inherited diseases 
together [16]. Similarly, subnetworks that represent protein complexes have been used to 
relate diseases with similar phenotypes and provide novel disease gene candidates when 
melded to association data [17]. The disease-associated genes themselves also seem to possess 
a number of characteristics within the interactome. Compared to the mean degree values of all 
proteins, many disease related proteins display relatively elevated degree and tend to interact 
with other disease-related proteins [18, 19]. This property has been used to propose likely 
candidate genes for disease association [20]. Taken together, it suggests that the intermediate 
nodes in the interactome play a contributory factor. In addition to the importance of highly 
interconnected “hub” proteins [21, 22], certain topological features were found to be 
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associated with essentiality/lethality [23]. Additional research has suggested that genes 
expressing proteins of similar importance also share topological characteristics in the 
interaction network [24]. These topological characteristics have been used to explain variable 
disease outcome [25], making an argument for their role in the progression of disease.  
To study this phenome-interactome network in human disease, we integrated data from 
several protein interaction networks with gene-disease relationships to create a set of sub-
networks that form functional biomodules for over 4,300 diseases in single-gene disease (SGD) 
and complex disease (CD) categories, as well as over 6,600 functional sub-networks derived 
from Gene Ontology (GO) classes. The diseases in the SGD category were primarily caused by 
aberrations in one of several individual genes in the derived sub-network, in contrast to those 
in the CD category where several genes in the derived sub-network often influenced the 
resultant disease phenotype.   
The subnetworks associated to human diseases and biological processes were built by the 
determination of all shortest pairs paths between all distinct associated genes found in the 
protein interaction network for each disease or biological process. Shortest paths in the 
interaction subnetwork are determined using Dijkstra’s shortest paths algorithm [26]. For 
example, Figure 1 illustrates a hypothetical disease of interest associated to UMLS concept 
‘UMLS:000000’, associated with genes A, B, C, D, and E. The shortest path between pairs {A,B}, 
{A,C}, {A,D}, {A,E}, {B,C}, {B,D}, {B,E}, {C, D}, {C, E}, and {D, E} would be analyzed, noting the 
identities of the original nodes, the original node also found in the protein interaction network 
(as many nodes are not represented within the network), the intermediate connecting nodes, 
and the respective counts of each class. This process discovers intermediate nodes X, Y, and Z in 




Figure 1: Derivation of an example subnetwork composed of five annotated genes and three intermediate genes 
We analyzed the structure and characteristics of these functional and disease networks using 
network analysis tools and unsupervised machine learning techniques described in detail in . 
Subnetwork Characteristics 
As expected, the OMIM-derived SGD set demonstrated a smaller range in size in terms of 
total gene count from 3 to 32 genes with a median of five genes, while the complex disease set 
was composed of networks of much more varied size, ranging from 3 to 127 genes, with a 
median of eight genes. The Gene Ontology derived background set had the largest range from 3 
to 968 genes. As shown in Figure S 2a-c, most subnetworks tended to remain small, generally 
involving between three and nine genes. The GO background set exhibits a long-tailed 
distribution with most networks remaining under seventeen genes in size. 
Classification accuracy 
Unsupervised Principal Components Analysis and k-means clustering methods were first 
attempted in order to assess the separability of the three classes of subnetworks. As shown in 
Table 1 and Figure S 1a and b, clustering mirrored the results of the PCA with high 
misclassification levels (misclassifying ~55% of the data), further demonstrating the poor 




Assigned to Cluster 





GO 59 4 16 
SGD 1220 435 932 
CD 158 31 89 
Table 1: Unsupervised k-means clustering illustrates the poor separability of the data, with 1631 (55.4%)  
instances incorrectly clustered 
As a result, machine learning techniques must be applied to derive the subtle 
differences between the CD, SGD, and GO sets. As shown in Table S 2a-i, the overall 
misclassification error rate remains relatively low across several subsets of the subnetwork 
parameter data, never exceeding 5%. Other measures – precision, recall, f-measure- exhibit 
very satisfactory performance. However, a close inspection of the results for the three class 
problems (SGD, GO, CD) reveals that the results for the SGD class are not satisfactory. 
Confusion matrices from these analyses show the classifier tends to assign those subnetworks 
to the GO class, an issue likely due to the single-point driver nature of single-gene disease. 
Further analysis of the data by breaking down the features into biological and topological 
characteristics further revealed the similarities between the SGD and GO set, further detailed in 
APPENDIX A. The separability of the SGD and CD sets as shown in Table S 2j demonstrates the 
differences in subnetwork characteristics between those primary involved with single-gene 
disorders and those associated with multigenic, complex disorders. A reclassification of all the 
study data was also done using a GO dataset that included only the “Biological Process” entries, 
with similar results. The complete results of the classifications as well as additional methods 




Figure 2: Variables ranked by importance in classification based on Gini coefficient. The most informative 
variables in classification were a mix of both biological and topological parameters. 
The most important variables in the classification of subnetworks to their individual classes is 
illustrated in Figure 2 as derived using the reduction in Gini index, a measure of the reduction in 
misclassification when a particular variable is used. 
Lessons from the analysis of disease- and function- associated subnetworks 
The relative paucity of data describing disease-associated subnetworks continues to 
present a serious challenge in the analysis of the functional biomodules underlying human 
disease. While the classification of complex disease-associated subnetworks appears to achieve 
reasonable results, the underlying heterogeneity of human disease, as evidenced by the SGD 
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Correctly Classified Instances 2795 94.94 % 
Incorrectly Classified Instances 149 5.06% 
TP Rate FP Rate Precision Recall f-Measure class 
0.101 0.003 0.5 0.101 0.168 SGD 
0.997 0.387 0.949 0.997 0.972 GO 
0.752 0.001 0.986 0.752 0.853 CD 
Table 2: Classification of CD, SGD, and GO classes using all variables. While the complex disease (CD) subnetworks 
and derived from the Gene Ontology (GO) demonstrated relatively good classification performance, the 
subnetworks associated with single gene dieases (SGD) were very poorly separable. 
It is notable that the variables with the highest influence are a mix of both topological 
and biological factors, confirming previous findings that characteristics from both categories 
play an important role in the susceptibility to biological disruption and resulting disease. The 
relative importance of clustering coefficients confirms recent results examining the differences 
between disease-associated genes and essential genes [27]. The inclusion of mean gene start 
locus and GC content confirm the relative importance of genomic localization and 
transcriptional propensity [28]. While the examination of individual factors increases 
confidence in the findings through recapitualation of established study results, the random 
forest is able to capture the interaction between these variables. These inter-variable 
interactions are a prime target for continued study. 
It is not completely surprising that the SGD subnetworks appear to bear a strong 
resemblance to the GO background considering the pathogenesis of diseases that arise from 
anomalies in a single gene. In many cases, the GO-derived subnetworks can be considered 
functional biomodules of the interactome. The disruption of certain genes in these functional 
biomodules is likely to manifest in the form of disease phenotypes if they are not serious 
enough to result in lethality. This can result in failures of protein complex assembly and 
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complementation such as in Xeroderma Pigmentosum, a single gene disease that can arise from 
any one of the seven known genes in the XPA-XPG complementation group associated with 
nucleotide excision repair [29]. As such, these two classes are relatively poorly separable even 
in a supervised machine learning context. 
As we expected, the differences between the networks formed by sets of genes 
associated with biological processes and those associated with human disease are subtle and 
not easily derived as they are, by definition, intimately linked. The similarity between the single 
gene disease-associated subnetworks and those derived from the Gene Ontology demonstrates 
the multiscale behavior of a single disruption in a functional biomodule, and its ability to cause 
debilitating effects. The need for additional data and high specificity data is made abundantly 
clear in this study, as demonstrated by the propensity for misclassification of complex disease-
associated subnetworks as well as the limited number of subnetworks derived from the data 
due to lack of representation in the interaction network. The limited availability of interaction 
propensity or data quality measures associated with individual interactions in the particular 
version of the interaction database we employed led us to treat all interactions as equally 
probable and equally correct. This may be a source of error in the process that may be 
ameliorated in the future with additional data and quantitative measures associated with the 
interactions. As more gene-disease association data becomes available, the effectiveness of this 
method should be re-evaluated. 
The transcriptome, proteome, and the challenges of data integration 
The transcriptome is a common metric for assessing the biological activity in cells, used with 
the implicit assumption that the activity of the proteome follows. The relationship between 
mRNA transcripts and proteins is described by the central dogma of molecular biology; the 
information in DNA is transcribed into mRNA, which is subsequently translated into protein 
products [30]. However, this transfer of information from DNA to protein is mediated by a large 
number of intermediary factors such as ribosome stalling during translation [31], nonsense-
mediated decay of transcripts [32], transcript degradation by small [33] and other noncoding 
RNAs, protein decay, and a large number of post-translational modifications [34]. 
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Understanding the role each of these distinct regulatory mechanisms plays in affecting the 
resulting abundance of protein is a central motivator for studying the transcript-protein 
abundance relationship.  
The task of correlating the transcriptome to the proteome has historically been subject to a 
number of challenges. In the past, the most restrictive of these has been the limited ability to 
sample both the proteome and the transcriptome. For example, early studies investigating this 
relationship often employed gel-based methods, which limited them to small subsets of genes 
due to these experimental limitations  [35, 36]. As a consequence, many of their results were 
inconclusive and were difficult to generalize to the broader set of genes.  
While not matching the beyond-exponential growth rate of nucleotide sequencing, the 
throughput of proteome profiling techniques has grown significantly. A number of methods 
have been applied for the quantitative profiling of proteins using both radio-labeled and label-
free methods, reviewed in [37-39]. While monitoring post-transcriptional modifications remain 
a challenge, these advances have enabled the profiling of nearly the entire proteome, 
estimated at 10-12,000 proteins [40]. 
These capacity increases from the development of mass spectrometry (MS) methods and 
the advent of DNA microarrays enabled large increases in the number of genes that could be 
studied simultaneously. These technologies were the first to enable the comparison of complex 
transcriptomes to equally complex proteomes. However, experimental results remained highly 
variable. For example, a study of transcript and protein levels across 98 genes in 78 lung 
adenocarcinomas using microarrays and a MALDI-MS method found highly varying correlation 
levels between r = -0.4 and 0.4 for each gene in their set, and a global correlation of r = -0.025 
[41]. A slightly larger study by Cox, et al using microarray and LC-MS measured a correlation of r 
= 0.63 in approximately 900 genes in developing mouse lung tissue [42]. A more recent study by 
Gry, et al. utilizing microarrays looking at 1066 genes across 23 cell lines found a correlation of r 
= 0.52 [43]. A similar study across the NCI-60 set of cell lines by Shankavaram, et al. observed 
correlations ranging from r = 0.48 to r = 0.58 in a set of 162 feature set of assayed proteins, 
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across four related microarray platforms [44]. An analysis looking at protein and transcript 
levels by Ghazalpour, et al. in 97 strains of mice found a correlation of only r = 0.27 [45]. 
The application of RNA-seq to this task, with its much greater dynamic range and specificity, 
refined the biological picture. A study combining  previously published SILAC-labeled protein 
abundance with separate RNA sequencing data in three cancer cell lines, A431, U251MG, and 
U2OS found transcript-protein relationships correlated at levels from r = 0.55-0.61 [46].  A 
similar study focusing on deeply profiling both the transcriptome and proteome in the HeLa cell 
line found a correlation of r = 0.6 [40].  
These studies used a diverse set of techniques for data integration – though all attempt to 
address two fundamental challenges in this process, noted in [47-49]; First, how to match 
transcripts to proteins to ensure that the same entities were being compared. Different gene 
annotation, definition, and naming schemes must be harmonized in order to ensure a fair 
comparison, a process complicated by the multiplicity of transcript isoforms and incomplete 
transcript and protein databases. The second major challenge is that of comparing the 
transcript and protein abundance values. Derived from two different technologies, the 
transcript and protein abundance values have very different ranges of sensitivity, distributions, 
and error profiles. The very computation of these abundance values is an important factor, but 
is beyond the scope of this research and is reviewed in [50-52] and [53, 54] for RNA-seq and 
label-free proteomics, respectively. RNA-seq is often quantified using the TopHat and Cufflinks 
suite of tools [55] using related sources of annotation. Quantification of protein abundance 
from MS experiments is more varied and largely dictated by the choice of experimental 
procedure and processing pipelines.  
The issue of integrating transcriptome data from RNA-seq and protein data from tandem 
mass spectrometry methods is an active area of research, and the focus of Chapter 3. While a 
number of studies have focused on examining the relationship between transcript abundance 
and the resulting protein products, methodologies and resultant correlation relationships vary 
significantly. In particular, few studies analyze the impact of their abundance measurement and 
data integration methods on the resulting relationship. Consequently, it is unclear how these 
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differences in bioinformatics methodology affect the final correlation. To address the issues of 
data integration, we construct a common reference database from the RefSeq database 
composed of corresponding transcript and protein sequences against which we applied the 
Trans-Proteomic Pipeline [56] and Abacus [57] for protein abundance quantification and an in-
house pipeline for RNA-seq quantification. This unique approach allowed for a one-to-one 
comparison of transcripts and protein products. Using this method to ensure proper 
comparison of genes, we normalize the abundance values derived from each of the 
experiments in the transcriptome and proteome.With the data derived with this methodology, 
we explored how technical factors, namely identification and counting methods in both 
transcriptome and proteome data, contribute to uncertainty in correlating transcript and 
protein abundances. In particular, we show how read mapping for transcriptome data and 
multiple assignment of MS spectra lead to variation in the correlation coefficient of abundance. 
The transcript-protein relationship and its role in disease and cancer 
One of the primary motivations for studying the transcript-protein abundance relationship 
and the factors that affect it is the desire to dissect the regulatory mechanisms of the cell [58]. 
To address this question, several studies have examined the influence of a number of 
regulatory factors on the correlation observed between protein and transcript abundance. For 
example, Vogel, et al. examine the role of sequence features that may affect transcription, 
degradation, or translation, such as 5’ and 3’ UTR lengths, local secondary structure, and the 
number of miRNA target sites on the transcript in the Daoy medulloblastoma cell line [59]. In a 
similar study, Schwanhäusser, et al. derive a quantitative model of protein abundance, noting 
that both transcript and protein half life have significant impacts on the transcript-protein 
abundance relationship [60]. In both of these studies, the authors note that sequence features 
play a role in the abundance of protein products in addition to transcript abundance, although a 
significant amount of this variability is still not accounted for. The biological role of the 
transcripts and proteins play a part in this – for example, several studies have observed that  
highly stable structural proteins have higher correlation with their cognate transcripts [43]. 
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Although the dysregulation of the transcript-protein relationship can play a role in disease, 
it has not been well studied. While a number of the studies analyzing the transcript-protein 
relationship are focused on cancer, most of these studies used microarray or older techniques, 
and suffer from the issues of small gene sets and limited dynamic range discussed earlier. On 
the other hand, the studies that were aimed at a thorough analysis of both the transcriptome 
and the proteome generally did so outside of a disease context.  
In the landmark “Hallmarks Of Cancer,” Hanahan and Weinberg broadly classify the set of 
biological characteristics commonly acquired by cancers into a set of six traits. These acquired 
traits, enabled by genome instability, are self-sufficiency in growth signals, insensitivity to 
growth-inhibitory signals, the evasion of apoptosis, limitless replicative potential, sustained 
angiogenesis, and tissue invasion and metastasis [61]. To these, the subsequent “next 
generation” of cancer hallmarks added the deregulation of cellular energetics and avoidance of 
immune destruction. In addition, it recognized the role of inflammation in promoting 
tumorgenesis and progression [62].  
Changes in the transcript protein relationship can have important functional consequences 
due to alterations in the regulatory structure of the cell, giving rise to the hallmark 
characteristics of cancer. In breast cancer, it has been observed that the stabilization of DNA 
Methyltransferase 1 (DNMT1) causes its dysregulation leading to aberrant genomic 
hypermethylation [63].  This is primarily seen as an increase in protein levels without an 
increase in the cognate transcript. There is also significant evidence that stabilization of 
transcription factors that regulate transcript abundance is a common mechanism of gene 
regulation, with several examples in human cancers. HIF-1a is a commonly studied transcription 
factors due to its widespread effects on cell survival and angiogenesis as well as its activation 
under the hypoxic stress often seen in tumors [64]. It has been shown to be stabilized by 
interaction with another transcription factor, YY1, itself implicated in tumorgenesis [65]. This 
stabilization was also noted as a change in protein abundance without an effect on mRNA level 
[66]. Another example is observed in the interaction of the LMO2 and SCL transcription factors, 
both of which have been implicated in hematopoietic cancers [67, 68]. The protein product of 
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the LMO2 gene, a central component of several transcription factor complexes, has been 
shown to be stabilized by interaction with SCL, which prevents its degradation allowing for 
more widespread transcription factor complex assembly [69].  
To address this paucity of cancer-focused research encompassing a comprehensive set of 
genes from the transcriptome and proteome, the work in Chapter 4 focuses on the 
characterization of the transcript-protein relationship in the RWPE prostate epithelial cell line 
and the VCaP prostate cancer cell line and compares the two. We focus on the transcript-
protein relationship within various biological functional classes, and how that relationship is 
altered in a cancer context. In particular, we use a novel transcript-protein discordance index to 
assess the level of transcript-protein dysregulation in VCaP when compared to RWPE. 
Application of methods to other studies 
The methods and knowledge developed in the course of these studies for profiling the 
landscape of the cellular transcriptome using RNA-seq were also applied to a number of other 
studies. The derived expression measurements were often used in tandem with other types of 
profiling to analyze multiple facets of biological activity. In Maher, et al. [70], an early version of 
the quantification methodology was used to contextualize the abundance of known and novel 
gene fusion transcripts in prostate cell lines in terms of the broader transcriptome. This was 
one of the first studies to utilize RNA-seq data to infer gene expression values from read 
mapping counts, and showed the relative abundance of several gene fusion transcripts such as 
the well-characterized TMPRSS2-ERG and the novel USP10-ZDHHC7 fusion transcripts 
compared to some of the most highly expressed genes in the transcriptome. This expression 
calculation technique was applied in Kim, et al. [71], where transcriptome sequencing derived 
expression values were integrated with microarray and NGS-derived DNA promoter 
methylation data to analyze the impact of differential methylation patterns in prostate cancers.  
The lessons in read mapping, detection, and dynamic range were also applied in 
contributions to studies using other sequencing-based methods to profile the genome and 
exome. Accurate read mapping and artifact filtering techniques derived from the development 
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of the RNA-seq quantification methodology were applied to an evaluation of variants in the 
transcribed portion of the genome, or exome, in Grasso CS, et al. [72] focused on castration-
resistant prostate cancer. These efforts led to increased detection of rare single-nucleotide 
variants and short insertions and deletions in the exome.  
Similarly, methods to filter out artifacts resulting from ambiguously mapping reads and 
aberrant characteristics of the sequencing process were applied to develop a pipeline for 
characterizing the structure of the cancer genome in a personalized oncology context in 
Roychowdhury S, et al. [73]. This method derived both copy number and aberrant mapping 
data across the sampled genomes and integrated them to increase confidence in the derived 
candidates. Consequently, this methodology was able to recover genome-scale rearrangements 
from low-depth genomic sequencing of a cancer sample, in absence of a corresponding normal 
sample, in a subset of the total four patients with advanced or refractory cancer enrolled in the 
study. These genomic rearrangements demonstrated the genomic basis for the RNA fusion 
transcripts observed in this study and several subsequent patients enrolled in the MI-ONCOSEQ 
personalized oncology program. 
List of contributions to publications 
 
1. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, 
Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, 
Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes 
DR, Pienta KJ, Chinnaiyan AM, Tomlins SA. The mutational landscape of lethal 
castration-resistant prostate cancer. Nature. 2012 Jul 12;487(7406):239-43. 
In this study, I developed a pipeline using the BWA short read aligner and samtools suite 
to discover single-nucleotide polymorphisms and short insertions and deletions (indels) 
specific to cancer across samples in our cohort.  
2. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, Kalyana-Sundaram S, 
Sam L, Balbin OA, Quist MJ, Barrette T, Everett J, Siddiqui J, Kunju LP, Navone N, Araujo 
JC, Troncoso P, Logothetis CJ, Innis JW, Smith DC, Lao CD, Kim SY, Roberts JS, Gruber SB, 
16 
 
Pienta KJ, Talpaz M, Chinnaiyan AM. Personalized oncology through integrative high-
throughput sequencing: a pilot study. Sci Transl Med. 2011 Nov 30;3(111):111ra121. 
In this study, I contributed structural variation and copy number results derived from a 
single channel of low-depth genomic sequencing of the cancer sample without a 
matched normal using the Breakdancer and ReadDepth tools. These results were 
derived from a comprehensive profiling pipeline I developed for the characterization of 
large scale variation in the genome. 
3. Kim JH, Dhanasekaran SM, Prensner JR, Cao X, Robinson D, Kalyana-Sundaram S, Huang 
C, Shankar S, Jing X, Iyer M, Hu M, Sam L, Grasso C, Maher CA, Palanisamy N, Mehra R, 
Kominsky HD, Siddiqui J, Yu J, Qin ZS, Chinnaiyan AM. Deep sequencing reveals distinct 
patterns of DNA methylation in prostate cancer. Genome Res. 2011 Jul;21(7):1028-41. 
I contributed gene expression profiling for RNA-seq data, used in conjunction with 
methylome (Methyl-seq) profiling data, to survey the effects of dysregulated 
methylation in prostate cancer. I also contributed assistance in optimizing the alignment 
of Methyl-seq derived reads. 
4. Maher CA, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, Jing X, Sam L, Barrette T, 
Palanisamy N, Chinnaiyan AM. Transcriptome sequencing to detect gene fusions in 
cancer. Nature. 2009 Mar 5;458(7234):97-101. 
Using an early version of the transcriptome quantitative profiling pipeline I developed, I 
contributed RNA-seq based gene expression to this study. This provided context for the 




Chapter 2: A Comparison of Single Molecule and Amplification Based 
Sequencing of Cancer Transcriptomes 
Introduction 
Sequencing samples at single-molecule resolution is seen as the next step in the 
evolution of Next Generation Sequencing (NGS). These technologies have already produced 
unprecedented amounts of data at nucleotide-level resolution, and are transforming our ability 
to observe biological systems. NGS technology has had a particular impact in the study of 
transcriptomes through mRNA sequencing, or RNA-Seq. Offering a wide dynamic range and 
truly global view, this NGS application is quickly supplanting existing approaches for monitoring 
complex transcriptomes where both transcript lengths and concentrations are highly 
heterogeneous. The multi-faceted nature of RNA-Seq has enabled in-depth analysis of 
transcript abundance [9, 74, 75], alternative splicing [76-79], novel transcript detection [80], 
biomarker discovery [81-83], pathogen detection and characterization [84-86], and gene fusion 
discovery [70, 87, 88].  
The first wave of ‘next generation’ sequencing platforms such as those from Applied 
Biosystems, Illumina, Ion Torrent, and Roche/454, utilize PCR based amplification steps in 
sample preparation and sequencing and are thus categorized as amplification based sequencing 
(AS) methods. A second set of platforms, described as ‘single molecule sequencing’ (SMS) [89] 
by Helicos and Pacific Biosciences, eliminate the amplification steps involved in the sample 
preparation and sequencing process and thus profess to provide a more accurate view of the 
transcriptome. 
AS techniques typically involve two amplification steps; the first amplification occurs 
during the creation of the double-stranded cDNA library from the fragmented mRNA. The 
cDNAs are ligated to a pair of adapter molecules, and PCR amplified. A second amplification 
step is carried out with the adapter-ligated single cDNA strands hybridized to primers bound to 
a glass or silicon substrate to produce local clusters of identical molecules using isothermal 
amplification or emulsion PCR. Taken together, these two steps have the potential to selectively 
introduce over-represented segments and genes into AS data. It has been observed that this 
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bias exists [90-93], however its effect on transcript coverage and quantification has not been 
thoroughly explored in complex samples with transcripts at variable concentration. The Helicos 
SMS protocol involves creation of single-stranded cDNA templates directly from mRNA and 
hybridization of these poly-adenylated templates to complementary oligomers bound to a glass 
slide for sequencing (Figure S 3). 
Results 
Assessment of SMS RNA-Seq through transcript profiling 
To systematically assess the differences between the two sequencing technologies, we 
analyzed RNA-Seq results from amplification-based sequencing (AS) and single-molecule 
sequencing (SMS) across a set of twelve cancer cell lines and tissue samples. In particular, our 
approach attempted to discover recurrent biases that may be introduced by the amplification 
steps implicit in AS. Our initial dataset used to evaluate quantification performance is 
comprised of samples from the prostate cancer cell lines DU145, RWPE, VCaP, and LnCaP, and 
one prostate cancer tumor tissue with a matched adjacent normal sample. Out of our set, three 
samples each of VCaP and LnCaP were structured as a time course study with 0h, 24h, and 48h 
time points. 
In our analysis of the two technologies, we chose to use the preferred alignment tool for 
each technology in a “best vs. best” approach. AS reads were aligned with the Bowtie aligner 
[94] while SMS reads were aligned with IndexDP [95] (Figure S 4). Reads aligning to known 
biological contaminants such as mitochondrial DNA, ribosomal RNA, and technology-specific 
contaminants such as adapter sequences and long oligomers, were filtered out of the data set 
prior to analysis.  
To assess the variation between SMS and AS technologies, we adopted a simple read 
counting procedure similar to other RNA-Seq quantification methodologies [9, 74]. Reads from 
single lanes of AS and SMS technologies run in parallel, were aligned to 56,722 University of 
California Santa Cruz (UCSC) transcripts (version hg18). We then enumerated reads per-
transcript and normalized based on the number of high quality, non-contaminant reads per 
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sample to obtain values in reads per million (RPM). To avoid uncertainty associated with multi-
mappings to gene isoforms, only single-best mapping methods were used to quantify the genes 
for comparison. Single best mappings were derived from AS reads by setting Bowtie to report 
only the single highest quality alignment per read. Single best alignments were derived from 
SMS reads by accepting alignments with the highest quality scores. Values from all gene 
transcript isoforms, as defined by UCSC, were summed to yield values in terms of alignments 
per million reads for each of the 29,416 genes. Coverage values in reads per kilobase per million 
(RPKM) were computed by summing RPKM values of the isoforms of each gene. Through a 
head to head comparison between AS and SMS reads of identical samples run in parallel on the 
two platforms, we observed a systematic over-representation of high expressing transcripts in 
AS as compared to SMS. This bias resulted in reduced coverage of mid- and lower-level 
expression genes leading to overall lower transcript detection sensitivity in AS. Reprocessing a 
subset of AS samples using IndexDP and repeating the analysis ruled out technical differences in 
read assignment as the cause of this representation bias. As the sequencing technologies and 
chemistries continue to advance, we expect AS platforms will overcome the limitation of low 
expressed transcript detection by enhanced throughput. 
Global properties of AS and SMS results 
Transcriptome sequencing was carried out in parallel on AS and SMS platforms for 12 
samples including 10 prostate cancer cell lines and 2 prostate cancer tissues. Overall, we 
generated 2.8 to 19.7 million raw AS and SMS reads in each of the 12 samples. Approximately 
30-60% of these reads passed initial filtering steps and aligned to our transcriptome reference. 
SMS reads were produced in two separate machine runs while AS reads were produced across 
6 independent machine runs. This procedure resulted in 2.1 – 15 million and 2.8 – 8 million 
reads for SMS and AS, respectively, which aligned to our transcriptome reference. In 10 out of 
the 12 samples used in the evaluation, SMS produced more alignable reads in absolute terms, 
with a median of 1.39x across all 12 samples. SMS results contained more reads aligning to 
known contaminants, ranging from 12% to 51% of total reads, with a median of 22%. The 
fraction of reads aligning to contaminants in AS ranged from 2.6% to 14% with a median of 
4.2%. SMS read length was variable and a filtering step restricted usable reads to a length range 
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between 24bp and 57bp in the first run, and 25bp and 64bp in our second run, yielding a read 
count-weighted mean length of approximately 33bp in each of the twelve samples (Table S1). A 
median of 97% of all SMS reads had lengths between 25bp and 47bp across all 12 samples 
(Figure S 5). AS reads were generated at a minimum length of 36bp in each sample, although 
the first and last several bases were ignored to produce high quality reads at least 34bp in 
length. All AS reads were considered to have a maximum of 36bp length. Reproducibility 
between technical replicates of the DU145 cell line was high for both AS and SMS methods, 
with a Pearson correlation of r=.98 for both technologies (Figure S 6). Reads from both AS and 
SMS were also aligned allowing for 25 maximum mappings to assess the distribution between 
uniquely- and multiply- mapped reads at the gene level, although only single-best mappings 
were used for quantification and comparison purposes. Both technologies achieved very similar 
unique mapping rates of 72% and 75% in AS and SMS, respectively. From this raw aligned data, 
we examined the relative distribution of reads across genes observed in our samples by 
comparing their normalized read counts. As expected, we observed broad agreement in terms 
of gene expression values between the technologies (Figure S 7). However, we observed a 
recurrent pattern of over-representation of high-abundance transcripts by the AS methodology 
as compared to SMS.  
Coverage bias in amplification-based sequencing 
Comparison of transcriptome reads of the same samples quantified in parallel from AS and 
SMS platforms reveals a distinct bias in AS results towards a slight overrepresentation of  highly 
expressed genes as compared to SMS, as shown in Figure 3A. This difference was qualitatively 
assessed by dividing the genes into quartiles of equal number, ordered by observed values in 
AS, with the first quartile representing the highest expressing genes, the second quartile 
representing mid-level expression genes, and the third and fourth quartile defining the genes 
with the lowest levels of transcripts (Figure 3B). Highly expressed transcripts tended to have 
more read coverage in AS, whereas SMS tended to cover the lower expressed transcripts more 
effectively. This additional coverage of high-concentration transcripts consistently appeared to 
be at the expense of lower-expressed transcripts, which tended to be more thoroughly 




Figure 3: Observed bias in amplification-based sequencing.  A. Single-best mapping method-based quantile-quantile plot 
demonstrates evidence of over-representation of highly expressed transcripts in amplification-based sequencing compared to 
single-molecule methods. B. Distribution of reads across genes by transcript concentration shows decreased SMS coverage of 
the most highly expressed genes, with those reads going to mid- and low-level expressors. C. Differences in the distribution of 
reads lead to increased sensitivity of low-expressing transcripts. D. Nine of the candidate genes seen above the 0.3 RPKM noise 
level demonstrated any amplification by RT-PCR, although only HIST1H4C showed high abundance. 
In order to ensure that these biases were not the result of using a different aligner for 
each technology, AS reads were re-aligned using the IndexDP aligner used for SMS reads for a 
subset of the samples, composed of the VCaP-24h, VCaP-48h, LnCaP-24h, LnCaP-48h, and 
DU145_1 samples (Figure S 8). Very high correlation of gene-level values comparing Bowtie and 
IndexDP alignments for the set of AS reads ruled out differences between alignment tools as 
the source of the observed biases. For example, correlation of gene-level values in the LnCaP-
24h sample was high between alignment methods at r = 0.97. Similarly high correlation levels 
above r = 0.95 were observed in the remaining samples. Similar patterns of high-expressor 
over-representation in AS were observed using IndexDP alignments of AS reads in place of 
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standard alignments using Bowtie as shown in Figure S 9. With methodological differences 
essentially ruled out, we attempted to observe the effects of this high-concentration coverage 
bias by examining the detection of transcripts at low levels.  
Increased SMS sensitivity results from high coverage of low-abundance 
transcripts 
To evaluate the effects of increased coverage in mid- to low- level transcripts in SMS, we 
calculated the number of genes observed above a noise threshold in only one of the two 
technologies. Using the 0.3 RPKM noise level cutoff based on Ramskold, et al. [96], the number 
of genes detected in only a single technology varied between a high of 4,851 and a low of 2,048 
and a high of 1,276 and a low of 145 in SMS and AS (Figure 3C), respectively, across the set of 
samples. A log-fold difference between the numbers of genes detected in only one of the SMS 
vs. AS technology was observed as we varied the cutoff value between 0.1 RPKM and 3.0 RPKM 
(Figure S 10) in 0.1 RPKM increments. These limits were chosen to examine the sensitivity of 
the two methods across a range of values starting from a near-zero noise level to an order of 
magnitude larger than previously reported. Stratification of the genes observed in a single 
technology into length classes of 0-300bp, 300-3000bp, and 3000+bp demonstrated that this 
was not due to differences in technology-specific sample preparation, as the AS protocol 
specifies a ~300bp size selection step that the SMS procedure does not require. This class 
shows relatively low representation across noise thresholds in both AS and SMS. We then took 
this evaluation one step further and examined the results from both SMS and AS techniques 
attempting to find genes detectable only in one technology. 
Uniquely detected genes in SMS 
In order to substantiate potential representation biases in the two platforms and the 
suggested additional sensitivity of SMS, we next queried for genes which were detected above 
a noise threshold by SMS, but were below that threshold in AS. We chose to analyze the DU145 
sample as it was the most thoroughly sequenced sample with two replicates run using each 
technology. Using a 0.3 RPKM threshold, we chose to test the expression of 23 genes in our 
DU145 samples using RT-PCR, ten of which demonstrated detectable amplification. 
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Additionally, we sequenced the DU145 cell line much more thoroughly in order to ensure that 
our detections were not due to technical factors in a single machine run. As shown in Figure S 
11, this set of genes had better sequencing coverage in SMS as compared to AS across the total 
94,427,789 reads generated in our second set of runs. This list was generated by examining the 
distribution of reads and coverage maps of the top 50 genes whose RPKM coverage showed the 
largest difference between AS and SMS techniques and had official HUGO names [97]. 
Candidates were chosen for the presence of long (>36bp) mapping reads and well-distributed 
read alignments across the length of the transcripts. Of the validated genes detected only by 
SMS, only HISTH1H4C was found to be present in the DU145 sample with high confidence, as 
shown in 
 
Figure 3D. Nine other candidate genes AK5, ACVRL1, AMHR2, CERKL, MAFA, MAGI2, 
PIP5K1B, FAM49A, and TPRXL showed weak amplification. In this set of genes, amplification 
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was only seen beyond cycle 30 making it difficult to confirm their presence. This weak 
amplification makes it difficult to determine if their detection in SMS is due only to increased 
sensitivity, or are an artifact of ambiguous mapping. We next sought to examine the over-
represented genes that may contribute to the reduction of sensitivity using amplification-based 
sequencing techniques. 
Consistent over-representation of high-expression genes in amplification-based 
sequencing 
Overall, 393 genes were found to be consistently within the set of the top 500 over-
represented genes according to normalized read mapping count in at least 40% of our samples 
(Table S 5). Of these 393 genes, ten genes were found to be over-represented by normalized 
read mapping count across all 12 of the samples considered in the study. The coverage maps of 
RPLP0 and RPL31, over-represented in all 12 samples, and SPINT2, over-represented in 11 
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samples, demonstrate this coverage bias in these three high expressing transcripts (
 
Figure 4A-C). We then examined the composition and distribution of reads in some of these 





Figure 4: High-concentration transcript bias leads to differences in gene coverage in amplification-based 
sequencing.  Coverage maps from amplification-based and single molecule sequencing demonstrate significantly 
greater coverage of A. RPLP0, B. RPL31, and C. SPINT2. Removal of reads with the same start positions, strictly 
suppressing amplification of specific mRNA fragments, significantly reduces the “spikiness” seen in these cases. D. 
Duplicate reads, defined as reads in excess of one per start locus and read length, are relatively evenly distributed 




Impact of duplicated reads in amplification-based sequencing 
The gene RPLP0 had much greater total mapping coverage in AS across all twelve samples 
(Figure S 12). To aggressively mitigate the effect of amplification in the coverage of this gene, 
duplicate reads were removed (allowing only 1 read per unique start location) for both 
technologies as done in previous studies [92, 93]. This resulted in suppression of many of the 
observed peaks in AS. In contrast, SMS coverage of the gene appeared to be relatively 
consistent across the length of the RPLP0 transcript before and after this procedure. This 
substantial difference in behavior between pre- and post- duplicate read removal for AS in 
comparison to SMS suggests that amplification is a significant contributory factor in the 
observed bias. Similar behavior is observed in the RPL31 and SPINT2 genes as well.  
We considered both alignment locus and read length in our definition of read duplication, 
allowing one read at each locus with a unique read length. Looking across the transcriptome 
using this definition of read duplication, we observed a roughly normal distribution along the 
length of all transcripts captured. A 3-fold difference in the median number of duplicate reads 
between AS and SMS across all transcripts observed in all samples was maintained across the 
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majority of the transcript length (
 
Figure 4D). This pattern of read duplication is similar to that observed in the literature 
between standard amplification-dependent and amplification-free sequencing methodologies 
[98]. Removal of duplicate reads, allowing only one read per locus, yielded inconsistent results 
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across the sample set (Figure S 13). In some cases, the procedure reduced the over-
representation in the highest expressing genes, however the bias appeared to remain in other 
samples. The procedure also drastically reduced the number of total usable reads in each 
sample by a median of 47% across the 12 sample dataset (Figure S 14). While this naïve 
methodology of duplicate read removal had some positive effect in reducing the discrepancies 
between AS and SMS in terms of transcript quantification, the drastic effects it has on the 
number of usable reads in AS suggests a different approach may be desirable. With this 
understanding of the impact of duplicated reads, we analyzed the set of recurrently over-






Figure 5: Global representation of Gene Ontology classes in Amplification-based sequencing. GO analysis of the 
392 most over-represented genes found using our recurrence analysis in the Molecular Function (MF) and 
Biological Process (BP) subtrees demonstrates that translational processes and components of the ribosome are 
over-represented across samples in amplification-based sequencing. 
Gene Ontology analysis of the set of 393 recurrently over-expressed genes 
Across the samples, genes associated with the cell’s replicative machinery comprised the 
largest portion of over-represented transcripts by total normalized number of mapping reads in 
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most samples. Gene Ontology analysis of the set of 393 consistently over-represented genes 
shows that they are components of the cell’s translational machinery (Figure 5), a class 
generally found at high levels in all twelve samples used in this evaluation. This again suggests 
that the amplification procedure implicit in AS library preparation exaggerates a particular bias 
towards these already-abundant transcripts. The total number of reads falling into each of the 
classes observed to be over-represented in AS was a mean of 2.23x higher as compared to SMS, 
although genes overlap between the classes. With less of a focus on high-concentration 
translational machinery and housekeeping genes, we then attempted to apply SMS in finding 
gene fusions in the transcriptome.  
Re-discovery of known gene fusions using single-molecule sequencing 
We evaluated the applicability of single read SMS in gene fusion discovery by 
attempting to re-discover known gene fusions in the VCaP cell line, known to harbor TMPRSS2-
ERG, in a de novo process. As shown in Figure S 15, we first aligned all possible reads against 
the transcriptome and genome using IndexDP. The non-mapping reads, which harbor chimeras, 
were subsequently aligned against the transcriptome returning those reads that had a partial 
alignment of at least 18 nucleotides. The portion of the read that fails to align is defined as the 
overhang. All reads having the same partial alignments, suggesting a common breakpoint, were 
clustered. All clusters were then compared to determine if the overhang from one breakpoint 
region had similarity to the overhang of an independent breakpoint thereby reconstructing the 






Figure 6: Single molecule sequencing “re-discovers” known gene fusions. Schematic of the intra-chromosomal 
rearrangement on chromosome 21 fusing TMPRSS2 (yellow) to ERG (purple). 
For this purpose, a sample of the VCaP cell line was sequenced more extensively in 2 
channels, generating 31,198,128 reads aligned to the transcriptome or genome. The VCaP 
sample was prepared with one channel each with and without fragmentation. The benchmark 
fusion between prostate-specific gene TMPRSS2 and ETS oncogenic family member, ERG [99], 
was found to be covered by 53 reads from generating 65 million reads in the VCaP cell line 
(Figure 6).  
Discussion 
This is the first study assessing the performance of RNA-Seq using single-molecule 
sequencing in comparison to existing amplification-based techniques. While the characteristics 
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of the SMS reads will vary depending on platform, we expect that the distribution of reads 
across varying transcript concentrations to remain relatively consistent. The SMS technique was 
able to generate more usable reads in ten of the twelve samples considered in the RNA-Seq 
quantification and coverage evaluation, producing a mean 78% more reads in these 10 samples. 
More importantly, these reads tended to be less concentrated at the very highest abundance 
transcripts as shown in Figure 3B, where fraction of total reads mapping to the highest 
abundance transcripts in SMS are 4% below that of AS. Because the AS technique amasses a 
large fraction of reads sequencing high- abundance transcripts, detection of lower abundance 
genes are reduced. The large differences between the highest and second-highest quartile of 
expressed transcripts suggests that this effect is non-linear as transcript abundance increases in 
the sample. The wide range of transcript expression in biological samples makes this skewed 
read distribution of coverage an important factor when profiling mRNAs at the nucleotide level, 
departing from models that may assume a linear correlation between transcript abundance and 
sequencing coverage.   
The number of duplicated reads observed in the samples across all transcripts was, not 
surprisingly, 3-fold higher in AS compared to SMS. The removal of duplicate reads is a well-
defined procedure in experiments involving DNA sequencing but is less clear-cut when 
sequencing the transcriptome where varying transcript concentrations naturally lead to reads 
of identical mRNA segments. This caveat is due to highly expressed transcripts contributing 
false positive duplicate reads due to random sampling of read start locations along the 
transcript, where high coverage naturally leads to repeated sequencing of identical segments. 
However, highly expressed transcripts in SMS would likely generate a large number of these 
aberrant false positives as well. As a result, this source of false positive duplicated reads is 
unlikely to be the major factor behind the large observed differences in the number of 
duplicates between AS and SMS. The removal of duplicated reads by filtering out all reads in 
excess of a single read for a single locus appears to be an incomplete solution that introduces 
several confounding factors when using single reads. First, the process of removing duplicates is 
inconsistent, affecting the biased representation of reads in only a subset of the 12 samples in 
the dataset. Second, the duplicate removal process also reduced the usable sequence yield 
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from each experimental run by nearly half, although this is an overestimation due to the naïve 
nature of the method. Finally, these duplicate removal methods impose a peak coverage limit 
for each transcript that is equivalent to the read length. The naïve process we applied for the 
elimination of duplicates is most certainly over-aggressive and the use of paired-end reads may 
be more effective, due to the production of additional mapping and sequence information that 
improves the process of duplicate identification and removal. However, the differences that 
result from the characteristics of these two methodologies can lead to disparities in the 
sequence coverage of genes along the spectrum of expression. 
Small differences in the distribution of reads at the highest quartile of expressed genes 
have a large effect on the coverage of the remaining expressed genes. For example, the lowest 
quartile of all genes seen in both technologies in the VCaP-24h sample composes 0.4% of the 
sum total of normalized reads seen in the highest expressed quartile by AS. A 1% reduction in 
the number of reads used to sequence the highest expressing genes in the forth quartile can be 
used to triple the coverage of the lowest expressing genes when reads are applied within the 
set. The result of shifting the read distribution to lower expressing genes is seen between the 
VCaP-0h and VCaP AS samples. Both samples yielded a relatively similar number of reads, with 
3,636,454 and 3,352,960 reads in VCaP-0h and VCaP, respectively. However, the VCaP-0h 
sample has more than twice the fraction of the total reads falling into the lowest 2 quartiles 
with 2.2% and 0.9%, in the respective VCaP-0h and VCaP samples. It comes as no surprise that 
in the VCaP-0h sample, we are able to observe 16,813 genes above the 0.3 RPKM noise 
threshold whereas in VCaP, we only observe 13,866 genes above this threshold. Similarly, the 
reduced high-abundance coverage bias across variable concentrations allows the SMS approach 
2- to 6-fold more coverage in the lower half of all expressed genes. The variable read length of 
the SMS reads contributes to quantification noise, compared to AS, due to the number of short 
reads which map ambiguously. These mis-mappings may contribute to the larger number of 
genes observed at the very lowest expression levels.  Examination of the reads mapping to 
genes only found in SMS shows the presence of more than 30% of long SMS reads (>36bp in 
length) in a median of 17% of the genes (approximating the read length distribution across all 
samples), leaving a 1.7-fold advantage in favor of SMS sensitivity if genes detected with only 
35 
 
short 24- to 35-mer reads are all considered detections due to noise. While a significant 
proportion of this noise is directly attributable to ambiguities in accurately mapping short 
reads, the presence of long (>36bp) aligned reads is not a guarantee of transcript presence. In a 
large number of the cases where detected genes have long reads aligned to them, false 
positives were attributable to these long reads mapping to repetitive elements or low 
complexity regions within the transcripts.  
Our PCR validation results suggest that using amplification to confirm transcripts 
exclusively detected by single-molecule sequencing (and missed by AS sequencing) is not ideal, 
since any sequence that is difficult to amplify will be hard to detect using AS RNA-Seq and hard 
to validate using an amplification-based system. Therefore, we cannot verify such transcripts 
unless an amplification-free technology is employed. Sample preparation differences may also 
contribute to differential representation of transcripts in the sequencing libraries, as AS 
involves a size selection step that SMS does not. In addition, the two protocols use differing 
fragmentation procedures which may affect the prevalence of detectable transcript fragments. 
This is one significant factor that may contribute to the detection of some genes above the 
noise threshold exclusively by AS. There may be other reasons for differences in the relative 
representation of transcripts in each technology. Some transcripts may be under-represented 
because they are hard to capture using SMS. Conversely, the amplification procedure may alter 
the apparent transcript abundance as some sequences may amplify highly leading to over-
representation in AS, which may increase their candidate transcript counts above the noise 
threshold. For some candidates seen in only one technology, increasing sequencing depth may 
be the most straightforward solution to the lack of resolution for low abundance transcripts. 
Some candidates may require modification of the library preparation protocol to ensure 
sufficient library complexity to capture these low-abundance transcripts. For example, the use 
of a normalized AS RNA-Seq library preparation protocol or the introduction of a greater 
amount of input RNA may increase the complexity of the library, possibly enabling higher 
sensitivity as a result. However, the paucity of published data addressing these topics at this 
time precludes a thorough examination of potential solutions. 
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However, while SMS confers the advantages of higher sensitivity and abrogation of 
issues stemming from read duplication, the technology has a number of confounding 
characteristics. First, SMS produces reads that are, on average, shorter than their AS 
counterparts, magnifying the issue of accurately mapping reads to their correct positions. While 
the inclusion of long 64bp reads confers an advantage, these are the minority of all reads 
produced. Approximately 60% of all SMS reads were 36bp or smaller across all samples. 
Second, the SMS methodology used in this evaluation produces reads that include randomly 
introduced gaps due to the incorporation of “dark bases” which do not produce photo-
detectable fluorescence. This characteristic requires the use of alignment algorithms that allow 
for the inclusion of insertions and deletions relative to the reference, and may complicate the 
detection of structural variation. We also observed a higher proportion of contaminant-
alignable reads in SMS compared to AS, although it is unclear whether this is a product of either 
the sample preparation procedure or a characteristic of the sequencing process. 
Altogether, these differences suggest that SMS has advantages in quantitative 
expression profiling and nucleotide-level assessment such as polymorphism detection in mid- to 
low- abundance transcripts although the lowest levels of detection are subject to noise due to 
mapping. However, the log-fold advantage SMS holds may be overcome as rapid advances in 
sequencing technology result in the production of increasing numbers of usable reads. 
Methods 
Preparation and sequencing of samples 
Sequencing libraries for the RNA-Seq evaluation set were prepared from a DU145 cell 
line (ATCC; HTB-81), an RWPE cell line (ATCC; CRL-11609), an androgen-induced VCaP cell line 
time course at 0h, 24h, 48h, an identical time course in the LnCaP (ATCC; CRL-1740) cell line, 
and a tissue sample from a prostate tumor paired with an adjacent normal sample. Sample 
preparation of the entire 12-sample set included the RNA fragmentation step to ensure 
consistency. Two replicates of a normal untreated VCaP cell line were run for gene fusion 
discovery evaluation, one each of fragmented and un-fragmented RNA. The fragmented sample 
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was included in the 12-sample evaluation set. The VCaP cell line was derived from a vertebral 
metastasis from a patient with hormone-refractory metastatic prostate cancer, and was 
provided by Ken Pienta (University of Michigan, Ann Arbor, MI). LNCaP or VCaP [100] cells were 
starved in phenol red free media supplemented with charcoal-dextran filtered FBS and 5% 
penicillin/streptomycin for 48 h before the addition of 1 nM synthetic androgen (R1881) as 
indicated. RNA was then isolated using the miRNeasy kit (Qiagen) according to the 
manufacturer’s instructions. Prostate tumor tissue was obtained from the University of 
Michigan tissue core. Identical samples were submitted for SMS and AS sequencing in all cases 
with the exception of the VCaP and LnCaP time course samples. The DU145, VCaP, RWPE, as 
well as the VCaP and LNCaP AS-sequenced time course samples were treated with DNAse. The 
VCaP and LNCaP time course samples submitted for SMS, as well as the PrCa and PrCa-Adjacent 
normal samples, were not treated with DNAse during sample preparation. Poly-A containing 
mRNA for these samples was isolated by two rounds of binding to Sera-Mag Magnetic Oligo(dT) 
beads, wash and elution in 10mM Tris buffer pH 7.5, according to manufacturer's instructions 
(Thermo Scientific, Indianapolis). The purified mRNA was immediately processed for library 
preparation. The VCaP and LNCaP time course AS sample mRNA was selected with oligodT 
linked beads according to manufacturer's instructions (Invitrogen). 
Amplification-based sequencing was done in paired-end mode run to a minimum of 
36bp per read and trimmed to a minimum of 34bp to remove low quality bases. For 
amplification-based sequencing, messenger RNA (2 µg) was fragmented at 85° C for 5 min in a 
fragmentation buffer (Ambion) and converted to single stranded cDNA using SuperScript II 
reverse transcriptase (Invitrogen), followed by second-strand cDNA synthesis using Escherichia 
coli DNA polymerase I (Invitrogen). The double stranded cDNA was further processed by 
Illumina mRNA sequencing Prep kit. Briefly, double-stranded cDNA was end repaired by using 
T4 DNA polymerase and T4 polynucleotide kinase, monoadenylated using an exo minus Klenow 
DNA polymerase I (3’to 5’ exonucleotide activity), and ligated with adaptor oligo mix (Illumina) 
using T4 DNA ligase. The adaptor-ligated cDNA library was then fractioned on a 3% agarose gel, 
and fragments corresponding to 280-320 bp were excised, purified, and PCR amplified (15 
cycles) by Phusion polymerase (NEB). The PCR product was again size selected on a 3% agarose 
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gel by cutting out the fragments  in the 300 bp range. The library was then purified with the 
Qiaquick Minelute PCR Purification Kit (Qiagen) and quantified with the Agilent DNA 1000 kit on 
the Agilent 2100 Bioanalyzer following the manufacturer’s instructions. Library (5-8 pM) was 
used to prepare flowcells for analysis on the Illumina Genome Analyzer II.  
Single-molecule sequencing was done on a Helicos HeliScope in single-read mode, 
resulting in useful reads ranging between 24bp and 61bp for the first set and 25bp and 64bp in 
length in the second set. polyA+ RNA was purified on an RNeasy MinElute column (Qiagen).  
Then 100ng of RNA (on average, between 86ng – 130ng) was heat fragmented by incubation at 
95C for 10 minutes or left un-fragmented. First strand cDNA was then made using the 
SuperScript III reagent kit (Invitrogen, Carlsbad CA) as follows: 500ng random hexamers, 2ul of 
10mM dNTP, and DEPC water were added to the RNA up to a volume of 25ul. The mixture was 
then incubated at 65C for 5 min and placed directly on ice for 2 minutes. Next, 5ul 10X buffer, 
5ul 0.1M DTT, and 10ul 25mM MgCl were added to each sample, and the, now 45ul, sample 
was incubated at 15C for 30 minutes. After this incubation time 2.5ul of RNaseOut (100U), and 
2.5ul of SuperScript III (500U) were added to each sample and the samples were incubated at 
42C for 30 minutes, 55C for 50 minutes, and 85C for 5 minutes. After the reverse transcription 
reaction, 1ul RNase H and 1ul of RNase I were added to each sample, followed by a 30 minute 
incubation at 37C. 
Samples were twice purified on DyeEx columns (Qiagen). cDNA samples were then Poly-
A tailed using the Helicos DGE assay reagent kit (Helicos, Cambridge MA), and the terminal 
transferase kit (NEB, Ipswich MA) as follows: 5ul Helicos Tailing control Oligonucleotide A was 
added to 20ul of each cDNA and the volume was adjusted to 35.5ul with water.  This mixture 
was then denatured for 5 minutes at 95C and placed directly on ice for 2 minutes.  Then, 5ul 
2.5mM CoCl, 5ul 10X terminal transferase buffer, 2ul Helicos polyA tailing dATP, and 1.2ul 
terminal transferase (24U) were added to each samples, followed by incubation at 42C for 
1hour, and then 70C for 10 minutes.  After the tailing reaction the samples were 3’ blocked as 
follows:  samples were denatured for 5 minutes at 95C and placed directly on ice for 2 minutes, 
300 pmoles biotin-dideoxy ATP (Perkin Elmer, Waltham MA) and 1.2ul terminal transferase 
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(24U) were then added, followed by 1 hour incubation at 37C, and a final 10 minute heat 
inactivation step at 70C. 3’ biotinylation of samples was used to assess sample molarity to 
inform HeliScope sample-loading for the sequencing reaction (according to manufacturer’s 
instructions). 
Alignment of reads 
The first read of AS read pairs was used in this study to compare to the single reads 
derived from SMS. SMS reads were aligned with the IndexDP aligner, while amplification-based 
sequencing reads were aligned with both the Bowtie and IndexDP aligners as shown in Figure S 
4. IndexDP alignments were filtered by NScore, defined as (5*#_match-4*#_error)/read_length) 
with a minimum of score 4, reporting at most 25 alignments per read. Reads between 24bp and 
57bp and 25bp and 64bp in length were used for sets 1 and 2, respectively. Bowtie was set to 
report alignments with at most two mismatches within a 32-base seed region, reporting at 
most 25 multiple alignments per read. The first base of all AS reads was trimmed to maximize 
quality. Single-best quality alignments were derived using Bowtie by setting the –best and –k 1 
parameters to report only the single highest quality alignment per read. Reads were aligned to 
the set of UCSC transcripts defined in hg18, downloaded from the UCSC Genome Browser at 
http://genome.ucsc.edu. Known contaminants were also included in the set of references. 
Bowtie alignments included references for mitochondrial DNA, adapter sequence, and 
ribosomal RNA. IndexDP alignments included references for poly-A, poly-T, poly-C, and poly-G 
oligomers. Re-alignment of AS reads using IndexDP was done using the same parameters as 
SMS reads, using the full length of the read. Reads from the PrCa sample were trimmed to 50bp 
from 75bp to meet technical limitations of the alignment program.  Sequence reads from this 
study have been deposited into the NCBI Short Read Archive with accession number 
SRA028835.1. 
Duplicate read removal 
Duplicate reads were removed from the data by analyzing the alignments to each UCSC 
transcript in the transcriptome reference. One read was allowed to align at each start locus 
(with and without consideration of read length). Reads with alignments to locations along the 
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reference transcript in excess to those were marked as duplicates and removed from the data 
set.  
Relative quantification of genes and coverage calculation 
Reads aligning to each UCSC transcript were counted at transcript level resolution and 
then summarized at the gene level using transcript to gene symbol mappings from the kgXref 
table downloaded from the UCSC Genome Browser at http://genome.ucsc.edu. Reads aligning 
to the known contaminant references were marked and not considered in the analysis. Genes 
were quantified using only the single-best mapping methodology. Single-best mappings were 
derived from IndexDP alignments by choosing alignments with the highest NScore, or an 
alignment randomly picked from the set of highest scores when multiple alignments are 
present with the same NScore value. Gene-level RPM values were derived by summing the 
number of aligned reads from each gene’s constituent transcript isoforms and dividing by the 
total number of usable reads. Read sums were calculated using R Statistical Environment [101]. 
RPKM values were computed for each observed UCSC transcript and summed for all isoforms of 
a gene to derive a gene-level RPKM expression value. Coverage levels were calculated by 
summing the read lengths of all reads aligning to all isoforms of each gene and dividing by the 
mean isoform length. 
Detection of genes observed in a single technology 
We derived a list of genes observed in only SMS or AS for the DU145 samples in this 
study by comparing the mean gene-level RPKM expression values of each pair of samples run 
on AS and SMS. A list of candidates was nominated by then sorting the list of genes with 
expression values above the noise threshold in SMS and below the threshold in AS by the 
observed differences. These genes were evaluated for mis-mappings by examining secondary 
and alternate alignments of the reads aligning to each candidate as shown in Figure S 16. The 
list was filtered to remove genes detected only by short reads and the top 50 remaining genes 
manually evaluated to have well-defined HUGO names, diffuse read distribution along the 
transcript length, and  the presence of long (>36bp) reads in both SMS technical replicates.  
Validation of Detected Single-Technology Transcripts by PCR 
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RNA was extracted from the cells using Qiazol based on Qiagen’s miRNeasy Minikit 
following the manufacturer’s instructions (Qiagen).  1 μg of total RNA was reverse transcribed 
into cDNA using SuperScript III (Invitrogen) in the presence of oligo dT and random primers. 
Quantitative PCR was carried out by Taqman assay method using gene specific primers and 
probes from the Universal Probe Library (UPL), Human (Roche) as the internal oligonucleotide, 
according to manufacturer’s instructions. GAPDH was used as housekeeping control gene for 
UPL based Taqman assay (Roche), as per manufacturer’s instructions.  
All assays were performed in duplicate using the primer sequences in Table S 8. 
Gene Ontology analysis of reads 
Gene Ontology (GO) analysis of over-represented genes was done in order to assess the 
most highly represented GO classes and determine the relative abundance of reads attributable 
to each GO class. This analysis was done with GeneCoDis2 tool [102]. Single GO classes resulting 
from this process were evaluated for their representation in terms of fraction of total 
sequenced reads across the 12-sample set. Relative representation  of reads attributable to 
each GO class was done by summing the number of single-best mapping alignments for each 
gene in each GO class as defined in the GO annotations for Homo Sapiens, downloaded from 
http://www.geneontology.org and dividing the total by the total number of reads in each 
sample.  
Gene fusion discovery in single-molecule sequencing 
The VCaP cell line was sequenced in two additional channels to evaluate the suitability 
of single molecule sequencing for the task of gene fusion detection. This was done by mining 
the reads in an effort to re-discover known gene fusions. All possible reads were first aligned 
against the transcriptome and genome using IndexDP. Non-mapping reads, which harbor 
chimeras, were subsequently aligned against the transcriptome returning those reads that had 
a partial alignment of at least 18 nucleotides. All reads having the same partial alignments, 
suggesting a common breakpoint, were clustered. All clusters were then compared to see 
determine if the overhang (portion of the read that fails to align) from one breakpoint region 
had similarity to the overhang of an independent breakpoint, thereby reconstructing the fusion 
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junction. Finally, all remaining non-mapping reads were aligned against the novel fusion 
junctions. This de novo approach enabled the re-discovery of the TMPRSS2-ERG gene fusion 




Chapter 3: A Framework for integrating transcriptome and proteome data 
 
Introduction  
mRNA transcript levels are often used in research studies as a rapid and simple measure 
of biological activity in cells, a proxy for protein abundance and activity. However, this 
relationship is complex – complicated by numerous external factors such as RNA translation 
rates and decay, degradation through the microRNA pathway, non-coding RNAs, and numerous 
post-translational modifications of protein products [103, 104].  
In the study described in the next two chapters, we use the VCaP and RWPE human 
prostate cell lines to study the transcript-protein relationship and extended the analysis to 
examine how that relationship is dysregulated in a cancer context. VCaP is derived from a 
vertebral metastatic lesion of a patient with castrate-resistant prostate cancer and serves as a 
model of prostate carcinoma; it expresses a large quantity of Prostate Specific Androgen (PSA) 
and Androgen Receptor (AR) and is known to be androgen-responsive [100]. RWPE serves as a 
model of normal prostate epithelium; it is derived from non-neoplastic prostatic epithelial cells, 
and is known to possess the characteristics of normal tissue [105]. 
In this chapter, we focus on addressing the challenges of quantification and integration 
of data from transcriptomic and proteomic experiments carried out using mRNA sequencing 
(“RNA-Seq”) and tandem mass spectrometry (“MS/MS”), respectively, and describe a novel 
methodology using a common sequence reference database with which we quantify relative 
abundance of transcript and protein in the VCaP and RWPE cell lines and analyze their 
relationship. With this methodology, we demonstrate how differing short read alignment and 
spectral counting methods and filtering processes impact the measurement of the transcript-
protein relationship.  
Background 
The correlation of protein and transcript levels is confounded by varying methodologies 
for identification, quantification, and data integration. The process of integrating this data 
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effectively is itself a topic of study [42, 47, 48, 106].  Early work studying this relationship relied 
on gel electrophoresis or liquid chromatography coupled with mass spectrometry (LC-MS) and 
microarrays to quantify transcript and protein abundances. Due to technical constraints, these 
studies were limited by the dynamic range of assay methodology and a small sample set of 
assay genes. The small, pre-selected gene sample sets typically found in these studies resulted 
in highly variable correlation measurements. 
Recent research examining the relationship between transcript and protein abundances 
has leveraged advances in next-generation sequencing to profile the transcriptome and higher 
throughput methods for proteome assessment to observe a more complete landscape of the 
cellular transcriptome and proteome [40, 107]. These studies have observed correlation 
between mRNA and protein abundance ranging from r = 0.3 to r = 0.6, examining 12,000-16,000 
mRNAs and 7,000-9,000 proteins in each sample. Previous studies focusing on smaller subsets 
of genes and other methods have shown more varied correlation values [43, 44, 108, 109]. A 
study combining  previously published isotope-labeled protein abundance values with separate 
RNA sequencing data in three cancer cell lines, A431, U251MG, and U2OS found transcript-
protein relationships in nearly 5,500 genes correlated at levels from r = 0.55-0.61., G-protein 
coupled receptors demonstrated the most disagreement in a focused examination of U2OS, a 
characteristic which they attributed to their limited ability to assay the protein products of this 
class of genes due to detection limitations [46, 110].  A similar study focusing on deeply 
profiling both the transcriptome and proteome in the HeLa cell line assembled an integrated 
dataset of approximately 8,600 genes, from which a correlation of r = 0.6 between transcript 
and protein levels was observed [40]. From this data, the authors estimated that a complete 
proteome comprised 10-12,000 genes in total. Most recently, a study profiled the proteome of 
the NCI-60 set of cancer cell lines and compared these profiles to microarray-derived mRNA 
abundance levels finding similar correlation levels [111]. The inclusion of all 59 NCI60 cell lines 
resulted in the largest dataset, comprising 10,350 genes, with an observed global correlation of 
r = 0.76. However, the number of proteins profiled in individual cell lines was much lower, with 
only 6,003 protein products seen in at least 5 samples, and the correlation between transcript 
and protein was noted to be lower in cancers with higher cellular heterogenity. 
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Results and Discussion 
RNA-seq and Proteomics Results 
To profile the transcriptome and proteome on a genome-wide scale, we use next-
generation mRNA sequencing (RNA-seq) and label-free tandem mass spectrometry (MS/MS). 
Our study is based on three replicate profiles of mRNA and protein of the VCaP and RWPE cell 
lines that were independently processed before integration in a database. To do an “apples-to-
apples” comparison of transcript and protein abundances, we assembled a common reference 
database derived from RefSeq containing 34,728 transcripts and matching protein sequences. 
This database of transcripts and corresponding peptide sequences was used to align RNA-seq 
reads and quantify peptides and proteins from MS/MS data (Figure 7). All data was collapsed to 
gene level granularity using a single representative transcript and protein isoform for each 
gene. This representative isoform was chosen as the highest abundance isoform observed in 
the proteome data across both cell lines, with transcript abundance used to break ties.  
Transcript data was summarized as the sum of all isoform read counts as a Reads Per Kilobase 
Million (RPKM) measure. Protein spectral counts were normalized by the length of these 
representative isoforms to produce a Normalized Spectral Count (NSpC) value for each gene.  
The RNA sequencing of three technical replicates of the VCaP and RWPE cell lines 
yielded a total of 15,998,482 and 14,887,668 reads for each cell line, respectively. MS/MS of 
three replicates each of VCaP and RWPE yielded a total of 557,642 and 606,145 peptide 
matching spectra, respectively. Our RNA-seq quantification had high correlation between 




Figure 7: Data Processing and Integration Pipeline. Three replicates of each sample were generated using MS/MS 
and RNA-seq and quantified against a common reference library of mRNA and protein sequences. Tandem mass 
spectrometry data were processed with the TPP and post-processed with Abacus to yield spectral count data. RNA-
seq reads were aligned to the common reference using Bowtie and post-processed with in-house Perl scripts to 
yield RPKM (reads per Kilobase million) quantification. 
Similarly, pair-wise correlations of spectral count between replicates in our MS/MS data 
show correlations of r = 0.97 in both the VCaP and RWPE replicates (Figure S 17). Quantification 
of protein abundance was performed using the Trans-Proteomic Pipeline (TPP) [112] and 





Figure 8: The data filtering and integration statistics producing the core and extended datasets. Data is merged 
to the gene level before filtering by FDR and integrated using 1% and 5% FDR thresholds resulting in the core and 
extended datasets, respectively. 
We used our False Discovery Rate (FDR) estimation procedure to threshold with which 
we filtered our data into two sets: a high-accuracy core dataset at 1% FDR to use for individual 
and set level analysis of genes, and a larger extended dataset at 5% FDR to use for correlation 
analysis (Figure 8). In our raw dataset, 13,130 and 14,741 genes were detected in either cell line 
at any level in the protein and transcript data, respectively. To achieve a 5% FDR in our 
extended dataset, we thresholded the minimum abundance to 1.8 and 3.6 RPKM for RNA-seq 
48 
 
data and minimum peptide probabilities to 0.9475 and 0.958 for protein data in VCaP and 
RWPE, respectively. Due to the high correlation between RWPE and VCaP in terms of both 
mRNA (r = 0.79, Spearman) and protein (r = 0.70, Spearman) abundance and common tissue of 
origin (
Figure S 18), we chose the extended dataset to include all genes which met the 5% FDR 
threshold in either cell line by either RNA-seq or MS/MS and was uniquely quantifiable by our 
proteomics approach. For our high-confidence 1% FDR core dataset, the abundance thresholds 
were set at 3.7 RPKM and 6.5 RPKM for RNA-seq data and minimum peptide probabilities of 
0.9855 and 0.9885 for VCaP and RWPE, respectively (Figure 9B and C,Figure S 19 and Figure S 
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20). To decrease noise in our fine-grained analysis, our core dataset also required detection of 
candidate genes at the 1% threshold in both the mRNA and protein data in either cell line. This 
process yielded a total of 10,938 unique genes in the 5% FDR extended dataset and 6,620 
unique genes in our 1% FDR core dataset. Overall, the large majority of genes were filtered out 
by lack of protein data passing our filtering thresholds and detection criteria. 
We used the extended dataset to examine the correlation between protein and 
transcript in both cell lines and observe how different alignment and counting methods for 
transcriptome and proteome data affect the relationship.  
Calculating FDR in transcriptome and proteome data 
To assess the false discovery rate (FDR) in our dataset, we followed a method similar to 
that of Ramskold, et al. [96] for the RNA-seq component of the study. Corresponding decoy 
intergenic sequences were sampled without replacement for each representative transcript in 
our database, for a total of 34,728 decoys. We aligned reads to the merged total set of these 
decoy and real mRNA transcripts. Abundance data was summarized at the gene level using the 
same transcript-gene mappings for both the real and decoy transcript set. FDR was calculated 
as the number of decoy genes detected divided by the number of non-decoy genes detected 
(Figure S 19). Across experiments in both cell lines, the decoy and real genes showed separated 
normal distributions, with decoys at a mean measured abundance of 0.46 RPKM and non-decoy 
genes at a mean abundance of 22.52 RPKM (Figure 9A). We did not find a bimodal distribution 
of transcriptome abundances as previously observed in other studies [113]. These studies have 
noted that a majority of the transcripts occupying the lower abundance peak are non-coding 
and small RNAs.  Hence we do not observe this due to our inclusion of only protein-coding 
genes in our common reference database. Using this methodology, we went on to examine 
how technical and methodological factors could be optimized in order to achieve the most 
accurate correlation betweenrelative transcript and protein abundances.  
We used the protein and peptide probability estimates provided by TPP and Abacus to 
control FDR in our protein data (Figure S 20). We used the peptide probability (independently 
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set according to our FDR thresholds) in combination with the protein probability (held at 0.9) to 
filter out noise in our proteome datasets (Figure 9B). Additionally, we marked and removed all 
keratin genes in an effort to reduce the number of known common contaminants in our data. 
Analyzing the impact of data processing methodology on correlation 
We used our extended dataset to characterize our experimental output in an effort to 
avoid including experimental noise in our analysis. In general, our RNA-seq data were more 
sensitive to low abundance elements than our protein dataset (Figure 9E). In both cell lines, of 
the transcripts detected at 4-8 RPKM in our extended dataset, we detect approximately 60% of 
the protein products from their cognate transcript. This number rises to 90% of the protein 
products for transcripts with relatively high abundance of more than 16 RPKM. Although both 
RNA-seq and MS/MS methods produce similar data with a similar distribution, this observation 
is expected, as our ability to observe the transcriptome at depth surpasses our ability to 
observe its corresponding proteome. Some of the detection characteristics are explained by the 
differing dynamic range of the MS/MS and RNA-seq methods and their efficiency at assessing 




Figure 9: Analysis of transcript and protein datasets. A. The distribution of real and decoy gene values. The mean 
abundance of all decoy genes is 22.52 RPKM while decoys have a mean abundance of 0.46 RPKM. B and C. True 
positive detections across FDR values in protein and transcript data.  D. Spearman correlation coefficient values for 
each alignment method and protein data reduction step in extended dataset. E. Protein detection at increasing 
transcript abundance levels. F. Distribution of RNA-seq reads and tandem MS spectra across all genes detected in 
the extended dataset for VCaP and RWPE. G. Most over-represented (as a fraction of all reads) Gene Ontology 




The impact of alignment and quantification methodology in RNA-seq 
Called multireads, a fraction of all transcriptome reads map to multiple locations [9]. 
While most of these reads map to a small number of locations, a few have a muchgreater 
number of candidate mapping loci. We speculated that the presence of repetitive elements 
found in many transcripts may confound accurate quantification of transcript abundance from 
RNA-seq through the highly ambiguous alignment of this subset of reads. In an effort to reduce 
this effect, we removed reads coming from known repeat elements in the human genome. We 
removed all reads aligning to RepBase H. Sapiens and simple repeat elements and repeated the 
analysis for all genes. On average, this process removed a mean of 9.6% and 12.6% of all reads 
across replicates of VCaP and RWPE, respectively. 
We also examined how our alignment and quantification methodology affected our 
correlation. Three transcriptome read alignment methods were evaluated to determine which 
best captured the relationship between transcript-protein with the hypothesis that 
concordance correlates with the performance of each methodology. Each of these alignment 
and counting methods resulted in a different number of reads assigned to each transcript 
(Figure S 22). The “unique” alignment policy is the most restrictive; where reads are required to 
map uniquely to a single position in the reference database. The “single best” alignment policy 
assigns reads to the best quality alignment among all found alignments as determined by the 
Bowtie aligner. The “all” alignment policy assigns reads to the best alignments up to 255 
locations. In general, correlations between mRNA and protein were better in VCaP than in 
RWPE and are used for comparison. Correlations were computed from log2-tranformed values 
(Figure 9D). The Spearman correlation derived from the gene abundances determined using the 
unique method was the poorest at r = 0.32. While the “all” policy produced a reasonable 
correlation level of r = 0.48, the false discovery rate of the method was extremely high. The 
“single best” method we chose to use produced results yielding r = 0.55 and r = 0.46 for VCaP 
and RWPE, respectively. The high FDR of the “all” method led us to hypothesize that repetitive 
elements in the transcriptome confounded the abundance calculation by dispersing many non-
unique reads onto many transcripts. Removal of these elements from the underlying 
transcriptome data yielded a negligible increase in correlation. Recent studies have suggested 
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that UTR elements in the transcriptome also confound accurate quantification of mRNA 
transcript abundances [96]. With that consideration, we also evaluated the effect of removing 
UTR sequences and reads that align to these regions from our abundance calculations. Removal 
of UTR reads in addition to repeat elements led to a small increase in correlation in both VCaP 
and RWPE with increases to r = 0.59 and r = 0.48, respectively.  
Processing of the RNA-seq data using the TopHat and Cufflinks suite of tools [55] yielded 
somewhat lower correlation, with Spearman r = 0.57 and r = 0.48 for VCaP and RWPE, 
respectively. Further analysis was carried out using our in-house tools as it allowed for more 
fine grained measurement and control over read mapping and counting. 
Filtering out multiple assignment of spectra in proteomics data 
Proteome data was filtered in an attempt to exclude quantification artifacts due to 
proteins that were indistinguishable based on the observed peptides, which leads to the 
assignment of spectra to both candidates. We used our process to eliminate the double 
counting of spectra inherent in this type of quantification.  This was done by choosing the 
protein with the highest peptide probability between proteins which are otherwise 
indistinguishable. Ties were broken by choosing proteins with the highest mRNA abundance 
value. The same was done between indistinguishable isoforms of a given protein based on 
spectral count with ties broken by mRNA abundance. Removal of quantification artifacts 
between like proteins to create a non-redundant set increased the correlation to r = 0.59 and r 
= 0.49 in VCaP and RWPE, respectively. We then created a reduced non-redundant set through 
the removal of artifacts from isoform uncertainty, which further increased the Spearman 
correlation to r = 0.61 and r = 0.51 in VCaP and RWPE, respectively. This non-redundant set was 
used for further analysis. 
Distribution of reads and spectra in the VCaP and RWPE datasets 
In both the transcriptome and proteome, a relatively small number of genes encompass 
the large majority of transcripts and proteins in a cell. As a result, a majority of machine 
dynamic range is concentrated on this small number of genes. In both cases, this concentrated 
allocation of dynamic range also means that the majority of transcripts and proteins are poorly 
54 
 
covered by reads and peptides (Figure S 23, Figure S 24). However, there were distinct 
differences between the two cell lines in our study in both proteome and transcriptome data. 
The distribution of reads in the VCaP and RWPE transcriptome data show marked differences 
(Figure 9F, Figure S 25); the top 30 highest abundance genes in VCaP comprised 25% of the 
total read density. To reach the same approximate total read density, the RWPE transcriptome 
data comprises the 75 highest abundance genes. This difference is attributable to the over-
expression of a set of genes associated with the VCaP cell line’s cancer origin. In contrast, the 
protein data showed a more similar distribution of abundance between the two cell lines. The 
difference is smaller in the protein data; in both VCaP and RWPE, the top 25% of peptide 
density is attributable to the top 71 and 102 genes, respectively. This is partially attributable to 
the use of dynamic exclusion in our protein data set, used to increase proteome coverage at the 
cost of reducing measurement accuracy at the highest end of the quantitative dynamic range. 
To examine the impact of the highest abundance genes in the context of dynamic range, we 
removed the top 100 most abundant genes and examined the distribution of remaining reads 
and spectra across the genes. This removal process had a much larger effect in the 
transcriptome data, bringing the distribution of reads over the dataset genes for VCaP closer to 
that observed in RWPE. 
We then sought to examine how the relative makeup of the underlying proteome and 
transcriptome data may better explain these distributions. By ranking Gene Ontology classes in 
terms of relative read and spectral fraction without normalization, we observed a 
compositional divergence in the underlying data in our transcript and protein datasets (Figure 
9G, Table S 9). The set of classes where transcript reads composed the largest relative 
proportion of the underlying data was dominated by translation associated classes such as 
translational elongation (GO:0006414) and gene expression (GO:0010467). A large number of 
reads in our transcriptome data were ribosomal in origin, explaining the heavy representation 
of these classes in the ranked list. To see if these ribosomal genes explained a large proportion 
of the observed differences, we removed them and reassessed the distribution (Figure S 25, 
Table S 10).  
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Our proteome data shows the use of a whole-cell lysate, with the largest fraction of 
genes annotated to the cytoplasm. With a mean of 1,594 observed genes, the topmost seven 
classes found in the high relative protein representation list tend to be significantly larger than 
those found on the high relative transcript enrichment list (which have a mean observed size of 
only 164 genes). This is consistent with the observation that proteins in general have longer 
half-lives in the cell, and are therefore more likely to be observed [60].  
Conclusion 
In this work, we describe a methodology for integrating transcriptome and proteome 
data in a manner that matches the reference transcriptome to the reference proteome, 
resolving a fundamental data mismatch issue that affects a number of previous studies to date. 
This is among the first studies to analyze the impacts of methodological differences in the 
quantification and filtering of transcriptome and proteome data. We demonstrate some of the 
sources of uncertainty that may degrade the fidelity of the observed transcript-protein 
relationship. Focusing on transcriptome data, we show that the treatment of ambiguously 
mapping multireads has significant effects on the derived transcript abundances, and 
downstream protein correlation. Looking at protein data, we show how filtering out artifacts 
stemming from the multiple assignment of spectra leads to a modest increase in the transcript-
protein correlation.  
This study is limited by a small number of samples, and the lack of biological replicates 
with which we can better define the inter-sample variances in transcript and protein. Future 
investigation into optimizing the integration of transcriptome and proteome data can leverage 
the increasing availability of publically accessible RNA-seq and tandem mass spectrometry data 
for large cohorts of samples. This increased sample heterogeneity will allow for better 
assessment of aberrations that arise from the highly variable transcriptomic and proteomic 
landscapes ultimately leading to more optimal methodologies. 




The benign immortalized prostate cell line RWPE was obtained from the American Type 
Culture Collection (ATCC).  VCaP cell line was derived from a vertebral metastasis from a patient 
with hormone-refractory metastatic prostate cancer [114], and was provided by Ken Pienta 
(University of Michigan, Ann Arbor, MI).   
Protein sample preparation 
Collection of VCaP and RWPE whole cellular protein extract was done in RIPA complete 
buffer supplemented with HALT Protease and Phosphatase Inhibitor Cocktail (Peirce 
Biotechnology).  Total protein extract was quantified with bicinchoninic acid.  50 mg aliquots of 
total cellullar proteins were first separated by 1D SDS-PAGE (4-12 % Bis-Tris Novex-Invitrogen, 
Carlsbad, CA).  Forty equal sized gel bands were excised and subjected to in-gel digestion as 
previously described [115].  Extracted peptides were reconstituted with mobile phase A prior to 
on-line reverse phase nanoLC-MS/MS (LTQ-Velos with Proxeon nanoHPLC, ThermoFinnigan).   
Peptides were eluted on-line to the mass spectrometer with a reverse phase linear gradient 
from 97 % A (0.1 % Formic acid in water) to 45 % B (0.1 % formic acid in acetonitrille).   Peptides 
were detected and fragmented in the mass spectrometer in a data dependent manner sending 
the top 12 precursor ions, excluding singly charged ions, for collisional induced dissociation.  
Raw spectra files were converted into mzXML by an in-house version of ReAdW.   
Parsing of transcript and protein sequence data 
The Genbank formatted flat files for the Human transcripts and proteins of RefSeq 
release 47 were parsed into a MySQL relational database using in-house software. For this 
extraction, only entries that had both a transcript and a corresponding protein product were 
considered.  The data extracted included paired transcript and protein identifiers along with the 
gene symbol of each pair.  Sequence information for both transcripts and their protein products 
were also extracted.  
Mass spectrometry and subsequent proteomic analysis 
ThermoFisher RAW files for all replicates were converted to mzXML file using msconvert.exe 
from the Proteo-Wizard suite [116]. Protein searches were performed using X!Tandem with the 
K-score plugin [117, 118].  The data was searched against the proteins of Human RefSeq 47 
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along with common proteomics contaminant proteins.  Reversed protein sequences were also 
included as decoy entries.  The X!Tandem results were post-processed using PeptideProphet 
and ProteinProphet (version 4.4.1). [56, 119, 120].  
Bioinformatics analysis of proteomics data 
A summary ProteinProphet XML file was generated from all of the independent 
PeptideProphet results as described for Abacus [57].  All of the PeptideProphet and 
ProteinProphet XML files were subsequently parsed into a MySQL relational database using in-
house software. 
Abacus was used to obtain a gene-centric summary of the total spectral counts across all 
three replicates of each cell line.  The Abacus results were then imported into the MySQL 
database. Parameters used for Abacus were: iniProbTH >= 0.5, minCombinedFilePw >= 0 and 
maxIniProb >= 0.5. Gene Symbol mappings for each protein were obtained from the RefSeq flat 
files described above.  
Decoy protein matches were also imported into the database as "decoy-gene" entries. 
These entries were used to compute false discovery rates (FDR) of the gene-centric proteomics 
data.  
Three probabilities were examined to determine which one provided the best 
discriminatory power between real genes and decoys.  The FDR was computed using: 
bestMaxIniProb, bestMaxPw, and bestLocalPw.  bestMaxIniProb is the maximum maxIniProb 
value observed among the all of the replicates. bestMaxPw is the maximum group probability 
observed for the gene from among all of the replicates. The bestLocalPw is the maximum 
protein probability observed for the gene from among each replicate.  bestMaxIniProb was 
selected as the best discriminator at FDR cut offs of 0.05 and 0.01. 
RNA-seq expression data 
RNA-Seq library generation and sequencing 
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Messenger RNA (2 µg) was fragmented at 85°C for 5 min in a fragmentation buffer 
(Ambion) and converted to single stranded cDNA using SuperScript II reverse transcriptase 
(Invitrogen), followed by second-strand cDNA synthesis using Escherichia coli DNA polymerase I 
(Invitrogen). The double stranded cDNA was further processed by Illumina mRNA sequencing 
Prep kit. Briefly, double-stranded cDNA was end repaired by using T4 DNA polymerase and T4 
polynucleotide kinase, monoadenylated using an exo minus Klenow DNA polymerase I (3′to 5′ 
exonucleotide activity), and ligated with adaptor oligo mix (Illumina) using T4 DNA ligase. The 
adaptor-ligated cDNA library was then fractioned on a 3% agarose gel, and fragments 
corresponding to 280–320 bp were excised, purified, and PCR amplified (15 cycles) by Phusion 
polymerase (NEB). The PCR product was again size selected on a 3% agarose gel by cutting out 
the fragments in the 300 bp range. The library was then purified with the Qiaquick Minelute 
PCR Purification Kit (Qiagen) and quantified with the Agilent DNA 1000 kit on the Agilent 2100 
Bioanalyzer following the manufacturer's instructions. The resulting library (5–8 pM) was used 
to prepare flowcells. Sequencing was done on an Illumina Genome Analyzer to produce single 
reads of 36 to 40bp. 
Transcript quantification by RNA-Seq 
We constructed a reference database composed of representative RNA sequences from 
RefSeq v47, matching decoy sequences, and known contaminants. Reads were aligned to this 
reference database using Bowtie version 0.12.5 using three alignment parameter sets, all 
allowing for two mismatches within a 32 base pair seed region. The “unique” alignment policy is 
the most restrictive; we require reads to map uniquely to a single position in the reference 
database using the arguments "--best -k 1 -m 1." The “single best” alignment policy assigns 
reads to the best quality alignment among all found alignments as determined by Bowtie using 
the arguments "--best -k 1." The “all” alignment policy uses the arguments “--best -k 255” to 
yield alignments to the best 255 locations. 
Reads mapping to repeat regions were removed by alignment to the set of RepBase 
v16.05 Human and simple repeats with Bowtie 0.12.5 without allowing for alignment 
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mismatches within a 32bp seed region. This process yielded a set of FASTQ files with reads 
stringently mapping to these known repeats removed.  
Expression values in terms of Reads per Kilobase per Million reads (RPKM) were computed for 
each transcript including and excluding reads that mapped to 5’ and 3’ untranslated regions 
(UTRs) and adjusting for the presence and absence of these UTR regions in the total length of 
the transcript. Lengths for 5’ and 3’ UTRs were computed by counting UTR sequence lengths 
downloaded from the UCSC Table Browser (http://genome.ucsc.edu/cgi-bin/hgTables) for each 
representative RefSeq transcript.  
Reads were mapped to the hg19 genome build using TopHat 1.4.0 using an annotation 
file containing all refSeq transcripts. FPKM measures were generated using Cufflinks 1.4.0 with 
multi-read correction enabled, using the same annotation as supplied to TopHat, masking out 
all genes on chrM as well as all rRNA and tRNA genes in the genome. Cufflinks was run using the 
“-G” option to limit quantification to genes in the annotation file. FPKM values for genes with 
the same name in the genes.fpkm_tracking file were summed to yield a gene-level list of 
abundance values. These results were merged with proteomics data on the basis of gene name 
or RefSeq isoform id. Abundance data were thresholded to exclude genes with FPKM values 
less than 0.3. 
Generation of Decoy Transcripts and Computation of False Discovery Rate 
Using a method similar to that of Ramskold, et al [96], a False Discovery Rate (FDR) was 
computed by aligning reads to transcripts and decoy sequences of matched lengths and 
computing the difference between the number of transcripts and decoys seen at varying RPKM 
expression thresholds. Decoy sequences were derived from sub-sampling intergenic regions of 
hg19 outside of gene annotations from RefSeq, UCSC, and Ensembl and outside known 
sequencing gaps.  
Comparison of RNA-seq data with spectral counts 
Consolidation of ambiguous transcriptional evidence 
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All transcripts had five expression values calculated for them: raw, reads-per-million, 
RPKM, RPKM excluding repeats, and RPKM excluding reads mapping to UTRs and repeat 
regions. Expression data for multiple transcripts sharing a common gene symbol were collapsed 
into a single gene entry.  Two different methods of collapsing the expression data were 
employed.  For the 'all' data category, the maximum observed value (for each expression 
calculation) was selected from all transcripts of a gene.  For the 'unique' or 'single best' data 
categories, the sum of the observed values for all shared transcripts was taken. 
Assignment of representative transcript and protein identifiers 
For each gene symbol with valid spectral count data, a representative protein identifier 
was selected. In cases where a gene symbol had multiple proteins associated with it, the 
protein with the largest number of unique spectral counts was selected. Ties were broken 
based upon the alphanumeric sorting of the remaining candidate protein identifiers and 
selecting the first one. The representative transcript for a gene symbol was taken to be the 
parent transcript of each representative corresponding protein.  
Selection of candidate genes common to transcript and proteomics data sets 
Two data sets were derived from unfiltered data at FDR levels of 1% and 5% using 
different metrics for quantification accuracy. The 5% FDR dataset was derived by filtering for 
genes with a bestLocalPw >= 0.9 and a bestMaxIniProb >= 0.9475 and 0.958 for protein data, or 
a minimum RNA-seq abundance of 1.8 and 3.6 RPKM, in VCaP and RWPE, respectively. 
Candidates in this data set had to match one of these 5% thresholds in either the protein or 
mRNA data to be included in the dataset.  The 1% FDR dataset was derived by requiring the 
gene to meet the 1% FDR criteria in both our RNA-seq and protein data in either cell line. A 
simple filter for keratins (a common artifact in tandem MS experiments) was applied by 
marking and removing genes with names matching “KRT” followed by a number.  
Correlation of transcript expression with spectral count data 
The final data sets used for analysis were derived from the repeat-removed sequence 
files, aligned using the single-best policy, and excluding UTR reads from quantification. For all 
candidate genes, the spectral counts were averaged together for each cell line using the mean.  
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The averaged spectral counts for each gene were then converted to NSpC values (normalized to 
the length of the representative protein identifier) using R [121]. Correlations were computed 
between log2-transformed RPKM and NSpC values, excluding values that were incomplete 





Chapter 4: The transcript-protein relationship in human prostate cancer 
 
Introduction 
Prostate cancer is the most common cancer afflicting men, with a 1 in 6 lifetime risk of 
the disease in the United States [122]. Its prevalence has made prostate cancer a subject of 
extensive molecular profling at the genome, transcriptome, and proteome levels. However, few 
studies have investigated the transcript-protein relationship in prostate cancer. Previous 
research in various human cancers using lower-throughput methods have specifically noted 
discordance in relative mRNA and protein abundance [41], including numerous dysregulated 
pathways in prostate cancer with mRNA-protein correlation at varying levels up to r = 0.68 
[123]. These pathways include functionally important molecular networks and pathways such 
as nF-kB, which mediates immune response, apoptosis, and inflammation and insulin signaling. 
More focused studies on specific genes have noted discordance in transcript-protein 
relationships in a number of cancers;  endometrial carcinoma where urokinase and tissue 
plasminogen activators were noted to diverge [124], acute myeloid leukemia where the 
transcript and protein expression of the breast cancer resistance protein ABCG2 was observed 
to be uncorrelated [125], and colorectal cancers where the transcription factor AP-2 (TFAP2A) 
was observed at moderate abundance at the transcript level while showing no protein 
detection [126]. Altogether, these studies suggest that dysregulation of the transcript-protein 
relationship may be a marker for the establishment and/or progression of cancer. 
The majority of previous genome-scale studies examined the relationship between 
transcript and protein within the context of single cell lines. In general, there has been a paucity 
of research leveraging ultra-high throughput technologies to assess the relationship between 
mRNA and protein abundance in the context of human cancers.  
Here, we use the VCaP and RWPE prostate cell lines as models for cancer and normal 
prostate epithelium. Using the abundance values derived from the method described in 
Chapter 3, we classify genes into functionally discrete categories based on their relative 
transcript-protein relationships within each of these cell lines and examined the impact of 
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protein and transcript half-life on this relationship. We then compared the relative transcript-
protein relationships across our two cell lines. Through this process, we identified genes where 
this relationship becomes dysregulated in our cancer model using novel discordance and 
concordance index values. We coupled the results of this analysis with the human protein 
interaction network and demonstrate how several biological processes closely interlinked with 
the Akt signaling pathway show transcript-protein relationship dysregulation in our cancer 
model. Additionally, we demonstrate how the integrative analysis of both transcriptome and 
proteome leads to insights about the variance in the proteome and transcriptome, and how 
these changes lead to discordance in the transcript-protein relationship.  
Results and discussion 
Transcript and Protein abundance in each of the cell line models 
To determine some of the biological factors that affect the transcript-protein 
relationship, we chose to separate the genes into approximate subsets based on their relative 
transcript and protein abundance. In order to capture genes that are otherwise ignored due to 
measurements of zero, we added a small adjustment factor of 0.2 to the RPKM and NSpC 
values before log2 transformation in this analysis. We divided the genes in VCaP and RWPE into 
four broad subsets based on the relationship we observed between protein and mRNA 
abundance (Figure 10A, Figure S 26, Table S 13). This was done by choosing genes 1.5 standard 
deviations away from the best fit line (ignoring points that have values less than 0.3 RPKM or 
NSpC) between mRNA and protein, and sub-selecting sets of genes that also showed a log2 
normalized spectral count or RPKM values less than 0.3 RPKM or NSpC. These thresholds 
ensured that we selected for two conceptual classes of genes: those that had significant 
differences in transcript and protein abundance and those which were only detected by a single 
method. Genes in each of these broad subsets were analyzed with DAVID to examine their 
functional composition with GO. 
The first two of these four subsets consisted of genes with higher protein or mRNA 
abundance with both detected. The latter two subsets yielded genes with either high protein or 
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mRNA abundance but little or no observed abundance of the corresponding transcript or 
protein. While many of the genes segregating into each of these broad sets are driven by 
functional biology, a subset are mis-categorized due to technical factors; in particular our 
limited ability to capture, detect, and quantify some genes. For example, genes with relatively 
high protein but very low mRNA abundance tended to be contaminants such as keratin typical 
of MS experiments of this kind, usually introduced during the sample handling process common 
to MS experiments [127]. This is reflected by the presence of classes such as keratinocyte 
differentiation in this class, even despite our effort to filter out the effect of these contaminants 
from our dataset (see Methods). An additional example is the well-known bias against 
membrane proteins [128, 129] in MS/MS experiments due to their low solubility resulting in 
their under-representation in the data. Biological factors that underlie some of these observed 
differences include different rates of transcript and protein turnover, which affects our ability 
to measure these genes.  
Genes with high mRNA abundances and little or no observed proteins tended to fall into GO 
classes such as regulation of transcription, composed of genes with low relative abundance or 
short half-lives, such as transcription factors. This class is larger than the corresponding class of 
genes with high protein but almost no detectable transcript, likely due to our ability to probe 
the transcriptome more deeply than the corresponding proteome with our data.  
Genes with higher levels of mRNA than protein encompassed some of the same transcription-
associated classes, although this group also composes a large abundance of ribosomal genes 
commonly found in mRNA as well as transporters. This category shows some of the classes not 
elucidated by previous studies using array-based techniques for profiling the transcriptome, 
due to the limited dynamic range of those methods. Genes with high protein but more modest 
amounts of mRNA were largely contained genes associated with the cytoskeleton and 
microtubules – this is expected as these proteins tend to be highly stable. This association of 
metabolic and structural component class genes with higher relative protein to transcript levels 
(compared to the association of regulatory genes to the converse group), along with the 
observation that these proteins are more long-lived than their associated transcripts, is 
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consistent with the concept that this core functionality of the cell is less subject to variation 
than genes with regulatory function [110, 130].  
Transcript-protein relationships within biological classes 
The correlation between transcript and protein abundance in cells is affected by many 
intermediary factors involving transcript and protein structure [131], translational delay [132], 
stability, and degradation. Correlation was calculated using the 5% FDR extended dataset. From 
the baseline Spearman correlation of r = 0.61 and r = 0.51 in the VCaP and RWPE cell lines, 
respectively, we attempted to find biological classes which exhibit relatively high and low 





Figure 10: Analysis of the transcript-protein relationship in VCaP and RWPE. A. Division of genes by relative 
protein-transcript relationship with zero values. B.  Plot of cancer-related GO class genes of interest. C. 
Relationship between GO class size and transcript-protein Spearman correlation coefficient. D. Relationship 
between transcript and protein abundance per Gene Ontology class. E. Distribution of transcript stability used to 
segment extended dataset into high and low stability sets. F and G. Correlation of transcript and protein levels for 




We first examined the distribution of genes in several cancer-related classes of interest - in 
particular kinases (and subclasses thereof) which often act as drivers in cancer (Figure 10B, 
Table S 11, Table S 12). As mediators of the cell cycle, kinases are frequently altered in cancers 
and can drive oncogenic processes. As a result, they are the focus of many targeted cancer 
therapies [133]. We examined the correlation and distribution of this class of genes (defined as 
genes mapped to GO Class GO:0016301 “kinase activity”), and obtained a correlation of r = 0.61 
and r = 0.44 with observations of 87 and 88 genes (out of 581 total annotated to the GO class) 
in VCaP and RWPE, respectively. The difference in correlation between the cell lines is likely 
attributable to the greater mean abundance of protein products in VCaP, measured at 2.89 
NSpC compared to 1.78 NSpC in RWPE, leading to better quantification accuracy.  
We also examined the class of transcription factors that affect cell signaling and proliferation. 
Relatively few genes observed in our extended dataset are annotated in GO as transcription 
factors, with a total of only five genes annotated to protein binding transcription factor activity 
(GO:0000988). This is likely due to the relatively low abundance of both transcript and protein 
of many of the genes in this class, resulting in their exclusion from our datasets. This small 
number of observations therefore led to the class being excluded from our GO analysis. The 
genes in this class that we observed; PITX1, HMGA2, HEY1,SMAD4,and LHX2,  were expressed 
relatively higher in our RWPE cells compared to our VCaP cancer cells, with a mean of 27.14 and 
12.82 RPKM, respectively. At first glance, we might expect that the increased transcriptional 
activity in cancer cells would imply increased abundance of transcription factors. However, 
these results are consistent with the observations in a number of published studies; the gene 
PITX1 [134]  was noted to be lower in prostate cancer cells compared to normal, HEY1 is 
excluded from the nucleus in prostate cancer tissues [135], and SMAD4 acts as a barrier to the 
growth and progression of prostate cancers [136]. Since the mechanism of action of these 
genes implies that they act as transcriptional repressors, it is not surprising that their levels are 
down-regulated in cancers.  
We then conducted a more unbiased analysis of the dataset using all Gene Ontology classes 
with 10 genes or greater observed in our dataset and calculated the Spearman correlation, the 
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associated p-values, and the mean abundance of transcript and protein for the genes in each 
class. The correlation within these classes scales with class size approaching the mean dataset 
correlation coefficient of r = 0.61 (Figure 10C) in VCaP as class sizes become large. Much of the 
variation in the data is seen in GO classes containing 16 or fewer observed genes. Previous 
studies have noted that the proteome exhibits a larger number of significantly differential 
genes in cancer than the transcriptome [137]. To examine whether the large differences in 
correlation in small GO classes was driven by larger proportional membership of significantly 
differential genes, we compared the mean protein abundance and the protein-transcript 
correlation p-value. The large variation in transcript-protein correlation within each GO class 
appeared to be an effect of sample size, as the Pearson correlation between the two factors in 
each class was r = -0.03 in VCaP and r = -0.05 in RWPE. A similar observation was made that 
higher transcript-protein correlations are seen in gene subsets with higher abundance [138]. 
Pearson correlation between the mean protein and transcript abundance in each GO class and 
Spearman correlation value yielded r = 0.12 and r = 0.04 in VCaP and r = 0.07 and r = 0.07 in 
RWPE, respectively. 
To study the genes in our dataset on the basis of biological function and localization, we 
analyzed the values by the median abundance of protein and transcript within individual Gene 
Ontology categories (Figure 10D). The most obvious outliers are members of ribosomal small 
subunit biogenesis and cytosolic small ribosomal subunit classes, with a very high relative 
transcript/protein ratio that reflect the large abundance of ribosomal gene mRNAs in our 
transcript data.  
The impact of stability in the transcript-protein abundance relationship 
Protein and transcript stability have been noted in the literature to have a significant impact on 
the relationship between transcript and protein abundance levels, and the effect is clearly 
visible in our dataset (Figure 10E). Using transcript and protein stability data from 
Schwanhäusser B, et al. [60] derived from NIH 3T3 mouse fibroblast cells, we assigned 
transcript and protein stability to the genes in our dataset through orthology. We separated the 
genes in our dataset into high and low transcript and protein stability groups by selecting one 
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standard deviation tails of the z-normalized stability distribution in each of the two cell lines. 
The differences in transcript-protein correlation between the high and low stability groups on 
the basis of transcript stability are the most marked. In VCaP, the correlation for the low and 
high stability transcripts is r = 0.404 and r = 0.71, respectively (Figure 10F-H). The difference is 
similar in RWPE where the correlation is r = 0.288 and r = 0.543 for the low and high stability 
transcripts, respectively. When comparing low and high stability groups on the basis of protein 
stability in the two cell lines, the difference is smaller with r = 0.419 and r = 0.572 for RWPE and 
r = 0.441 and r = 0.799 for VCaP for low and high stability proteins, respectively (Figure S 27 and 
Figure S 28). 
Comparison of VCaP and RWPE cell lines 
To examine aberrations in the protein-mRNA abundance relationship specific to cancer, we 
compared the relative transcript - protein ratios between the VCaP and RWPE cell lines. We 
applied our core dataset to ensure accurate gene level quantification.  
For functional analysis, we selected the most concordant and discordant genes. In the large 
majority of cases, the relationship between transcript and protein abundance between the two 
cell lines is unchanged. For this purpose, the data were analyzed along two axes to measure the 
genes with the most concordant and most discordant transcript-protein relationships (Figure 
11A). The genes with the highest transcript-protein concordance were found by using an index 
value derived from adding the normalized RPKM transcript fold change value to the normalized 
protein fold change abundance value between VCaP and RWPE (as described in Methods). The 
most discordant genes were found by the derivation of a similar index value of the normalized 
protein abundance subtracted from the normalized RPKM transcript value. The index values 
where both z-transformed and p-values were computed using these scaled distributions of 




Figure 11: Detecting Dysregulation of transcript-protein relationships in prostate cancer. A. z-transformed fold 
changes of transcript and protein observed between VCaP and RWPE and major Gene Ontology class clusters in 
red and orange classes, corresponding to enrichment in protein and transcript abundance, respectively. 
Representative GO classes for each annotation cluster were chosen by examining overlap between DAVID clusters 
and LRPath results with FDR ≤ 0.05, in order of observed genes B. Number of GO classes resulting from LRPath 






Ontology and pathway analysis with concordance and discordance indices 
LRPath was used due to its ability to evaluate enrichment of classes and pathways in aggregate 
without requiring the use of cutoff values [139]. This is particularly important in our analysis of 
genes nominated by our index values as significance cutoff thresholds are not well defined. 
Although it relies on the use of cutoff values, we also applied DAVID [140, 141] to our dataset to 
leverage it’s clustering of resultant classes. For consistency with our previous analysis looking 
within each cell line, we selected genes using a 1.5 standard deviation cutoff from perfect 
concordance and discordance. 
Analysis using our discordance and concordance indices in LRPath produced 727 and 619 GO 
classes and 114 and 56 Biocarta and KEGG pathways with a p-value ≤ 0.05 in VCaP and RWPE, 
respectively (Table S 14, Table S 15). The selection of identical classes in both of these classes 
led us to evaluate the effects of this gene overlap between high correlation and high anti-
correlation due to our selection process. Genes typically considered significant (p <= 0.05) by 
the discordance index had their p-values adjusted to non-significant values when they were 
also in the significant tail distributions of the genes in the concordance index. The dataset with 
these modified p-values was re-analyzed with LRPath. Major themes from our primary analysis 
remained statistically significant, suggesting that the effect of genes in overlapping regions is 
relatively small. The majority of classes we observed to be significant in our initial analysis 
demonstrated increased statistical significance. With this subtraction of overlapping genes, the 
discordance and concordance indices produced a respective 619 and 599 GO classes as well as 
114 and 56 KEGG and Biocarta pathways with a p-value ≤ 0.05 . While the reduction of 
overlapping classes between the highly concordant and discordant class sets was relatively 
modest (Figure 11B), we chose to use this dataset for further analysis in an effort to minimize 
noise data in our analysis. 
DAVID clustering of the same GO classes and pathways from Biocarta and KEGG revealed that 
many of our resultant classes fall in a small number of biological themes. We used our DAVID 
results to guide our manual classification of discordance-derived LRPath results into broad 
biological categories. In the case of where protein levels are overabundant, we see broad 
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classes of protein metabolism and modification, cell cycle and structure, ion binding, and 
GTPase regulation. In the converse case, we see the broad clusters including classes associated 
with the cell membrane, mitochondria and energy metabolism, phosphorylation, and lipid 
metabolism.  
 
Figure 12: The dysregulated networks surrounding Akt. A. Network closely linked to Akt formed by genes 
constituting the GTPase regulator activity, polyol metabolic process, guanyl-nucleotide exchange factor activity, 
and regulation of immune response classes. B and C. Distribution of genes in the GTPase regulator activity and 
activation of immune response Gene Ontology classes highlighted in red in the context of all dataset genes. 
73 
 
The sets of discordant genes were of particular interest as they suggest a number of biological 
processes are dysregulated on a post-transcriptional level. Correlation analysis of fold changes 
by Gene Ontology class in this set of genes finds a number of processes in the two cases where 
the transcript-protein relationship is significantly dysregulated in VCaP compared to RWPE. 
Similar to our correlation analysis of transcript and protein abundance within each cell line, we 
observed a correlation between GO class size and Spearman correlation coefficient with higher 
variance coming from smaller classes. As expected, the set of correlation values has a roughly 
normal distribution centered on the correlation coefficient of r = 0.42 for the broader dataset. 
This pattern holds when we separate the resultant classes by GO tree as well. Because of the 
correlation between GO class size and the resultant observed correlation, we thresholded the 
classes to exclude those with less than 10 observed genes. The most concordant and discordant 
GO classes by tree  can often be explained by the differing stabilities of the protein and mRNA, 
such as the classes involving genes associated with cell spindle and microtubules which have 
very long half-lives. In these two examples, structural role of the protein yields higher stability 
leading to higher abundance than the comparatively shorter-lived complementary mRNA.  
Using this correlation data, we examined GO classes with below-mean correlation coefficients 
between cell lines and ranked them by the difference in correlation between VCaP and RWPE. 
This nominated candidate classes that showed large differences in correlation where the 
transcript-protein relationship was drastically altered. This set included a number of voltage-
gated ion channel classes and the smoothened signaling pathway.  The presence of the ion 
channel classes reflects the activity of voltage-gated potassium and sodium channels observed 
to play a role in the growth and metastasis of prostate cancer cells [142-144]. The genes in 
these classes go from highly correlated in RWPE, with Spearman correlation coefficients in the r 
= 0.8 range, to essentially uncorrelated (Spearman correlation falling to the r = 0.1 to 0 range) in 
VCaP. Similarly, correlation of the genes in the smoothened signaling pathway goes from r = 
0.77 in RWPE to r = -0.03 in VCaP. The Smoothened (SMO) gene itself is known to act as an 
oncogene, and this pathway is known to stimulate hedgehog signaling, which is noted to be 
activated in advanced and metastatic prostate cancer [145, 146] and is associated with 




Figure 13: Insights from joint transcriptome-proteome analysis. Heatmap of log-odds ratios for KEGG and Biocarta 
pathways with p-values ≤ 0.05 in each of four categories – results derived from protein only, transcript only, 
discordance index, and concordance index data. 
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Dysregulation of the transcript-protein relationship surrounding Akt 
A common thread we observe in our results is the association of a number of deranged 
pathways and processes upstream and adjacent to the PI3K/AKT signaling pathway, which plays 
a role in several biological processes central to the development of cancer including apoptosis, 
differentiation, and cellular metabolism. These adjoining and connected pathways and 
biological classes include members of the GTPase regulation and signaling classes, metabolism 
of the polyol substrate central to Akt signaling, immune response, and the set of guanyl 
nucleotide exchange factors. The genes that underlie these associated pathways and processes 
form a tightly interconnected network with the Akt pathway (Figure 12A).  
In many cases, the activation of the Akt pathway is owed to a number of factors, such as the 
deletion or inactivation of the PTEN gene, which acts as a phosphatase on the PIP3 substrate, or 
the activation of upstream kinases. While PTEN is not deleted in either VCaP or RWPE, we 
observe that a number of genes in the PI3K/Akt pathway, such as PIK3R1, a regulatory subunit 
of PI3K, and SOS1, an inositol phosphatase, show significant mRNA-protein discordance with 
observed within the top 4% most discordant genes in the core dataset (Figure S 29). 
The transcript-protein relationship for the genes in these four pathways and classes are not all 
uniformly dysregulated – in many cases, only a small subset of genes in the set show large 
changes in the relationship (Figure 12B,C). Because only genes meeting the p ≤ 0.05 significance 
threshold from LRPath analysis are included in the network, not all interactions are included. 
GTPase regulator activity, which includes 59 genes, although only 9 of these genes have 
discordance-based p ≤ 0.05. This class includes SMAP1, which has been implicated in 
oncogenesis, and is thought to act as a tumor suppressor in intestinal cells [148]. The Polyol 
metabolic process class is intrinsically associated with genes that mediate the processing of 
PIP2 to PIP3 substrate of the Akt pathway, a substrate that is central to Akt signaling. In this 
class is an example of the direct interactions to the Akt signaling pathway, specifically the 
activation of IKK by MALT1, which contributes to T-cell activation[149]. The immune response 
class relates Akt to the effect its activation has on immune resistance – providing tumors with 
immune resistance and apoptotic escape [150]. Upstream of Akt, the set of guanyl nucleotide 
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exchange factors are known to activate Ras though the removal of GDP [151]. This process then 
leads to Akt induction [152]. Not all of these networks dignal directly into the PI3K/Akt 
pathway; much of the connectivity of the GTPase regulator activity class is though 
intermediates, including notable genes such as ERBB2, PRC1, and YWHAG which are often 
aberrant in regulation or structure in cancers. The class of guanyl nucleotide exchange factors is 
a subset of genes with GTPase regulator activity, and is similarly attached to the network.  
Analysis of joint analysis results 
Our pathway and Gene Ontology analysis nominated a number of biological pathways 
which showed significant numbers of member genes with dysregulated transcript-protein 
relationships in our prostate cancer model that were brought to the forefront by joint analysis. 
To examine if this joint analysis provided insights that neither transcript- or protein-based 
analysis could alone, we compared our results against these isolated analyses.  
We took the mRNA and protein data individually and derived the set of significant GO 
classes to observe the significant classes from the viewpoint of mRNA and protein in isolation. 
This process yielded 684 and 814 total classes with p-values ≤ 0.05 in mRNA and protein, 
respectively. We then compared these classes to the ones derived using our discordance and 
concordance indices.  The joint analysis class sizes are comparable to those in the isolated 
analysis examples, but they are compositionally quite different. The joint analyses nominated 
265 and 96 categories that were exclusive to the discordance and concordance methods alone.  
In a more focused examination of these results, we examined the level of association 
between the biological processes we identified and the methodology we used looking at only 
the highest significance (p ≤ 0.01) KEGG and Biocarta pathways (Figure 13). Using the odds ratio 
as a metric for evaluating the association strength of these pathways with the variance in their 
underlying genes, we clustered these classes in an attempt to dissect the drivers of 
discordance. In the context of our discordance index, a negative log-odds indicates an 
association whereby the protein abundance is greater than the corresponding transcript in 
VCaP relative to RWPE. A positive log-odds value indicates the contrary; that the transcript 
abundance is enriched in RWPE compared to VCaP without a corresponding increase in protein 
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abundance. In a majority of cases, the discordance between protein and mRNA abundance is 
driven by differences at the protein level with little change at the transcript level. A smaller, 
corresponding set of pathways is nominated chiefly by changes in the transcriptome. These 
observations agree with previous observations that the proteome is more dynamic than the 
transcriptome [110]. More interestingly, there is a set of pathways whose association by the 
discordance index is driven by more subtle changes in both their transcript and protein 
abundances moving in opposite directions - we observe this because of the directionality of the 
LRPath enrichment test.  
This set of pathways is split into two broad categories – pathways where transcript levels are 
decreased in opposite of increasing protein abundance, and the converse where transcript 
levels are increased while protein abundances are decreased. In the first case where transcripts 
are observed to be higher in abundance while there is a decrease in protein abundance, is 
composed of ten pathways. These include pathways associated with neurodegenerative 
diseases and cellular metabolism. While the three neurodegenerative diseases included in this 
category might first appear to be noise, likely nominated together since they contain many of 
the same genes, recent observations linking an inverse relationship between the incidence of 
Alzheimer’s disease and cancer [153] as well as the application of cancer drugs to treat 
Alzheimer’s disease [154] suggests that they may share some common molecular dysfunction. 
The second instance is composed of eleven pathways, broadly covering cell cycle-related 
classes and pathways involved in specific cancers. The observation of cell cycle and cancer 
specific classes is expected, as the evasion of apoptosis and insensitivity to anti-growth signals 
is a major hallmark of cancers [61] with many cancers sharing similar molecular dysregulation. 
While the pathways in both of these classes are nominated as interesting candidates in both 
analyses, the use of joint analysis brought them to the forefront of our analysis.  
Conclusion 
In summary, we show that the transcript-protein relationship is affected by a number of 
biological factors. Our classification of genes by their relative transcript and protein abundance 
in VCaP and RWPE demonstrates that the relationship is subject to the stability and resulting 
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half-life of the constituent transcript and protein, with a large number of short-lived 
transcription factors picked up exclusively in transcriptome data. The effect of transcript and 
protein stability is reinforced by our integration of transcript and protein stability data from the 
literature and the observation that genes with above-average protein or transcript stability 
have higher abundance correlation between transcript and protein levels. Other studies have 
suggested that sequence features also contribute quite significantly to the transcript-protein 
relationship, and this is a clear path for further examination. 
We then examine the transcript-protein relationship to find both individual genes and biological 
classes of genes where this relationship is dysregulated in a cancer context by comparing VCaP 
to RWPE. To achieve this goal, we derive novel discordance and concordance index values for 
all candidate genes in our dataset. Focusing on the candidates nominated through GO class and 
pathway enrichment analysis based on our discordance index, we find that several biological 
pathways surrounding the PI3K/Akt signaling pathway exhibit significant discordance. Coupled 
with evidence in the literature that modifying the stability of genes serving a regulatory role, 
these results may suggest an alternate pathway for the induction of functional networks 
conferring growth, survival, and immune and apoptotic escape in cancer. Furthermore, analysis 
of the pathways uniquely nominated through our joint analysis, in particular cases where 
transcript and protein levels move in opposite directions, elucidated possible mechanisms that 
may underlie the inverse relationship observed between cancer and neurodegerative disease. 
Our study is limited by the small number of samples involved and the use of relatively 
immature RNA-seq technology. The inclusion of additional biological replicates and additional 
cancer types may lead to broader insights about the nature of the dysregulation of the 
transcript-protein relationship in cancer and its larger implications in the establishment and 
progression of the disease. The application of even higher throughput transcriptome 
sequencing techniques (optimally in concert with higher mass accuracy MS/MS profiling) will 
help improve the accuracy of transcript-level measurement, and increased transcript coverage 
will provide nucleotide level information that allows for the attribution of dysregulation to 




Derivation of index values 
We computed several index values to quantify the transcript-protein abundance relationship in 
our two cell lines. Using the transcript and protein abundances, we computed the ratios of 
transcript and protein between the cell lines. We added a value of 0.2 to the values in our fold 
change calculations in order in order to avoid division by zero values. This value was chosen 
because it is below the threshold for a single spectra detected in many of the three replicates 
for each cell line as well as falling below the abundance cutoffs for transcriptome data, and 
should not significantly alter any results.  
                        
            





                     
           





These values were then z-transformed using the scale function in R to derive z_logratiotranscript 
and z_logratioprotein. Values for the concordance and discordance index for each gene were 
computed from these z-transformed transcript and protein log ratios 
                                                        Equation 3 
                                                        Equation 4 
 
The index values were then z-normalized. 
p-values were derived from these two log-ratio index values, based on a fit of the normal 
distribution. A correction was applied in an attempt to remove noise from genes that 
overlapped between highly concordance and high discordant genes. We used the commonly 
significant p ≤ 0.05 level as a basis cutoff value where these genes would have their p-values 
adjusted to non-significant values. 
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Gene Ontology analysis of correlation data 
Gene Ontology analysis was carried out using DAVID (http://david.abcc.ncifcrf.gov/) [140] and 
LRPath (http://lrpath.ncibi.org) [139] as well as the Gene Ontology (GO.db) and KEGG 
(KEGG.db) Bioconductor packages in R[155]. The entirety of the core and extended datasets 
were used as backgrounds in DAVID analysis when analyzing genes derived from those 
respective datasets. DAVID analysis of broad categories  in each cell line was done using GO FAT 
terms. Analysis of genes comparing the cell lines in DAVID was done using all GO terms as well 
as KEGG and Biocarta pathway entries. LRPath was used to analyze candidate genes in the 
comparison of VCaP and RWPE and between protein and mRNA levels in each cell line. Gene 
identifiers were converted from RefSeq to Entrez IDs using mappings in Bioconductor for 




Chapter 5: Conclusion 
 
In this work, I have compared the strengths and weaknesses of emerging single-molecule NGS 
technology in contrast to an established method employing amplification in the context of a 
cancer gene expression study. From this, we note several broad conclusions; single-molecule 
methods appear to better sample the low-abundance genes in the transcriptome, and the 
experimental results may better represent the underlying distribution of abundances in the 
transcriptome. However, these advantages are quickly degraded by the rapid increase in 
sequencing capacity from competitive amplification based methods. Additionally, the Helicos 
methodology used remained at an average read length and yield disadvantage. It is not clear 
whether other single molecule methods may improve on these disadvantages. While we were 
able to clearly distinguish the TMPRSS2-ERG fusion prevalent in prostate cancers in the VCaP 
cell line, the longer read lengths of other methods are likely more advantageous in comparison. 
The broader impact of this research in gene expression estimation from mRNA sequencing is 
most apparent in the contributions of gene expression data to other studies, as noted in the 
introduction. While many methodologies exist for the derivation of expression levels from RNA-
seq data today [9, 156-160], this early methodology for RNA-seq data provided expression 
estimation before the majority of other methods had been made public. 
The constantly evolving nature of massively parallel sequencing, and continuing development 
of single molecule methods, makes the insights extensible to future sequencing methods. While 
the SMS method applied in our study had read length and read volume disadvantages, future 
methods may sidestep these issues while retaining a sampling methodology free of 
amplification. Although the specifics of future developments in sequencing remain to be tested 
in depth, we can infer that future single-molecule based methods may exhibit more even 
coverage of transcripts being sequenced in addition to less concentrated sequencing of the very 
highest abundance transcripts.  
82 
 
Employing the knowledge and techniques developed for transcriptome profiling, we then 
aimed to integrate parallel transcriptome and proteome data. Specifically, to construct a 
standardized framework and methodology for the integration of knowledge from these two 
scales of biology, ensuring like comparisons between transcript and protein levels, with 
measurable parameters. This work addresses the issue of highly varying methods for 
integrating transcriptome and proteome data, a significant source of ambiguity in many 
previous integrative studies of these scales of biology.  
The framework we developed utilizes a novel common reference of corresponding transcript 
and protein sequences such that enables the direct comparison of the transcript and protein 
abundances across thousands of genes while reducing the noise from isoform uncertainty. The 
development of a decoy transcript sequence based method for estimating false discovery rate 
in RNA-seq data as part of this effort enables direct management of noise levels from 
transcriptome data. By setting forth this standardized pipeline and methodology, we hope to 
increase comparability of these integrative experiments across multiple studies by reducing the 
cumulative effect of methodological variation. 
We apply this framework to characterize the transcript-protein relationship in the VCaP and 
RWPE human prostate cell lines often used in cancer research. This research demonstrated the 
significant impact of transcript and protein stability on the transcript-protein relationship, and 
showed how this relationship is dysregulated in a number of functionally significant biological 
networks in our VCaP cancer model compared to our RWPE model of normal prostate 
epithelium. Several of these networks closely interact with the PI3K/Akt signaling pathway 
commonly seen to be deranged in cancers, where it is known to confer survival and growth 
advantage. Coupled with emerging knowledge that stabilization of transcripts or proteins are a 
pathway by which cancer cells sidestep regulatory mechanisms, we suggest that dysregulation 
of the transcript-protein relationship constitutes a possible mechanism by which cancers attain 
some of the hallmarks of cancer enabled by factors not related to genome stability. 
While this work is a contribution to our understanding of the mechanisms that govern the 
transcriptome-proteome relationship and an examination of how well we interrogate the 
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transcriptome, it is only a small step in building a comprehensive understanding of the complex 
interactions underlying the changes we see in biology and disease, and many challenges remain 
to be solved. 
Assessment of the proteome still remains a challenge. While MS/MS technologies have made 
great strides in sensitivity, dynamic range, and capacity, they are still insufficient for the 
characterization of the proteome with its tremendous number of post-translational 
modifications. For example, our study (and other studies utilizing label-free MS/MS) do not 
measure phosphorylated versions of the proteins under study, despite phosporylation being a 
crucial component of molecular activation in cancers. 
The ultimate goal of much of integrative bioinformatics is the derivation of methods and 
knowledge that can be translated to patients to optimize and improve the treatment of disease. 
This is already being explored in the realm of personalized medicine. While patient care has 
always been to a great extent personalized to individuals, we are now beginning to leverage the 
tremendous knowledge brought on by high throughput technologies.  Next generation 
sequencing is seeing particular use in the cancer field, with an increasing focus on guiding 
patient therapy using insights from sequencing [73]. This is an result of the increasing 
application of multiple molecular “omic” technologies in cancer, referring to the genomic, 
transcriptomic, proteomic, and other methods of molecular characterization. The previous 
product of this trend was the development of prospective genomic signatures for cancer 
prognosis [161-164] seen in the past decade, a number of which have been commercialized and 
applied to patient care [165, 166].  
The massive throughput and plummeting costs of these new technologies has also sparked 
increased efforts to quantify individuals’ genetic backgrounds to profile disease risk. The most 
exhaustive of these is the iPOP, or Personal Omics Profiling effort, which fuses data from the 
transcriptome, genome, proteome, and metabolome [167].  Using data sampled over the 
course of 14 months from a single individual, the authors developed a disease risk profile based 
on observed variants in the patient’s genome which ultimately revealed a high susceptibility to 
Type 2 Diabetes. This is only one example of how data from the multiple scales of biology can 
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be fused to affect health outcomes positively, with the promise of improving the quality and 
lowering the cost of health care. 
As genomic and proteomic profiling increase in capacity and become cheaper and more 
reliable, such exhaustive profiling of individuals will become commonplace. The proliferation of 
these molecular profiling efforts underscores the need for the development of methods for 
integrating diverse data such as those from the genome, transcriptome, and proteome. With 
advances in both technology and methods, we can begin to fully leverage the power of this 















Data Extraction  
The disease and biological process associated subnetworks are built from two fundamental 
components. First, a protein interaction network is used to define the relationships and 
interactions between the proteins considered in the study. The second is a database of genes 
relating them to diseases and biological processes. 
Protein interaction data was retrieved from the Michigan Molecular Interaction Index (MiMi) 
[168], which integrates interaction and annotation data from BIND , the Gene Ontology, HPRD, 
DIP, the BioGRID, IntAct, InterPro, IPI, the Max-Delbrueck Center for Molecular Medicine 
protein interaction database, Pfam, ProtoNet, SwissProt, and RefSeq. This process yielded 
12,318 unique protein-protein interactions involving 6199 unique Entrez Gene identifiers. 
Gene-disease relationships were derived from two sources; the Online Mendelian Inheritance 
in Man (OMIM) [169] and the PhenoGO database [170]. Gene-Disease associations in PhenoGO 
not using Entrez Gene identifiers were translated using mappings from HUGO [171]. Diseases in 
these two resources were defined in terms of coded Medical Subject Heading (MeSH) [172] and 
Unified Medical Language System (UMLS) [173] identifiers. The unfiltered, translated data set 
resulted in 3469 Entrez identifiers associated to 2325 phenotype codes. OMIM mappings found 
in the mim2gene file supplied by NCBI already employ Entrez Gene identifiers and no 
translation was necessary for the OMIM data. Entries in the OMIM database were filtered to 
include only gene-disease references, resulting in 1846 distinct Entrez indentified genes 
annotated to OMIM-defined diseases. 708 of the identifiers found in the OMIM mappings are 
also present in the MiMi interaction data set. Gene Ontology [174] data and biological 
annotation was extracted from BioMart [175] using data from Ensembl version 47 built from 
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the NCBI36 release of the human genome. MeSH and UMLS term descriptors were retrieved 
directly from the NLM. 
Data was extracted from MiMi using SQL queries for human-specific interactions from the 
National Center for Integrative Biomedical Informatics SQL server using SQL Server 
Management Studio Express. 
Subnetwork Generation 
The generated results were split into three distinct classes. A “background” set was generated 
from a priori knowledge from the Gene Ontology, consisting of the subnetworks formed by the 
classes represented in the “Biological Process” and “Molecular Function” trees of the Gene 
Ontology. This process resulted in the generation of 6,606 GO-associated subnetworks. A 
“single gene disease” (SGD) subnetwork set was generated from the contents of OMIM, 
producing 2,079 subnetworks. A “complex disease” (CD) set was built from the PhenoGO 
annotations, composed of 2,317 subnetworks in total.  
We separate the OMIM and PhenoGO sets for two reasons. The primary factor for the 
separation is the drastically different underlying focus of both of these resources, although they 
do share some commonly annotated diseases. PhenoGO contains data describing both single 
gene and multi-gene complex disease, whereas OMIM is primary focused on single gene 
diseases. The secondary factor is curation; the OMIM data is manually curated while PhenoGO 
is a computationally derived data source. 
Derivation of the subnetworks was done using the Boost Library version 1.43.1 
(http://www.boost.org/) and version .9 of the Boost Graph Library bindings to Python 
(http://osl.iu.edu/~dgregor/bgl-python/) using ActiveState ActivePython version 2.4.3 
(http://www.activestate.com/). 
Subnetworks that resulted in errors in the software were removed from the set, as the memory 
requirements for processing a number of large, dense networks was beyond the memory 
capacity of our workstation. 
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Data Characterization and Filtering 
Resulting subnetworks in each of the three data sets was topologically characterized using a set 
of Perl scripts employing the Boost Graph Library interface. Subnetworks are topologically 
characterized based on node count, clustering coefficient, observed edge fraction, average 
degree, maximum degree, radius, diameter, cyclicity, and biconnectivity. Biological 
characteristics noted for each subgraph include mean gene start location, mean gene end 
location, mean length, strand, mean PFAM domain annotation count, mean ProSite annotation 
count, mean number of signal domains, mean number of transmembrane domains, and mean 
G-C content fraction. The networks are filtered for size, imposing a minimum of three nodes 
found in the interaction network. 79 and 278 subnetworks passed this filter from the SGD and 
CD sets, respectively. 2590 of the subnetworks generated from the Gene Ontology passed this 
filter. This final filtered set was used to train and test the classifier. 
Because the data in the PhenoGO resource spans drugs, cell types, and other biological 
contexts not directly associated with disease, the subnetworks formed by this resource were 
filtered using the UMLS metathesaurus. Therefore, only genes associated with MeSH and UMLS 
terms are used to create the subnetworks. To restrict the set, a list of UMLS and MeSH codes 
was derived using a Perl script containing a total of unique terms. Of the 423,550 terms in the 
UMLS and MeSH that met these rules, the UMLS composed 419,087 terms and MeSH 
composed 5,563 terms. This process of restricting the set yielded a dramatic reduction in the 
number of subnetworks in the disease set. 
The data from the biological and topological characterization for each of the classes was then 
filtered for size using a perl script, constraining the set to networks of size between 3 and 9999 
nodes. 79 and 278 subnetworks passed this filter from the OMIM and PhenoGO sets, 
respectively. 2590 of the subnetworks generated from the Gene Ontology passed this filter. 
Parameterization/Characterization of Subnetworks 
To characterize subnetworks structurally, we chose a number of well-defined metrics to 
measure their size, density, and connectivity. Subnetworks are characterized based on node 
count, clustering coefficient, average degree, maximum degree, radius, diameter, cyclicity, and 
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biconnectivity. Cyclicity and biconnectivity are handled as Boolean variables with values of 
either 1 (True) or 0 (false). To account for the biological characteristics of the constituent genes 
of these subnetworks, we use biological characteristics for the constituent genes extracted 
from BioMart. These factors accounted for positional and orientation effects, biological role of 
the protein product, and physical stability. Factors include mean gene start location, mean gene 
end location, mean length, strand, mean PFAM domain annotation count, mean ProSite 
annotation count, mean number of signal domains, mean number of transmembrane domains, 
and mean G-C content fraction.  
Parameterization of subnetworks was done using a series of Perl scripts using the Perl-Graph 
library version .84 (http://search.cpan.org/dist/Graph/) as well as the Boost Graph Library 
Bindings for Perl version 1.4 (http://search.cpan.org/~dburdick/Boost-Graph-1.4/). These 
libraries were used to determine the topological characteristics of each of the subnetworks. 
Factors include the average degree, maximum degree, node count, radius, and diameter for 
each subnetwork.  Each subnetwork was also tested for cyclicity and biconnectivity.  
During the parameterization process, a number of entries were removed from the set as the 
subnetworks they formed were not computable within the memory limits of our workstation. 
These classes are GO:0007218 : “neuropeptide signaling pathway”, GO:0045893: “positive 
regulation of transcription, DNA-dependent”, and  GO:0006937: “regulation of muscle 
contraction”. 
Machine Learning and Classification 
The Waikato Environment for Knowledge Analysis (Weka), version 3.4.12 [176] was used to 
train and test a random forest classifier with a stratified 10-fold cross validation methodology 
using the built-in weka.classifiers.trees.RandomForest component. In this case, the cross-
validation approach was chosen due to the relative paucity of data from the disease subsets. 
Each random forest was composed of 100 trees, each taking into account four random 
parameters from the data. In all, a total of nine classifications were done in an attempt to 
discretize the three sets of subnetworks using varying parameter sets and amalgamations of 
the two disease sets. Because the Weka random forest classifier did not provide variable 
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importance measures, the analysis was repeated using the randomForest package in R 2.7.1, 
which provided nearly identical results. Principal components analysis of the data was done 
using PAST [177]. 
The parameterized data was split into 3 sets for the biological and topological groups. The first 
set composed of all three data sources comprising three distinct classes. The second set 
assigned “normal” and “disease” flags to the subnetworks derived from the Gene Ontology, and 
OMIM and PhenoGO, respectively. The third subset was composed of only disease subnetworks 
derived from OMIM while maintaining the GO background set.  
The first classification was done on a set combining all SGD and CD subnetworks into a single 
larger disease class in comparison to the GO-derived background set. The second classification 
used only the SGD subset of the data in comparison to the GO data. The third classification used 
each subset of data in its own discrete class.  These subsets were further separated into three 
groups depending on the underlying parameters available to the classifier. These groups used 
parameters exclusively from the topological and biological parameter sets, as well as the 
combined parameterization. 
It can be seen that overall the biological characteristics prove more informative than the 
topological ones and achieve a lower misclassification error rate, ranging between 2.89 and 
3.70%. On the other hand, for the topological characteristics the misclassification error rate was 
around 10% for the three class problem. However, when the CD class was excluded, the 
topological characteristics matched the performance of the biological ones. Further, an 
inspection of Sup. Tables 2e and 2f suggests that the presence of the SGD class is the source of 
the significantly higher misclassification error rate with respect to the topological features. In 
most cases, the presence of the large number of representative GO subnetworks leads to a high 
classification accuracy. However, it is useful to examine the true positive (TP) rate of 
classification between the combined “disease” set, a combination of the SGD and CD sets, and 
the GO background. In the combined parameterization and biological parameter only cases, the 
TP rate of this combined set is relatively good, at 61% and 72%, respectively. Examination of the 
TP rates for classifying into the three distinct classes revels that the subnetworks in the SGD set 
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appear to be poorly distinguishable from the background GO set. However, the CD set appears 
to have predictive power setting it apart from the GO background. This similarity between the 
GO and SGD sets likely leads to the poor classification accuracy seen between the two sets as 
reflected in the poor TP values for the SGD set in Sup. Tables 2e, 2f, 2h, and 2i. 
Feature Analysis 
A factor analysis was done using the RandomForest package in R 2.7.1 in each of the biological 
parameter only, topological parameter only, and combined parameter groups to determine the 
relative influence of each of the parameters in determining class membership in each of the 
classification sets. The random forest was set to use 4 variables per tree and 100 total trees for 










Figure S 1: Principal Components Analysis demonstrates the poor separability of the data. A principal 
components analysis of the combined sets using all the parameters, suggests that the difference between disease-
related subnetworks and the GO baseline subnetworks are subtle and not easily derived. When the PCA is done 
over just the CD and SGD sets, we see a similar pattern where there is no clear separation. However the non-
continuous nature of the features may be a confounding factor when applying the PCA approach. With that in 
mind, a simple k-means clustering approach was taken where k = 3 to represent the three source types. A. 
Principal components analysis of all sets using all parameters. 95% of data points fall within the ellipse. B. Principal 
components analysis of SGD and CD sets using all parameters. 95% of data points fall within the ellipse. 
  












































=== Run information ===  
 
Scheme:       weka.clusterers.SimpleKMeans -N 3 -S 10  
Relation:     combined_data  
Instances:    2944  
Attributes:   20  
average gene start  
average gene end  
average length  
average gene strand  
average pfam count  
average prosite count  
average # of singnal domains  
average # transmembrane domains  
average GC content  
observed edges/total possible edges  
average node degree  
max node degree  
radius  
diameter  





             source  
             phenotype code  
Test mode:    Classes to clusters evaluation on training data  




Number of iterations: 6  
Within cluster sum of squared errors: 1660.859140812153  
 
Cluster centroids:  
Variables Cluster 0 Cluster 1 Cluster 2 
Variable 
average gene start  
average gene end  
average length  
average gene strand  
average pfam count  
average prosite count  
average # of singnal domains  
average # transmembrane 
domains  
average GC content  







































possible edges  
average node degree  
max node degree  
radius  
diameter  
node count  
cyclicity  
biconnectivity  






































Clustered Instances 1437 ( 49%) 470 ( 16%) 1037 ( 35%) 
 
Class attribute: source  
 Assigned to Cluster 




e SGD/OMIM 59 4 16 
GO 1220 435 932 
CD/PhenoGO 158 21 89 
 
Incorrectly clustered instances :    1631.0     55.4008 % 
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Table S 2: Classification results from each of nine classification attempts using complete GO set 
Biological Parameters Only 
A. Biological parameters only: dataset split into “disease” and “normal” classes 
 
Out of bag error: 0.0309 
 
Correctly Classified Instances 2836 96.2988 % 
Incorrectly Classified Instances 109 3.7012 % 
Kappa statistic 0.8064 
Mean absolute error 0.1287 
Root mean squared error 0.216 
Relative absolute error 60.339 % 
Root relative squared error 66.1667 % 
Total Number of Instances 2945 
TP Rate FP Rate Precision Recall f-Measure class 
0.995 0.272 0.964 0.995 0.979 GO 
0.728 0.005 0.956 0.728 0.827 Disease 
 
Confusion Matrix: 
Classified as:  
a b  Actual assignment 
2576 12 a = GO/Normal 





B. Biological parameters only: dataset split into CD, SGD, and GO classes 
 
Out of bag error: 0.0309 
 
Correctly Classified Instances 2832 96.163 % 
Incorrectly Classified Instances 113 3.837 % 
Kappa statistic 0.8008 
Mean absolute error 0.0893 
Root mean squared error 0.1801 
Relative absolute error 61.2569 % 
Root relative squared error 66.7931 % 
Total Number of Instances 2945 
TP Rate FP Rate Precision Recall f-Measure class 
0.165 0.003 0.565 0.165 0.255 SGD 
0.867 0.001 0.992 0.867 0.925 CD 
0.996 0.283 0.962 0.996 0.979 GO 
 
Confusion Matrix: 
Classified as:  
a b c Actual assignment 
2578 1 9 a = GO 
36 241 1 b = CD 
65 1 13 c  = SGD 
 
C. Biological parameters only: SGD and GO classes 
 
Out of bag error: 0.0274 
 
Correctly Classified Instances 2590 97.1129 % 
Incorrectly Classified Instances 77 2.8871 % 
Kappa statistic 0.1974 
Mean absolute error 0.0527 
Root mean squared error 0.1661 
Relative absolute error 91.1176 % 
Root relative squared error 97.9961 % 
Total Number of Instances 2667 
TP Rate FP Rate Precision Recall f-Measure class 
0.127 0.003 0.556 0.127 0.206 SGD 
0.997 0.873 0.974 0.997 0.985 GO 
 
Confusion Matrix: 
Classified as:  
a b  Actual assignment 
2580 8 a = GO 
69 10 b = SGD 
 
 
Topological Parameters Only 
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D. Topological Parameters Only: dataset split into “disease” and “normal” classes 
 
Out of bag error: 0.0853 
 
Correctly Classified Instances 2675 90.8628 % 
Incorrectly Classified Instances 269 9.1372 % 
Kappa statistic 0.4646 
Mean absolute error 0.1475 
Root mean squared error 0.2732 
Relative absolute error 69.1481 % 
Root relative squared error 83.7012 % 
Total Number of Instances 2944 
TP Rate FP Rate Precision Recall f-Measure class 
0.392 0.02 0.729 0.392 0.51 Disease 
0.98 0.608 0.921 0.98 0.95 GO 
 
Confusion Matrix: 
Classified as:  
a b  Actual assignment 
2535 52 a = GO/Normal 
217 140 b = Disease 
 
E. Topological Parameters Only: dataset split into CD, SGD, and GO classes 
 
Out of bag error: 0.0832 
 
Correctly Classified Instances 2688 91.30% 
Incorrectly Classified Instances 256 8.70% 
Kappa statistic 0.4863 
Mean absolute error 0.1016 
Root mean squared error 0.2241 
Relative absolute error 69.7015 % 
Root relative squared error 83.1102 % 
Total Number of Instances 2944 
TP Rate FP Rate Precision Recall f-Measure class 
0.038 0.004 0.214 0.038 0.065 SGD 
0.493 0.011 0.83 0.493 0.619 CD 
0.985 0.608 0.922 0.985 0.952 GO 
 
Confusion Matrix: 
Classified as:  
a b c Actual assignment 
2548 28 11 a = GO 
141 137 0 b = CD 





F. Topological Parameters Only: SGD and GO classes 
 
Out of bag error: 0.0315 
 
Correctly Classified Instances 2581 96.81% 
Incorrectly Classified Instances 85 3.19% 
Kappa statistic 0.0586 
Mean absolute error 0.0543 
Root mean squared error 0.1716 
Relative absolute error 93.8315 % 
Root relative squared error 101.201 % 
Total Number of Instances 2666 
TP Rate FP Rate Precision Recall f-Measure class 
0.038 0.003 0.25 0.038 0.066 SGD 
0.997 0.962 0.971 0.997 0.984 GO 
 
Confusion Matrix: 
Classified as:  
a b  Actual assignment 
2578 9 a = GO 







G. All parameters: dataset split into “disease” and “normal” classes 
 
Out of bag error: 0.0452 
 
Correctly Classified Instances 2791 94.803 % 
Incorrectly Classified Instances 153 5.197 % 
Kappa statistic 0.7128 
Mean absolute error 0.1269 
Root mean squared error 0.2191 
Relative absolute error 59.5021 % 
Root relative squared error 67.1287 % 
Total Number of Instances 2944 
TP Rate FP Rate Precision Recall f-Measure class 
0.611 0.005 0.94 0.611 0.74 Disease 
0.995 0.389 0.949 0.995 0.971 GO 
 
Confusion Matrix: 
Classified as:  
a b  Actual assignment 
218 139 a = Disease  





H. All parameters: dataset split into CD, SGD, and GO classes 
 
Out of bag error: 0.0438 
 
Correctly Classified Instances 2795 94.9389 % 
Incorrectly Classified Instances 149 5.0611 % 
Kappa statistic 0.7225 
Mean absolute error 0.0886 
Root mean squared error 0.1815 
Relative absolute error 60.7398 % 
Root relative squared error 67.2984 % 
Total Number of Instances 2944 
TP Rate FP Rate Precision Recall f-Measure class 
0.101 0.003 0.5 0.101 0.168 SGD 
0.997 0.387 0.949 0.997 0.972 GO 
0.752 0.001 0.986 0.752 0.853 CD 
 
Confusion Matrix: 
Classified as:  
a b c Actual assignment 
8 70 1 a = SGD  
7 2578 2 b = GO 
1 68 209 c  = CD 
 
I. All parameters: SGD and GO classes 
 
Out of bag error: 0.0281 
 
Correctly Classified Instances 2591 97.1868 % 
Incorrectly Classified Instances 75 2.8132 % 
Kappa statistic 0.2332 
Mean absolute error 0.0498 
Root mean squared error 0.1594 
Relative absolute error 86.0831 % 
Root relative squared error 93.9883 % 
Total Number of Instances 2666 
TP Rate FP Rate Precision Recall f-Measure class 
0.152 0.003 0.6 0.152 0.242 SGD 
0.997 0.848 0.975 0.997 0.986 GO 
 
Confusion Matrix: 
Classified as:  
a b  Actual assignment 
12 67 a = SGD  





J. All parameters: SGD and CD classes 
=== Run information === 
Scheme:       weka.classifiers.trees.RandomForest -I 100 -K 4 -S 1 
Relation:     OMIM-PhenoGO-weka.filters.unsupervised.attribute.Remove-R2 
Instances:    357 
Attributes:   19 
              source 
              average gene start 
              average gene end 
              average length 
              average gene strand 
              average pfam count 
              average prosite count 
              average # of signal domains 
              average # transmembrane domains 
              average GC content 
              observed edges/total possible edges 
              average node degree 
              max node degree 
              radius 
              diameter 
              node count 
              cyclicity 
              biconnectivity 
              clustering coefficient 
Test mode:    10-fold cross-validation 
 
=== Classifier model (full training set) === 
Random forest of 100 trees, each constructed while considering 4 random features. 
Out of bag error: 0.1232 
Correctly Classified Instances 315 88.2353 % 
Incorrectly Classified Instances 42 11.7647 % 
Kappa statistic 0.5965 
Mean absolute error 0.1785 
Root mean squared error 0.2972 
Relative absolute error 51.6603 % 
Root relative squared error 71.5991 % 
Total Number of Instances 357 
TP Rate FP Rate Precision Recall f-Measure class 
0.519 0.014 0.911 0.519 0.661 SGD 




Classified as:  
a b  Actual assignment 
274 4 a = CD  






Table S 3: Ranked Features By Parameter Type. A. Biological Parameters Only B. Topological Parameters Only  C. 
Combined Parameterization 
A. 
                                        GO  SGD/OMIM CD/PhenoGO MeanDecreaseAccuracy MeanDecreaseGini 
averageGeneStart                 0.2783482 1.0280783 0.9059960            0.2757494         84.56684 
averageGeneEnd                   0.2768157 0.9394527 0.8925733            0.2747467         82.32455 
averageLength                    0.2644807 1.2301754 0.9510359            0.2876197         89.97404 
averageGeneStrand                0.1758904 0.1357294 0.9539724            0.2776031         63.51283 
averagePfamCount                 0.2730130 0.5254745 0.8856997            0.2717815         68.71366 
averagePrositeCount              0.2732054 0.7780531 0.8667791            0.2729219         71.44485 
averageSingnalDomainCount        0.2126032 1.1321489 0.9215645            0.2744301         46.04487 
averageTransmembraneDomainsCount 0.2369126 0.7511460 0.9107138            0.2746473         41.26618 
averageGCContent                 0.2527932 1.1863229 0.9633071            0.2872784         90.52120 
 
B. 
                             GO   SGD/OMIM  CD/PhenoGO MeanDecreaseAccuracy MeanDecreaseGini 
observedEdgeFraction 0.23001163  0.5940764 0.90312482           0.24675347        93.847995 
averageNodeDegree    0.18907358 -0.1896722 0.92494854           0.25118579        73.325193 
maxNodeDegree        0.23248537 -0.0195584 0.75146118           0.23964507        45.595834 
radius               0.14363009  0.3341730 0.73797260           0.17620126        10.558500 
diameter             0.16504637  0.3258433 0.89950612           0.21990106        24.283709 
nodeCount            0.24716779  0.1174077 0.62814917           0.24756213        47.349672 
cyclicity            0.07668406  0.1599157 0.05666838           0.08233893         2.229017 
biconnectivity       0.05281318  0.2182699 0.47637630           0.10961336         3.538654 
clusteringCoefficent 0.28966769  0.9925351 0.96101890           0.28810431        97.553541 
 
C. 
                                         GO  SGD/OMIM CD/PhenoGO MeanDecreaseAccuracy MeanDecreaseGini 
averageGeneStart                 0.25577147 0.6187922 0.8782965            0.2631096        58.025555 
averageGeneEnd                   0.24189366 0.8649050 0.8823725            0.2517155        54.866536 
averageLength                    0.21860181 1.0476172 0.9157395            0.2702029        53.928221 
averageGeneStrand                0.21222727 0.4779712 0.8899448            0.2613027        37.971447 
averagePfamCount                 0.24589871 0.7138733 0.8139401            0.2557329        51.837923 
averagePrositeCount              0.24653767 0.8026352 0.8288924            0.2553449        51.873560 
averageSingnalDomainCount        0.17608440 0.8725259 0.8494207            0.2504462        28.695867 
averageTransmembraneDomainsCount 0.17643006 0.8016404 0.8587388            0.2398903        25.758543 
averageGCContent                 0.20630777 1.0249891 0.9042456            0.2621500        57.568889 
observedEdgeFraction             0.22721854 0.9567640 0.8553682            0.2424491        39.992423 
averageNodeDegree                0.24357245 0.6044357 0.8350696            0.2586311        33.451690 
maxNodeDegree                    0.23311884 0.5687222 0.7704013            0.2418791        23.089282 
radius                           0.19372018 0.5507024 0.5725879            0.1942285         9.303571 
diameter                         0.22263432 0.7683270 0.7232573            0.2295851        16.473967 
nodeCount                        0.23954530 0.7925986 0.8041791            0.2430081        25.501844 
cyclicity                        0.11050759 0.2201386 0.5157050            0.1559355         3.013125 
biconnectivity                   0.07642597 0.1890160 0.2993280            0.1074229         1.420956 





APPENDIX B: Chapter 2 Supplementary Figures and Tables 
 
Figure S 3: Single-molecule mRNA-sequencing. mRNAs are purified using poly-A selection and then fragmented. 1st-strand 
cDNA is synthesized from the fragmented mRNA, and then poly-A tailed using terminal transferase. Polyadenylated cDNA 
fragments are hybridized to poly-T oligomers bound to a glass substrate, excess A bases are “filled ,“ and then “locked” with an 
A, C, or G base attached to a virtual terminator. The sequencing process then occurs with repeated cycles of virtual terminator 





Figure S 4: Read alignment with Bowtie and IndexDP. Bowtie was used for amplification-based sequencing read alignment and 
IndexDP for single molecule read alignment. While different in their parameters, the effective alignments and specificity 
between the aligners are similar, although Bowtie has a slightly higher cutoff 
 
 
Figure S 5: Length distribution of aligned SMS reads. Aligned SMS read lengths varied between 24bp to 57bp in our first set of 





Figure S 6: Sample Profiling Reproducibility in SMS and AS. Bowtie was used for amplification-based sequencing read 
alignment and IndexDP for single molecule read alignment. Pearson correlation for log2-transformed, normalized tag counts is 




Figure S 7: Log2 correlation between amplification-based and single-molecule sequencing. Log2 correlation between single-
molecule and amplification-based RNA-Seq single-best read mappings in these samples show that in broad terms the two 





Figure S 8: Correlation between IndexDP and Bowtie alignment of amplification-based sequencing reads. The correlation 





Figure S 9: IndexDP realignment of amplification-based sequencing reads. Alignment of amplification-based sequencing reads 
using the IndexDP alignment tool used to align single-molecule reads shows persistence of the observed bias in amplification-






Figure S 10: Unique gene detection in AS and SMS across threshold values, by transcript length. The pattern of increased 
sensitivity in SMS is uniform as the baseline noise level is varied from 0.1 to 3.0 RPKM. Low representation by short transcripts 





Figure S 11: Expression values of validation candidate genes showing amplification.  Out of the set of genes chosen for RT-PCR 
validation for their detection over the 0.3 RPKM noise threshold by only SMS, diffuse read alignment pattern, and the presence 




Figure S 12: RPLP0 coverage in other samples. Coverage plots of the over-represented gene RPLP0 in the LNCaP-24h, LNCaP-






Figure S 13: Quantile-quantile plot of AS and SMS reads with duplicates removed. Reads in excess of a single read per aligned 
locus were removed from both AS and SMS data sets. The result of this procedure was inconsistent across the data set; some 













Coverage DU145_1 DU145_2 LNCaP-0h LNCaP-24h LNCaP-48h VCaP-0h VCaP-24h VCaP-48h PrCa PrCa-AdjNorm RWPE VCaP 
(0-1] 3,659 3,621 3,659 3,987 4,019 5,953 5,082 5,192 4,588 6,089 3,738 5,045 
(1-10] 3,806 3,826 3,802 3,206 3,120 2,066 2,418 2,235 2,986 1,199 3,681 2,137 
(10-100] 370 377 363 286 255 117 172 132 187 63 309 143 
 
Figure S 14: Effect of duplicate removal in AS. Reads in excess of a single read per aligned locus were removed from both AS 
and SMS data sets, resulting in (A) a median 47% drop in the number of usable reads across the 12 samples in the evaluation 














All Reads 7,791,975 7,959,245 7,979,414 5,874,909 5,571,152 3,676,805 4,375,569 3,294,043 5,317,180 2,998,413 8,270,801 3,806,236 
























Total Usable AS Reads Before/After Duplicate Removal 




Figure S 15: Gene Fusion Discovery Using SMS Reads. All possible reads were aligned against the transcriptome and genome 
using IndexDP. The set of non-mapping reads (some of which harbor chimeras) were subsequently aligned against the 
transcriptome, returning reads that had a partial alignment of at least 18 nucleotides. All reads having the same partial 
alignments, suggesting a common breakpoint, were clustered. All clusters were then compared to determine if the non-aligning 
“overhang” portion of the read from one breakpoint region had similarity to the overhang of an independent breakpoint, 





Figure S 16: Alternate mappings for genes detected by SMS only in DU145. We analyzed alternate mappings for 
the reads attributable to each of the nine genes we observed to be detectable only by SMS in DU145 using reads 
from both replicates. In all nine cases, reads mapped most strongly to the genes of interest, suggesting that the 
detection of these genes is not an artifact of mis-mapping. The top 20 alternate mappings, ordered by mapping 
read count, are shown in the graph. 
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A. Amplification-Based Sequencing 
Sample Name 






24h VCaP-48h PrCa 
PrCa-
AdjNorm RWPE VCaP 




7,709,472 7,875,168 7,820,929 5,790,207 5,513,448 3,636,454 4,297,981 3,272,200 7,748,986 2,871,802 8,038,501 3,352,960 
Contaminant 
Reads: 




5,818,322 5,942,613 5,530,586 4,126,612 3,959,711 2,281,328 2,931,544 2,325,189 5,849,652 2,303,763 5,590,474 2,477,323 
Percent Unique 75.5% 75.5% 70.7% 71.3% 71.8% 62.7% 68.2% 71.1% 75.5% 80.2% 69.5% 73.9% 
Multi-Mapping 
Reads: 
1,891,150 1,932,555 2,290,343 1,663,595 1,553,737 1,355,126 1,366,437 947,011 1,899,334 568,039 2,448,027 875,637 
Percent 
Multimapping 
24.5% 24.5% 29.3% 28.7% 28.2% 37.3% 31.8% 28.9% 24.5% 19.8% 30.5% 26.1% 
Total 
Mappings: 







36 36 36 36 36 36 36 36 36 36 36 36 
Mean Read 
Length: 
36 36 36 36 36 36 36 36 36 36 36 36 
Min Read 
Length: 
36 36 36 36 36 36 36 36 36 36 36 36 
 
B. Single-Molecule Sequencing 













9,665,231 15,012,289 5,633,863 8,120,878 4,489,176 6,266,115 5,957,786 5,067,698 4,709,102 2,130,950 13,294,348 12,713,722 
Contaminant 
Reads: 
2,940,337 4,728,776 1,623,475 1,796,861 1,211,422 1,132,989 1,001,764 693,123 4,921,275 717,235 5,333,893 3,540,399 
Unique Mapping 
Reads: 
7,543,462 11,719,852 4,263,248 6,232,105 3,377,187 4,663,004 4,564,718 3,862,102 3,085,428 1,542,533 10,214,631 9,737,305 
Percent Unique 78.0% 78.1% 75.7% 76.7% 75.2% 74.4% 76.6% 76.2% 65.5% 72.4% 76.8% 76.6% 
Multi-Mapping 
Reads: 
2,121,769 3,292,437 1,370,615 1,888,773 1,111,989 1,603,111 1,393,068 1,205,596 1,623,674 588,417 3,079,717 2,976,417 
Percent 
Multimapping 
22.0% 21.9% 24.3% 23.3% 24.8% 25.6% 23.4% 23.8% 34.5% 27.6% 23.2% 23.4% 
Total Mappings: 35,091,411 54,881,579 20,016,203 26,912,318 15,869,700 20,525,342 18,151,466 15,215,471 32,088,861 7,702,501 51,058,659 44,504,047 
Max Read 
Mength: 
63 57 63 63 63 63 63 63 57 57 57 57 
Mean Read 
Length: 
34.23 33.5 33.7 33.98 32.83 33.54 33.89 33.55 33.18 32.13 33.73 33.5 
Min Read 
Length: 
25 24 25 25 25 25 25 25 24 24 24 24 











































































RPS18 12 · · · · · · · · · · · · 
GNAS 12 · · · · · · · · · · · · 
RPLP0 12 · · · · · · · · · · · · 
RPL8 12 · · · · · · · · · · · · 
RPL31 12 · · · · · · · · · · · · 
RPS8 12 · · · · · · · · · · · · 
CYC1 12 · · · · · · · · · · · · 
GNB2 12 · · · · · · · · · · · · 
rpl10a 12 · · · · · · · · · · · · 
OK/SW-cl.12 12 · · · · · · · · · · · · 
RPS14 12 · · · · · · · · · · · · 
SLC25A3 11 · · · · · · · · · · · 
 
UBB 11 · · · · · · · · · · · 
 
RPS5 11 · · · · · · · · · · · 
 
RPL7A 11 · · · · · · · · · · · 
 
EIF1 11 · · · · · · · · · · · 
 
UQCRC1 11 · · · · · · · · · · · 
 
PFKL 11 · · · · · · · · · · · 
 
RPS10 11 · · · · · · · · · · · 
 
RPL18A 11 · · · · · · · · · · · 
 
RPL3 11 · · · · · · · · · · · 
 
ENO1 11 · · · · · · · · · · · 
 
RPL37A 11 · · · · · · · · · · · 
 
EIF3I 11 · · · · · · · · · · · 
 
RPL29 11 · · · · · · · · · · · 
 
EEF2 11 · · · · · · · · · · · 
 
PSAP 11 · · · · · · · · · · · 
 
PPP2R1A 11 · · · · · · · · · · · 
 
GNB2L1 11 · · · · · · · · · · · 
 
RPL13A 11 · · · · · · · · · · · 
 
SPINT2 11 · · · · · · · · · · · 
 
SHISA5 11 · · · · · · · · · · · 
 
RPS11 10 · · · · · · · · · · 
  
BTF3 10 · · · · · · · · · · 
  
GPX4 10 · · · · · · · · · · 
  
ATP5A1 10 · · · · · · · · · · 
  
KRT18 10 · · · · · · · · · · 
  
KIAA0088 10 · · · · · · · · · · 
  
ACTG1 10 · · · · · · · · · · 
  
RPS9 10 · · · · · · · · · · 
  
RPL10A 10 · · · · · · · · · · 
  
RPL12 10 · · · · · · · · · · 
  
ATP5B 10 · · · · · · · · · · 
  
RPS3 10 · · · · · · · · · · 
  
RPSA 10 · · · · · · · · · · 
  
MTCH1 10 · · · · · · · · · · 
  
PYCR1 10 · · · · · · · · · · 
  
LRP10 10 · · · · · · · · · · 
  
ALDOA 10 · · · · · · · · · · 
  
EEF1A1 10 · · · · · · · · · ·     
NME2 10 · · · · · · · · · ·     
RPS20 10 · · · · · · · · · ·     
C19orf48 10 · · · · · · · · · ·     
RPL18 10 · · · · · · · · · ·     
RPL13 10 · · · · · · · · · ·     
P4HB 10 · · · · · · · · · ·     
OAZ1 10 · · · · · · · · · ·     
EEF1G 10 · · · · · · · · · ·     
UBC 10 · · · · · · · · · ·     
 
Table S 5: Recurrently over-represented genes in amplification-based sequencing in ten or more samples.  Of the 
393 genes are recurrently within the top 500 over-represented genes by total read count in five (40%) or more 






 Q1 Q2 Q3 Q4 
DU145_1 678,716.20 82,650.17 15,312.21 1,756.09 
DU145_2 682,755.30 80,340.18 13,794.63 1,455.81 
VCaP-0h 679,511.10 83,560.23 20,066.82 2,400.37 
VCaP-24h 681,607.20 77,752.04 18,903.67 2,624.63 
VCaP-48h 688,925.40 75,791.22 18,493.60 2,544.35 
LnCaP-0h 658,971.00 97,176.66 21,592.82 2,512.66 
LnCaP-24h 678,955.60 86,868.69 17,595.02 2,044.48 
LnCaP-48h 653,867.40 100,158.20 24,825.49 3,424.91 
PrCa 610,787.00 107,986.40 33,056.41 4,683.91 
PrCa-AdjNorm 581,561.70 121,731.20 41,077.92 7,530.44 
RWPE 688,043.60 83,353.84 16,642.86 1,740.82 




 Q1 Q2 Q3 Q4 
DU145_1 673,250.40 86,579.46 11,608.48 299.67 
DU145_2 676,079.70 84,926.77 10,734.94 233.56 
VCaP-0h 724,435.80 67,473.25 15,836.85 1,688.69 
VCaP-24h 731,422.10 63,380.33 10,563.88 519.48 
VCaP-48h 713,318.90 68,976.03 11,508.96 602.30 
LnCaP-0h 683,466.00 83,738.35 11,073.12 440.38 
LnCaP-24h 703,435.10 70,455.56 8,175.45 192.68 
LnCaP-48h 705,382.50 70,566.91 7,889.93 170.70 
PrCa 610,253.20 70,574.82 9,521.59 293.01 
PrCa-AdjNorm 592,366.00 64,313.02 12,772.42 278.15 
RWPE 680,671.10 71,476.63 10,868.36 245.32 
VCaP 711,504.06 52,559.02 6,843.76 0.00 
 
Table S 6: Sum of normalized expression values per quartile by sample in AS and SMS. We observe that the 
number of reads aligning to transcripts seen in the third and fourth quartiles is consistently greater in A. SMS than 







Coverage DU145_1 DU145_2 LnCaP-0h LNCaP-24h LNCaP-48h VCaP-0h VCaP-24h VCaP-48h PrCa PrCa-AdjNorm RWPE VCaP 
(0 -1] 3,875 3,420 4,459 4,109 5,008 4,691 4,920 5,169 4,971 6,841 3,432 3,513 
(1 - 10] 3,871 3,917 3,638 3,765 3,270 3,579 3,321 2,937 3,514 1,745 4,314 4,316 
(10 -100] 922 1,410 432 752 331 401 423 365 289 110 1,054 992 
(100 - 1000] 66 105 35 59 27 49 31 31 23 3 80 83 





Coverage DU145_1 DU145_2 LnCaP-0h LNCaP-24h LNCaP-48h VCaP-0h VCaP-24h VCaP-48h PrCa PrCa-AdjNorm RWPE VCaP 
(0 -1] 3,299 3,261 3,421 3,767 3,804 5,656 4,776 4,964 4,300 5,033 3,433 4,879 
(1 - 10] 3,721 3,731 3,537 3,069 2,982 2,213 2,508 2,288 3,033 2,077 3,525 2,290 
(10 -100] 752 769 790 598 561 208 332 272 395 221 695 282 
(100 - 1000] 63 63 73 45 47 56 54 35 33 19 72 40 
(1000 - 
10000] 
0 0 3 0 0 3 2 0 0 1 3 0 
 
Table S 7: Gene-level read coverage of observed transcripts. A. and B. illustrate the number of genes with 





Sequence UPL Probe # 
agacccccaccatcccta 71 
cgcatcatctgagctaggc 
 cgcaatgtgctggtcaag 76 
gttgccgatgtccaggtaat 
 tgttattgatggatttccaagaga 61 
ccaaatcgggggtacagatt 
 ctgattatgaagatcagggtgatg 55 
tctcaaatcttccatgaaacctc 
 ccctacatcccatccacct 30 
ggtctgcatcccaacagtct 
 ctatgggccttggcagtg 55 
gagctccctcagcccatc 
 acccattccggattatgga 62 
ttgcttgcacagacctttga 
 ttttcatgggtggcctct 71 
tgccaatgatgttactcagacc 
 gcatgcaaacgttagaacca 22 
ggctacttcgctagcagatcc 
 gaagttgcatcagaggtccat 69 
aaacaattacatgttactttggaatca 
 ctgcaagacatccaagatcg 57 
aacctgagggcatttagcag 
 ctgcaagacatccaagatcg 68 
aacctgagggcatttagcag 
 aagaggtggcaacaacctaca 17 
gatgcaataattgtctttagtgtcct 
 aagaggtggcaacaacctaca 75 
gatgcaataattgtctttagtgtcct 
 ttctacaagcgcagcaagg 58 
cagggtccagtaattgccttt 
 cgtaaggtgctccgggata 37 
gagccaaacggcgaatag 
 ctatacggagcacgccaag 76 
cctgacgttttagggcatatactac 
 tactggccttggctgtgc 71 
cacagggttttcaccaacct 
 agcgagaagtgccaactcc 39 
ttgtacaggtcccgctcttt 
 gcagaagatggaccagcaat 88 
tgtgctttccccattgattt 
 gggacaggtcccagaatatg 70 
gcctacttccggcagacc 
 tcctagctgaatgctataacctctg 15 
ggcatccttcagggtcttc 
 gtcattgaaaatccccagtacttt 9 
aattattatcaggcggtcttgg 
 gcttctgtgcttgacgtctattt 53 
ggataattctggtgcggaga 
 agcagccttgatgaagaagc 38 
gaagaagatgaaattgtggttgc 
 tgggctcaaacaatccttct 13 
atcctgggtcctgctctgta 
 tgggctcaaacaatccttct 16 
atcctgggtcctgctctgta 
 Table S 8: Primers used for validating transcripts seen only by SMS. All experiments were performed in duplicate using two 
primer pairs per candidate gene when possible. 
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APPENDIX C: Chapter 3 and 4 Supplementary Figures and Tables  
 
Figure S 17: Reproducibility between replicates. A. RWPE RNA-seq, B. VCaP RNA-seq, C. RWPE tandem MS, and D. 
VCaP tandem MS. Data are derived from the extended dataset. 
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Figure S 18: Correlation between VCaP and RWPE by RNA-seq and tandem MS. Within both the transcriptome 
and proteome data, both cell lines showed relatively high similarity in abundance profile. This is expected, owing 





Figure S 19: False Discovery Rate estimation in RNA-seq data. We measured the FDR at increasing RPKM cutoffs 




























Figure S 20: False Discovery Rate estimation in protein data. We used the output of TPP and Abacus to determine 
appropriate parameter values for controlling FDR in our protein data. Three parameters were considered to 




Figure S 21: RNA-seq False Discovery Rate estimation methodology. We used a methodology similar to that of 
Ramskold, et al. to estimate FDR in our RNA-seq data. Corresponding decoy sequences were sampled without 
replacement from the intergenic regions in hg19 for each representative transcript in our database, for a total of 
34,728 decoys. These decoy sequences were of equal length as the real transcripts. We aligned reads to the 
merged total set of these decoy and real mRNA transcripts. Abundance data was summarized at the gene level 
using the same transcript-gene mappings for both the real and decoy transcript set. FDR was calculated as the 






Figure S 22: Comparison of mapping methodologies. The number of reads assigned to this hypothetical gene, 

















Figure S 25: Distribution of reads and spectra among observed genes in VCaP and RWPE. A and B. Distribution of reads and 
spectra, respectively, across extended dataset. C and D. Distribution of reads and spectra, respectively, across extended dataset 
after removal of top 100 most abundantly observed genes. E and F. Distribution of reads and spectra, respectively, across 


















A. PI3K/Akt Pathway colored by transcript fold change 
 




C. PI3K/Akt Pathway colored by discordance index 
 




Figure S 29: PI3K/Akt Signaling Pathway colored by VCaP/RWPE transcript fold change, protein fold change, discordance 
























GO:0005739 1109 4669 0.087974 0.095673 0.07436 0.092678 0.189368 0.239181 0.220921 0.283798 mitochondrion CC 
GO:0000166 1371 7290 0.194515 0.126364 0.190091 0.148335 0.295258 0.226834 0.287902 0.230131 nucleotide binding MF 
GO:0016020 2213 12613 0.153828 0.12507 0.143564 0.1261 0.176585 0.191634 0.207733 0.238873 membrane CC 
GO:0005524 1037 5332 0.105549 0.062988 0.120108 0.083077 0.210816 0.128989 0.199519 0.127243 ATP binding MF 
GO:0005515 3215 17433 0.43172 0.38374 0.453007 0.400261 0.505604 0.44195 0.530704 0.452411 protein binding MF 
GO:0005743 251 980 0.026316 0.036553 0.016199 0.026615 0.060533 0.08263 0.086684 0.119398 mitochondrial inner 
membrane 
CC 
GO:0005634 3676 19673 0.391271 0.342794 0.437047 0.391448 0.423686 0.383929 0.442599 0.379974 nucleus CC 
GO:0006810 361 2081 0.033341 0.030051 0.036993 0.034407 0.061443 0.06892 0.065442 0.074691 transport BP 
GO:0005654 744 3572 0.099669 0.09049 0.109085 0.106917 0.144546 0.128082 0.165531 0.140452 nucleoplasm CC 
GO:0005783 702 3602 0.067749 0.049968 0.06281 0.051301 0.090773 0.08754 0.106616 0.111975 endoplasmic reticulum CC 
GO:0005737 3603 19916 0.441512 0.423029 0.451041 0.438006 0.492567 0.460282 0.409522 0.388043 cytoplasm CC 
GO:0005886 1462 12903 0.138727 0.097976 0.175349 0.125197 0.166759 0.135185 0.195319 0.158953 plasma membrane CC 
GO:0015031 340 1395 0.027568 0.019526 0.031146 0.02519 0.054205 0.056471 0.047257 0.047685 protein transport BP 
GO:0005759 175 707 0.015747 0.014125 0.011658 0.013385 0.048689 0.049274 0.063661 0.065725 mitochondrial matrix CC 
GO:0008380 241 928 0.040935 0.029537 0.045753 0.041021 0.066799 0.063403 0.088998 0.082265 RNA splicing BP 
GO:0007264 214 1077 0.016956 0.011659 0.016244 0.012738 0.025088 0.04462 0.017212 0.033747 small GTPase mediated 
signal transduction 
BP 
GO:0000398 157 540 0.032946 0.024053 0.03559 0.032637 0.05655 0.055835 0.07599 0.07214 nuclear mRNA splicing, 
via spliceosome 
BP 
GO:0016787 690 3423 0.047288 0.030796 0.052173 0.040299 0.079969 0.061638 0.078641 0.058643 hydrolase activity MF 
GO:0005625 242 1442 0.033228 0.025399 0.032718 0.030957 0.058825 0.056057 0.042506 0.046765 soluble fraction CC 
GO:0007596 250 1917 0.029639 0.021224 0.047444 0.035119 0.047667 0.051767 0.055077 0.053919 blood coagulation BP 
GO:0042470 77 349 0.029361 0.021334 0.02447 0.021969 0.065558 0.050236 0.065648 0.059203 melanosome CC 
GO:0006457 144 531 0.033489 0.028962 0.024752 0.025576 0.061372 0.057592 0.057928 0.053851 protein folding BP 
GO:0005794 648 3435 0.061752 0.039819 0.061565 0.04393 0.078185 0.067553 0.050552 0.057415 Golgi apparatus CC 
GO:0006915 438 2403 0.042704 0.032036 0.058945 0.047421 0.061623 0.059639 0.080756 0.064667 apoptosis BP 
GO:0016491 299 1501 0.02977 0.030428 0.02361 0.025715 0.05671 0.057085 0.046014 0.051143 oxidoreductase activity MF 
GO:0006184 102 550 0.010289 0.00823 0.010677 0.010086 0.020955 0.034412 0.017564 0.029229 GTP catabolic process BP 
GO:0051082 98 344 0.024217 0.020695 0.01991 0.020996 0.052397 0.046814 0.051097 0.045701 unfolded protein 
binding 
MF 
GO:0005525 231 1254 0.060679 0.039976 0.038858 0.031914 0.052462 0.063898 0.039386 0.050232 GTP binding MF 
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GO:0005975 200 1020 0.024052 0.021633 0.017535 0.016672 0.050279 0.043944 0.046034 0.035814 carbohydrate metabolic 
process 
BP 
GO:0005789 444 2314 0.041613 0.029469 0.039817 0.031186 0.056872 0.051719 0.071712 0.07196 endoplasmic reticulum 
membrane 
CC 
GO:0016021 1943 13912 0.12101 0.087015 0.131349 0.102517 0.113958 0.107536 0.157464 0.162976 integral to membrane CC 
GO:0016887 98 452 0.012205 0.009056 0.017111 0.012567 0.040621 0.028672 0.040845 0.031311 ATPase activity MF 
GO:0055085 356 2525 0.026425 0.018163 0.035169 0.026055 0.044846 0.037765 0.073076 0.064187 transmembrane 
transport 
BP 
GO:0030168 118 1016 0.018543 0.014129 0.025386 0.0188 0.03097 0.033428 0.026838 0.021531 platelet activation BP 
GO:0006200 57 250 0.010276 0.008265 0.01488 0.011231 0.037708 0.027206 0.037888 0.029462 ATP catabolic process BP 
GO:0071013 76 253 0.020642 0.013563 0.020474 0.01616 0.035179 0.032437 0.049203 0.044187 catalytic step 2 
spliceosome 
CC 
GO:0005488 444 2312 0.036697 0.025843 0.043748 0.033315 0.063443 0.044471 0.050021 0.040373 binding MF 
GO:0016192 140 650 0.015684 0.011262 0.012281 0.010297 0.029401 0.02962 0.020429 0.021862 vesicle-mediated 
transport 
BP 
GO:0007411 187 1316 0.026703 0.017955 0.033987 0.02185 0.047809 0.036 0.03761 0.026808 axon guidance BP 
GO:0006006 67 398 0.014176 0.0149 0.00765 0.008658 0.032216 0.032131 0.018375 0.019913 glucose metabolic 
process 
BP 
GO:0016740 443 2029 0.035523 0.028693 0.036035 0.031104 0.053771 0.045869 0.044094 0.044486 transferase activity MF 
GO:0003779 198 1222 0.02335 0.014653 0.041177 0.026135 0.051253 0.031213 0.052974 0.018345 actin binding MF 
GO:0022904 78 282 0.010255 0.020979 0.005435 0.015013 0.020438 0.0374 0.023662 0.042602 respiratory electron 
transport chain 
BP 
GO:0005856 606 3308 0.058544 0.049213 0.068653 0.059094 0.075452 0.065535 0.058636 0.057366 cytoskeleton CC 
GO:0019904 115 612 0.016441 0.010636 0.018995 0.014849 0.024966 0.026482 0.025474 0.025061 protein domain specific 
binding 
MF 
GO:0003924 141 752 0.051805 0.033419 0.031734 0.026263 0.037428 0.048955 0.029556 0.040638 GTPase activity MF 
GO:0006096 29 178 0.012121 0.013327 0.005838 0.007203 0.028142 0.028531 0.01505 0.015198 glycolysis BP 
GO:0007165 628 4542 0.055654 0.035406 0.060299 0.047832 0.057791 0.050545 0.052423 0.057563 signal transduction BP 
GO:0030971 11 114 0.008649 0.013232 0.00639 0.007568 0.002349 0.002947 0.002149 0.002198 receptor tyrosine 
kinase binding 
MF 
GO:0005102 104 961 0.019482 0.025224 0.011788 0.015031 0.013495 0.014749 0.012046 0.013139 receptor binding MF 
GO:0030335 52 409 0.012279 0.014638 0.008741 0.00927 0.004928 0.003818 0.004085 0.003286 positive regulation of 
cell migration 
BP 
GO:0043204 17 147 0.007913 0.013147 0.003291 0.006161 0.001894 0.00223 0.001287 0.001591 perikaryon CC 









GO:0008284 169 1279 0.024954 0.027856 0.022127 0.020966 0.013436 0.016408 0.013145 0.014832 positive regulation of 
cell proliferation 
BP 
GO:0042593 31 234 0.008001 0.013105 0.004395 0.008346 0.001536 0.001405 0.000556 0.000758 glucose homeostasis BP 
GO:0042169 20 156 0.009194 0.013515 0.00502 0.00719 0.001926 0.001807 0.001364 0.001288 SH2 domain binding MF 
GO:0030425 90 621 0.014277 0.016652 0.009139 0.009908 0.006296 0.004904 0.004103 0.00385 dendrite CC 
GO:0030178 15 91 0.008028 0.012949 0.003788 0.006333 0.001007 0.001104 0.000798 0.000806 negative regulation of 
Wnt receptor signaling 
pathway 
BP 
GO:0048511 10 50 0.007609 0.01282 0.002664 0.005756 0.000733 0.000941 0.000422 0.000589 rhythmic process BP 
GO:0051726 41 220 0.010682 0.014616 0.007175 0.008948 0.004053 0.002682 0.003899 0.002658 regulation of cell cycle BP 
GO:0017148 17 103 0.012083 0.017088 0.004837 0.007757 0.004038 0.005022 0.00348 0.004328 negative regulation of 
translation 
BP 
GO:0040008 49 250 0.012202 0.016526 0.006266 0.009479 0.004183 0.004333 0.003603 0.004451 regulation of growth BP 




GO:0008270 1143 7162 0.08386 0.056167 0.097387 0.071519 0.063901 0.03945 0.052274 0.036237 zinc ion binding MF 
GO:0043065 111 646 0.023501 0.031212 0.017939 0.022638 0.017138 0.014452 0.023832 0.019535 positive regulation of 
apoptosis 
BP 
GO:0015934 10 38 0.01072 0.020035 0.003991 0.009229 0.001625 0.003015 0.0019 0.003331 large ribosomal subunit CC 
GO:0003674 386 2105 0.032772 0.041671 0.029448 0.037419 0.024899 0.024256 0.01994 0.021453 molecular_function MF 
GO:0003729 41 211 0.018466 0.03554 0.010563 0.020871 0.011923 0.015733 0.012499 0.0158 mRNA binding MF 
GO:0006413 40 130 0.02094 0.034275 0.015848 0.022013 0.01182 0.014019 0.008007 0.009614 translational initiation BP 
GO:0042273 10 27 0.00958 0.025192 0.008277 0.029077 0.002437 0.004166 0.002072 0.003698 ribosomal large subunit 
biogenesis 
BP 
GO:0042254 28 85 0.012562 0.027733 0.006095 0.015637 0.003273 0.004885 0.003691 0.005367 ribosome biogenesis BP 
GO:0003746 17 79 0.045285 0.031812 0.019935 0.017412 0.009052 0.008462 0.00547 0.005422 translation elongation 
factor activity 
MF 




GO:0042274 11 34 0.01533 0.044131 0.00912 0.034037 0.003152 0.007661 0.002373 0.00585 ribosomal small subunit 
biogenesis 
BP 
GO:0019843 21 58 0.019626 0.05317 0.007958 0.028844 0.003456 0.007446 0.003089 0.007005 rRNA binding MF 
GO:0005730 429 1900 0.075173 0.114545 0.077831 0.109151 0.06936 0.06276 0.087932 0.077141 nucleolus CC 
GO:0006364 84 236 0.029006 0.073513 0.023985 0.070573 0.014488 0.019575 0.017418 0.021468 rRNA processing BP 
GO:0015935 16 62 0.028931 0.075786 0.013817 0.049943 0.005064 0.011855 0.003696 0.008872 small ribosomal subunit CC 
140 
 
GO:0030529 95 416 0.083171 0.118695 0.050943 0.080217 0.053682 0.051568 0.062281 0.061747 ribonucleoprotein 
complex 
CC 
GO:0022625 34 109 0.056064 0.125895 0.02712 0.086786 0.010801 0.025034 0.007495 0.01728 cytosolic large 
ribosomal subunit 
CC 
GO:0003723 504 2292 0.15269 0.240052 0.12157 0.191674 0.119267 0.127315 0.135635 0.138667 RNA binding MF 
GO:0022627 32 100 0.061937 0.173238 0.026142 0.097605 0.013409 0.031887 0.008975 0.022414 cytosolic small 
ribosomal subunit 
CC 
GO:0005840 143 469 0.10628 0.26614 0.047984 0.156328 0.032801 0.071278 0.027883 0.060417 ribosome CC 
GO:0005829 1634 8692 0.369316 0.532487 0.280537 0.403723 0.328059 0.332868 0.253661 0.257336 cytosol CC 
GO:0005622 1180 6697 0.21673 0.365107 0.157222 0.266877 0.11459 0.14503 0.092671 0.113584 intracellular CC 
GO:0016032 268 1111 0.16874 0.38648 0.085608 0.241387 0.068255 0.111621 0.064276 0.091472 viral reproduction BP 
GO:0003735 144 479 0.148243 0.363859 0.067451 0.223718 0.034281 0.082215 0.028148 0.067506 structural constituent 
of ribosome 
MF 
GO:0016070 238 871 0.177833 0.390017 0.092348 0.245842 0.062642 0.107733 0.049697 0.08822 RNA metabolic process BP 
GO:0016071 203 746 0.174226 0.386783 0.08873 0.242156 0.058775 0.100212 0.045669 0.080137 mRNA metabolic 
process 
BP 
GO:0010467 361 1446 0.239667 0.432129 0.13933 0.28462 0.105771 0.139605 0.109123 0.129832 gene expression BP 
GO:0019058 83 284 0.152063 0.37148 0.06692 0.221226 0.033965 0.074026 0.023085 0.051966 viral infectious cycle BP 
GO:0006415 77 273 0.147869 0.366752 0.064603 0.218601 0.028355 0.068282 0.019052 0.047151 translational 
termination 
BP 
GO:0019083 74 259 0.14759 0.366594 0.06421 0.218302 0.028125 0.068055 0.018949 0.047024 viral transcription BP 
GO:0031018 92 374 0.148621 0.367162 0.065323 0.219685 0.02855 0.068491 0.020632 0.049269 endocrine pancreas 
development 
BP 
GO:0044267 240 929 0.224395 0.423099 0.111249 0.262106 0.075603 0.111339 0.065452 0.089585 cellular protein 
metabolic process 
BP 
GO:0006412 220 775 0.215326 0.418099 0.10781 0.260924 0.058624 0.10269 0.044418 0.081367 translation BP 
GO:0006414 85 309 0.190688 0.39615 0.083582 0.235132 0.035123 0.074307 0.023796 0.051742 translational elongation BP 














GO:0005739 1032 4669 0.09926 0.142869 0.076408 0.111656 0.188687 0.243711 0.216344 0.280198 mitochondrion CC 
GO:0000166 1356 7290 0.224941 0.188664 0.200768 0.180257 0.305077 0.246353 0.295978 0.246213 nucleotide binding MF 
GO:0005524 1027 5332 0.123656 0.099365 0.128403 0.106872 0.218386 0.140819 0.205702 0.137004 ATP binding MF 
GO:0005743 250 980 0.03097 0.058022 0.017356 0.034335 0.062727 0.090161 0.089242 0.12816 mitochondrial inner 
membrane 
CC 
GO:0005737 3565 19916 0.445929 0.438844 0.454505 0.45111 0.496185 0.470572 0.412106 0.39499 cytoplasm CC 
141 
 
GO:0005759 175 707 0.018556 0.022439 0.012511 0.017287 0.050565 0.053971 0.065701 0.07087 mitochondrial matrix CC 
GO:0015031 340 1395 0.032485 0.031017 0.033424 0.032532 0.056293 0.061854 0.048772 0.051418 protein transport BP 
GO:0007264 214 1077 0.019981 0.01852 0.017432 0.016451 0.026054 0.048872 0.017763 0.036389 small GTPase mediated 
signal transduction 
BP 
GO:0006810 360 2081 0.039265 0.047674 0.039643 0.044258 0.063702 0.075229 0.067415 0.080216 transport BP 
GO:0005515 3178 17433 0.448299 0.433091 0.462981 0.43902 0.513955 0.459592 0.539346 0.468704 protein binding MF 
GO:0005654 735 3572 0.106254 0.109415 0.112952 0.124094 0.147627 0.134567 0.169323 0.147688 nucleoplasm CC 
GO:0006184 102 550 0.012124 0.013074 0.011458 0.013026 0.021762 0.037691 0.018127 0.031517 GTP catabolic process BP 
GO:0007596 250 1917 0.034926 0.033716 0.050915 0.045355 0.049503 0.056701 0.056842 0.05814 blood coagulation BP 
GO:0000398 157 540 0.038823 0.038209 0.038194 0.04215 0.058729 0.061156 0.078425 0.077788 nuclear mRNA splicing, via 
spliceosome 
BP 
GO:0008380 241 928 0.048237 0.046921 0.0491 0.052977 0.069372 0.069446 0.091851 0.088705 RNA splicing BP 
GO:0005829 1557 8692 0.262183 0.26837 0.232019 0.240008 0.311367 0.290212 0.242185 0.226858 cytosol CC 
GO:0005625 240 1442 0.038842 0.039951 0.034975 0.039852 0.061067 0.06138 0.043863 0.050421 soluble fraction CC 
GO:0003723 452 2292 0.08184 0.076481 0.089095 0.090659 0.106192 0.097684 0.126881 0.118968 RNA binding MF 
GO:0042470 77 349 0.034599 0.03389 0.02626 0.028373 0.068084 0.055024 0.067752 0.063837 melanosome CC 
GO:0016787 688 3423 0.055667 0.048812 0.055952 0.051953 0.082878 0.067271 0.080744 0.062608 hydrolase activity MF 
GO:0005783 701 3602 0.077613 0.076899 0.066882 0.065562 0.093984 0.095303 0.109859 0.120361 endoplasmic reticulum CC 
GO:0051082 98 344 0.028536 0.032875 0.021367 0.027116 0.054415 0.051275 0.052735 0.049279 unfolded protein binding MF 
GO:0006457 144 531 0.039462 0.046008 0.026563 0.033031 0.063736 0.063081 0.059785 0.058066 protein folding BP 
GO:0016887 98 452 0.014382 0.014386 0.018363 0.01623 0.042186 0.031404 0.042155 0.033762 ATPase activity MF 
GO:0006200 57 250 0.012109 0.01313 0.015968 0.014505 0.039161 0.029799 0.039102 0.031769 ATP catabolic process BP 
GO:0016192 140 650 0.018482 0.01789 0.013179 0.013299 0.030534 0.032442 0.021084 0.023574 vesicle-mediated transport BP 
GO:0016491 299 1501 0.03508 0.048337 0.025337 0.03321 0.058895 0.062526 0.047489 0.055147 oxidoreductase activity MF 
GO:0030168 118 1016 0.021851 0.022445 0.027243 0.02428 0.032163 0.036614 0.027698 0.023216 platelet activation BP 
GO:0071013 76 253 0.024324 0.021545 0.021972 0.020871 0.036535 0.035529 0.05078 0.047646 catalytic step 2 
spliceosome 
CC 
GO:0005975 200 1020 0.028343 0.034365 0.018818 0.021531 0.052216 0.048132 0.04751 0.038618 carbohydrate metabolic 
process 
BP 
GO:0042645 34 112 0.006444 0.006803 0.00621 0.007291 0.022262 0.02055 0.036773 0.038771 mitochondrial nucleoid CC 
GO:0000278 272 1081 0.028805 0.029037 0.031756 0.033226 0.051933 0.041821 0.038406 0.03328 mitotic cell cycle BP 
GO:0055085 356 2525 0.031139 0.028854 0.037742 0.033649 0.046573 0.041364 0.075418 0.069212 transmembrane transport BP 
GO:0002576 45 357 0.011946 0.014557 0.016129 0.015933 0.021802 0.02656 0.015792 0.013425 platelet degranulation BP 
142 
 
GO:0005741 84 462 0.008351 0.008846 0.008403 0.008253 0.016479 0.020752 0.02238 0.0317 mitochondrial outer 
membrane 
CC 
GO:0006915 435 2403 0.049705 0.049205 0.062406 0.058532 0.062395 0.060944 0.082184 0.06648 apoptosis BP 
GO:0019904 113 612 0.019319 0.016825 0.020337 0.019094 0.025661 0.028521 0.02573 0.026039 protein domain specific 
binding 
MF 
GO:0006006 67 398 0.016705 0.023669 0.00821 0.011182 0.033457 0.035193 0.018964 0.021472 glucose metabolic process BP 
GO:0016032 195 1111 0.026019 0.036531 0.023095 0.030517 0.041766 0.048009 0.046819 0.048067 viral reproduction BP 
GO:0016020 2211 12613 0.181184 0.198637 0.153947 0.162782 0.183354 0.209874 0.214391 0.257573 membrane CC 
GO:0005634 3648 19673 0.409774 0.388218 0.448025 0.431147 0.42985 0.399201 0.449588 0.394075 nucleus CC 
GO:0007411 182 1316 0.031131 0.028281 0.03622 0.02803 0.049295 0.039214 0.038685 0.028824 axon guidance BP 
GO:0003779 198 1222 0.027515 0.023277 0.04419 0.033753 0.053228 0.034188 0.054672 0.019781 actin binding MF 
GO:0005681 70 268 0.012993 0.013471 0.011549 0.013466 0.022802 0.024298 0.029582 0.031289 spliceosomal complex CC 
GO:0003697 51 172 0.00989 0.01 0.011558 0.014558 0.021256 0.020783 0.025645 0.023001 single-stranded DNA 
binding 
MF 
GO:0005794 648 3435 0.072767 0.063254 0.066069 0.056734 0.081197 0.073992 0.052172 0.06191 Golgi apparatus CC 
GO:0005694 184 874 0.021503 0.017247 0.023532 0.018393 0.03011 0.027744 0.027563 0.023922 chromosome CC 
GO:0005198 103 749 0.016371 0.012043 0.024662 0.0176 0.038161 0.022215 0.043212 0.031903 structural molecule activity MF 
GO:0006397 160 770 0.023358 0.020199 0.025587 0.02499 0.034313 0.030336 0.045759 0.040588 mRNA processing BP 
GO:0006096 29 178 0.014283 0.021171 0.006265 0.009302 0.029227 0.03125 0.015532 0.016388 glycolysis BP 
GO:0048471 277 1631 0.053092 0.065101 0.04363 0.048169 0.055118 0.054442 0.049994 0.047978 perinuclear region of 
cytoplasm 
CC 
GO:0009615 84 497 0.018879 0.032182 0.013248 0.024227 0.014377 0.021446 0.013418 0.018223 response to virus BP 
GO:0006874 22 218 0.008425 0.015768 0.005154 0.011775 0.003491 0.00339 0.003735 0.004583 cellular calcium ion 
homeostasis 
BP 
GO:0030496 59 305 0.017821 0.027685 0.012322 0.016528 0.016963 0.014623 0.01982 0.017406 midbody CC 
GO:0008134 178 1054 0.027869 0.028639 0.030417 0.031061 0.026542 0.015191 0.030668 0.013764 transcription factor binding MF 
GO:0043565 248 2052 0.023547 0.020015 0.021701 0.020183 0.00921 0.006563 0.009088 0.007237 sequence-specific DNA 
binding 
MF 
GO:0003674 375 2105 0.032016 0.035818 0.027151 0.027919 0.02398 0.021681 0.01864 0.018491 molecular_function MF 
GO:0042995 98 638 0.018776 0.030108 0.013554 0.016287 0.010364 0.015822 0.004928 0.006366 cell projection CC 
GO:0006351 338 2278 0.038969 0.036239 0.038198 0.038142 0.022869 0.0219 0.017758 0.016409 transcription, DNA-
dependent 
BP 
GO:0030308 67 445 0.014944 0.026705 0.008565 0.013658 0.010609 0.011599 0.008288 0.010009 negative regulation of cell 
growth 
BP 
GO:0043065 110 646 0.022072 0.031978 0.016832 0.020268 0.01747 0.015256 0.024327 0.020565 positive regulation of 
apoptosis 
BP 
GO:0003700 489 3558 0.047693 0.039547 0.050307 0.047403 0.024664 0.022753 0.020303 0.018451 sequence-specific DNA MF 
143 
 
binding transcription factor 
activity 
GO:0019903 33 216 0.01557 0.025841 0.00907 0.012494 0.013619 0.008153 0.014578 0.00833 protein phosphatase 
binding 
MF 
GO:0030971 11 114 0.010192 0.02102 0.006858 0.009774 0.002439 0.003228 0.002218 0.00237 receptor tyrosine kinase 
binding 
MF 
GO:0005080 26 170 0.013196 0.023987 0.007296 0.012311 0.006216 0.006098 0.004532 0.005658 protein kinase C binding MF 
GO:0043025 106 723 0.019945 0.030821 0.015667 0.015833 0.01164 0.012804 0.007669 0.006857 neuronal cell body CC 
GO:0032880 17 114 0.010869 0.021926 0.004917 0.009165 0.002589 0.003901 0.001982 0.002928 regulation of protein 
localization 
BP 
GO:0043204 17 147 0.009325 0.020885 0.003532 0.007956 0.001967 0.002443 0.001328 0.001716 perikaryon CC 
GO:0030335 52 409 0.01447 0.023254 0.00938 0.011973 0.005118 0.004182 0.004216 0.003544 positive regulation of cell 
migration 
BP 
GO:0048511 10 50 0.008967 0.020365 0.002859 0.007434 0.000761 0.001031 0.000436 0.000635 rhythmic process BP 
GO:0030178 15 91 0.00946 0.020571 0.004065 0.00818 0.001046 0.001209 0.000823 0.000869 negative regulation of Wnt 
receptor signaling pathway 
BP 
GO:0043547 37 254 0.01185 0.022199 0.006395 0.009413 0.003807 0.002789 0.003222 0.002332 positive regulation of 
GTPase activity 
BP 
GO:0042169 20 156 0.010834 0.021469 0.005387 0.009285 0.002 0.001979 0.001408 0.001388 SH2 domain binding MF 





GO:0051726 41 220 0.012588 0.023218 0.0077 0.011557 0.004209 0.002938 0.004024 0.002866 regulation of cell cycle BP 
GO:0005622 1074 6697 0.113946 0.107319 0.109151 0.099066 0.0908 0.086897 0.073798 0.067046 intracellular CC 
GO:0016021 1943 13912 0.142596 0.138229 0.140959 0.132399 0.118348 0.117785 0.162512 0.175735 integral to membrane CC 
GO:0001934 42 278 0.012272 0.022345 0.006966 0.009953 0.001985 0.001729 0.001464 0.001509 positive regulation of 
protein phosphorylation 
BP 
GO:0030425 90 621 0.016824 0.026453 0.009808 0.012796 0.006538 0.005371 0.004234 0.004152 dendrite CC 
GO:0046872 1775 10580 0.140818 0.112463 0.147036 0.126006 0.111399 0.091297 0.100019 0.084938 metal ion binding MF 
GO:0040008 49 250 0.014378 0.026252 0.006724 0.012242 0.004344 0.004746 0.003719 0.0048 regulation of growth BP 
GO:0017148 17 103 0.014239 0.027146 0.005191 0.010018 0.004194 0.0055 0.003591 0.004666 negative regulation of 
translation 
BP 
GO:0005102 104 961 0.022957 0.040069 0.01265 0.019413 0.014015 0.016154 0.012432 0.014168 receptor binding MF 
GO:0006355 931 5999 0.09235 0.077149 0.10105 0.090573 0.060527 0.051787 0.062389 0.052149 regulation of transcription, 
DNA-dependent 
BP 
GO:0008270 1140 7162 0.096292 0.070918 0.103422 0.083522 0.066123 0.041933 0.053771 0.038123 zinc ion binding MF 
GO:0010467 288 1446 0.109598 0.109048 0.080747 0.086352 0.080727 0.07866 0.093105 0.08943 gene expression BP 




GO:0003746 17 79 0.053363 0.050535 0.021394 0.022488 0.009401 0.009269 0.005645 0.005846 translation elongation 
factor activity 
MF 
GO:0006414 12 309 0.051882 0.051894 0.02092 0.02244 0.007357 0.007139 0.005042 0.005226 translational elongation BP 
GO:0044267 167 929 0.091601 0.094704 0.050612 0.057277 0.049396 0.0477 0.048033 0.046032 cellular protein metabolic 
process 
BP 
GO:0006412 80 775 0.076759 0.077957 0.043805 0.04771 0.025011 0.021246 0.017179 0.014978 translation BP 


























































































GO:0000155 6 56 -0.14516 0.783795 0.028571 1 1.706637 4.125767 2.85886 4.322668 0.810463 1 two-component sensor 
activity 
MF 
GO:0005123 7 68 -0.13188 0.778058 0 1 1.885487 3.284669 2.069755 2.950255 0.805816 1 death receptor binding MF 
GO:0006264 6 34 0.274419 0.598705 -0.02857 1 2.968612 3.337416 2.914576 3.463296 0.640528 1 mitochondrial DNA 
replication 
BP 
GO:0006809 6 54 0.533425 0.275753 -0.02857 1 4.49339 3.884449 5.127782 4.151512 0.321354 1 nitric oxide biosynthetic 
process 
BP 
GO:0006978 6 105 0.077446 0.884063 -0.02857 1 1.58638 4.46804 0.96182 4.910636 0.897912 1 DNA damage response, 
signal transduction by p53 
class mediator resulting in 
transcription of p21 class 
mediator 
BP 
GO:0007096 7 23 0.126086 0.787647 0 1 2.919312 4.08101 2.94712 4.026579 0.814014 1 regulation of exit from 
mitosis 
BP 
GO:0030217 7 83 -0.10794 0.817813 0 1 1.06325 3.954415 1.741783 3.563928 0.840723 1 T cell differentiation BP 
GO:0032402 6 32 -0.35827 0.48559 0.028571 1 1.943608 2.525552 1.977075 2.876346 0.531068 1 melanosome transport BP 
GO:0043240 6 33 0.776588 0.069294 0.028571 1 0.312925 2.929093 0.033833 2.449059 0.099714 1 Fanconi anaemia nuclear 
complex 
CC 





GO:0030897 12 40 0.383211 0.218846 0.006993 0.99123 2.950357 3.619346 2.904523 3.716765 0.262104 0.996
353 
HOPS complex CC 
GO:0045022 9 34 -0.15323 0.693881 -0.01667 0.98157 2.466359 3.382254 2.745233 3.604485 0.728725 0.987
153 
early endosome to late 
endosome transport 
BP 
GO:0009953 8 106 0.080765 0.849222 -0.02381 0.97678
6 





GO:0022857 11 127 0.058339 0.864713 -0.01818 0.96757
6 





GO:0042776 11 56 0.058339 0.864713 -0.01818 0.96757
6 
7.787493 7.93148 7.96804 7.943038 0.881019 0.974
087 
mitochondrial ATP synthesis 
coupled proton transport 
BP 
GO:0000780 7 52 -0.03206 0.945605 -0.03571 0.96349
2 






GO:0014047 7 112 -0.03184 0.945977 -0.03571 0.96349
2 
3.744536 4.540525 4.603214 5.134869 0.954255 0.970
98 
glutamate secretion BP 
GO:0034361 7 57 0.348357 0.443831 0.035714 0.96349
2 





GO:0001947 12 112 0.112892 0.726846 0.020979 0.95616
9 
0.781019 3.707599 0.205568 3.844372 0.757618 0.965
101 
heart looping BP 
GO:0021510 9 48 -0.01271 0.97411 -0.03333 0.94839
1 
2.1024 4.196527 1.798366 4.22595 0.977507 0.957
747 
spinal cord development BP 
GO:0005665 10 30 -0.19658 0.586209 0.030303 0.94571 4.88888 6.077029 5.301099 5.665269 0.628196 0.955
812 
DNA-directed RNA 
polymerase II, core complex 
CC 
GO:0007076 11 56 0.744044 0.008648 0.027273 0.94598
4 










GO:0001578 8 66 0.199837 0.635162 0.047619 0.93487
1 





GO:0005885 6 24 0.060362 0.909568 0.085714 0.91944
4 
5.862062 6.215573 5.845399 6.01438 0.922372 0.930
932 
Arp2/3 protein complex CC 
GO:0006402 6 42 0.154606 0.769939 -0.08571 0.91944
4 
3.600288 3.537144 3.18834 3.402525 0.798258 0.930
932 
mRNA catabolic process BP 
GO:0008430 6 46 0.331697 0.520702 0.085714 0.91944
4 
5.001446 5.287518 5.188867 5.312317 0.567057 0.930
932 
selenium binding MF 
GO:0019370 6 82 0.178169 0.735575 0.085714 0.91944
4 





GO:0019509 6 14 0.329718 0.523346 0.085714 0.91944
4 
4.536792 4.931061 5.370887 4.85833 0.569618 0.930
932 
L-methionine salvage from 
methylthioadenosine 
BP 
GO:0032012 6 51 -0.12423 0.814612 -0.08571 0.91944
4 
2.946582 4.808346 4.049818 4.762404 0.838318 0.930
932 





GO:0042719 6 15 0.214519 0.683157 0.085714 0.91944
4 




protein transporter complex 
CC 
GO:0050873 6 63 0.254166 0.626961 0.085714 0.91944
4 
3.766627 4.328653 3.900917 3.734092 0.667089 0.930
932 
brown fat cell 
differentiation 
BP 
GO:0051775 6 33 0.260688 0.617826 -0.08571 0.91944
4 
3.57828 3.666702 2.98081 4.502902 0.658089 0.930
932 
response to redox state BP 
GO:0005249 13 204 -0.0197 0.949074 0.038462 0.90620
2 





GO:0005852 14 36 0.000727 0.998031 0.037363 0.90351
5 
5.654854 7.128447 5.656926 7.336547 0.998031 0.921
992 
eukaryotic translation 
initiation factor 3 complex 
CC 
GO:0017016 7 70 0.216712 0.640676 0.071429 0.90634
9 
3.34035 4.908538 2.823527 5.431044 0.679081 0.921
992 
Ras GTPase binding MF 
GO:0042994 7 28 0.086827 0.853152 -0.07143 0.90634
9 
1.593033 4.282385 0.807175 4.045346 0.871982 0.921
992 
cytoplasmic sequestering of 
transcription factor 
BP 
GO:0046902 7 42 -0.02229 0.962174 0.071429 0.90634
9 
4.105835 5.641096 4.102837 5.547346 0.967147 0.921
992 
regulation of mitochondrial 
membrane permeability 
BP 
GO:0060170 7 51 -0.37459 0.407732 0.071429 0.90634
9 
0.520899 2.96779 -0.10098 3.868971 0.453943 0.921
992 
cilium membrane CC 
GO:0070776 7 20 0.62817 0.130868 0.071429 0.90634
9 





GO:0006595 10 41 0.056151 0.877556 0.054545 0.89163
9 





GO:0005838 8 25 -0.04318 0.919138 -0.07143 0.88199
4 





GO:0030216 14 143 0.053804 0.855052 -0.05055 0.86759
6 
4.11148 3.986381 4.967306 4.158697 0.873349 0.886
745 
keratinocyte differentiation BP 
GO:0004540 10 49 0.0664 0.855388 0.066667 0.86475
4 
3.044213 3.402404 3.177262 3.300741 0.873349 0.884
304 
ribonuclease activity MF 
GO:0035035 10 65 0.056663 0.876447 0.066667 0.86475
4 





GO:0005762 12 53 -0.10149 0.753637 -0.06294 0.85168
2 





GO:0000060 8 48 0.295673 0.477076 0.095238 0.84012
9 
3.499068 5.574924 3.960934 5.353057 0.522493 0.860
48 
protein import into nucleus, 
translocation 
BP 
GO:0004180 8 64 0.172182 0.683483 0.095238 0.84012
9 
4.566439 4.856274 4.754083 4.633416 0.718193 0.860
48 
carboxypeptidase activity MF 
GO:0004708 7 56 -0.16974 0.71598 -0.10714 0.83968
3 
2.976688 4.748909 4.189957 4.67014 0.748141 0.860
48 
MAP kinase kinase activity MF 
GO:0004812 8 18 0.045462 0.914876 -0.09524 0.84012
9 







GO:0007613 7 125 0.208374 0.653882 0.107143 0.83968
3 
1.379606 3.500382 1.184834 3.592548 0.690446 0.860
48 
memory BP 
GO:0007616 8 56 -0.08513 0.841159 -0.09524 0.84012
9 
0.666376 3.591943 0.709482 3.530432 0.861081 0.860
48 
long-term memory BP 
GO:0016574 7 16 -0.04364 0.925981 -0.10714 0.83968
3 
4.264455 5.277682 4.573467 5.030299 0.937062 0.860
48 
histone ubiquitination BP 
GO:0034045 7 40 -0.17632 0.705304 -0.10714 0.83968
3 





GO:0051298 7 24 0.403053 0.369952 0.107143 0.83968
3 
0.509864 2.244409 0.101317 2.542946 0.418104 0.860
48 
centrosome duplication BP 
GO:0070652 7 25 -0.07939 0.865641 0.107143 0.83968
3 
1.726521 2.996759 1.876996 3.306382 0.881042 0.860
48 
HAUS complex CC 
GO:0005763 18 51 0.004591 0.985576 0.05676 0.82419
7 





GO:0016758 10 76 0.219678 0.541981 0.090909 0.81141
7 
1.127205 3.601567 0.914634 3.885428 0.586619 0.835
914 
transferase activity, 
transferring hexosyl groups 
MF 
GO:0031080 10 32 0.344109 0.33024 0.090909 0.81141
7 
4.472784 4.096785 4.450308 4.133036 0.377168 0.835
914 
Nup107-160 complex CC 
GO:0000127 6 18 -0.14164 0.788964 0.142857 0.80277
8 
3.802158 5.203798 4.033205 5.121666 0.814077 0.827
891 
transcription factor TFIIIC 
complex 
CC 
GO:0005869 6 14 0.146653 0.781598 0.142857 0.80277
8 
3.93185 5.354414 3.658466 5.329118 0.808622 0.827
891 
dynactin complex CC 
GO:0006970 6 60 0.146807 0.781372 0.142857 0.80277
8 
3.959046 4.787542 4.124674 4.797692 0.808622 0.827
891 
response to osmotic stress BP 
GO:0008045 6 55 0.525475 0.284335 0.142857 0.80277
8 
1.054204 3.8056 0.963417 3.690749 0.330761 0.827
891 
motor axon guidance BP 
GO:0009967 6 40 0.150969 0.775266 0.142857 0.80277
8 
1.979504 3.022653 2.059615 3.072051 0.803353 0.827
891 
positive regulation of signal 
transduction 
BP 
GO:0016597 6 69 0.758267 0.08059 0.142857 0.80277
8 
5.681765 5.033042 5.265131 4.799985 0.113175 0.827
891 
amino acid binding MF 
GO:0032040 6 18 0.643882 0.167649 -0.14286 0.80277
8 
5.125832 4.970863 4.949758 4.303314 0.209292 0.827
891 
small-subunit processome CC 
GO:0033197 6 24 0.036412 0.945407 -0.14286 0.80277
8 
3.727987 5.07015 4.210584 4.861769 0.954255 0.827
891 
response to vitamin E BP 
GO:0035329 6 40 0.192038 0.715484 0.142857 0.80277
8 
1.335753 3.886391 0.906091 3.938212 0.748141 0.827
891 
hippo signaling cascade BP 
GO:0042791 6 18 -0.14164 0.788964 0.142857 0.80277
8 
3.802158 5.203798 4.033205 5.121666 0.814077 0.827
891 
5S class rRNA transcription 
from RNA polymerase III 
type 1 promoter 
BP 
GO:0042797 6 18 -0.14164 0.788964 0.142857 0.80277
8 
3.802158 5.203798 4.033205 5.121666 0.814077 0.827
891 
tRNA transcription from 





GO:0045821 6 46 0.109416 0.836531 0.142857 0.80277
8 
1.622886 3.225132 0.953598 3.465567 0.857246 0.827
891 
positive regulation of 
glycolysis 
BP 
GO:0050872 6 32 0.305533 0.555962 0.142857 0.80277
8 
3.470047 4.050053 4.327572 3.433872 0.600414 0.827
891 
white fat cell differentiation BP 
GO:0051787 6 17 0.704671 0.11795 0.142857 0.80277
8 
3.480283 4.52336 3.558056 3.518262 0.155957 0.827
891 
misfolded protein binding MF 
GO:0072321 6 23 0.311223 0.548238 0.142857 0.80277
8 





GO:0004860 8 83 -0.37973 0.353493 -0.11905 0.79300
6 
2.451951 4.469697 1.94218 4.225808 0.401837 0.824
37 
protein kinase inhibitor 
activity 
MF 
GO:0015450 8 32 -0.01361 0.974492 0.119048 0.79300
6 






GO:0005385 7 63 -0.26329 0.568351 -0.14286 0.78254 1.906459 3.302833 1.979942 3.121176 0.61108 0.814
36 
zinc ion transmembrane 
transporter activity 
MF 
GO:0045039 7 17 0.291589 0.525756 0.142857 0.78254 5.904888 4.894105 5.6878 4.427176 0.571922 0.814
36 




GO:0048010 7 143 0.224831 0.627888 0.142857 0.78254 2.036957 4.292898 2.629081 4.548084 0.66771 0.814
36 
vascular endothelial growth 
factor receptor signaling 
pathway 
BP 
GO:0009303 9 48 -0.06875 0.860493 0.116667 0.77562
8 
3.037248 4.014229 3.778786 4.467472 0.8781 0.808
466 
rRNA transcription BP 
GO:0009434 9 84 -0.21274 0.582624 -0.11667 0.77562
8 





GO:0080008 9 49 0.279484 0.466411 0.116667 0.77562
8 
1.868996 4.498818 1.576045 4.807762 0.512814 0.808
466 
CUL4 RING ubiquitin ligase 
complex 
CC 
GO:0005753 12 72 0.170314 0.596662 0.097902 0.76628
8 
7.632982 7.860837 7.926093 7.830071 0.638694 0.800
017 
mitochondrial proton-
transporting ATP synthase 
complex 
CC 
GO:0008076 13 303 -0.02124 0.945086 0.093407 0.76458
2 





GO:0007093 11 57 0.042351 0.901603 0.118182 0.73425
2 
2.617307 3.788773 2.445362 3.9771 0.914772 0.767
394 
mitotic cell cycle checkpoint BP 
GO:0001078 6 47 0.107315 0.839645 -0.2 0.71388
9 
1.42974 1.48496 1.239537 1.787778 0.859984 0.746
513 
RNA polymerase II core 
promoter proximal region 
sequence-specific DNA 
binding transcription factor 
activity involved in negative 




GO:0005786 6 24 0.379296 0.45834 0.2 0.71388
9 
6.498161 6.241037 6.452568 6.019001 0.505083 0.746
513 




GO:0006699 7 80 0.222599 0.631397 0.178571 0.71309
5 
4.865813 4.340004 4.890856 4.431447 0.671075 0.746
513 
bile acid biosynthetic 
process 
BP 
GO:0016601 6 43 -0.0092 0.986205 0.2 0.71388
9 
3.823909 5.341234 2.615023 5.908155 0.987728 0.746
513 
Rac protein signal 
transduction 
BP 
GO:0016705 6 125 -0.02907 0.956404 0.2 0.71388
9 
2.737547 4.24624 3.438236 4.468448 0.962732 0.746
513 
oxidoreductase activity, 
acting on paired donors, 
with incorporation or 
reduction of molecular 
oxygen 
MF 
GO:0030132 6 34 -0.18242 0.72941 -0.2 0.71388
9 
5.888782 5.723061 5.45786 6.291793 0.759477 0.746
513 
clathrin coat of coated pit CC 
GO:0030658 6 67 0.293838 0.571927 0.2 0.71388
9 
3.852178 3.319619 3.693018 3.616373 0.614585 0.746
513 
transport vesicle membrane CC 
GO:0032886 7 36 0.668333 0.100772 0.178571 0.71309
5 





GO:0033189 6 44 -0.30745 0.553355 -0.2 0.71388
9 
1.901814 2.491207 1.735519 2.491306 0.597931 0.746
513 
response to vitamin A BP 
GO:0042220 6 66 -0.30999 0.549914 -0.2 0.71388
9 
2.830842 3.892832 2.878781 3.800731 0.594543 0.746
513 
response to cocaine BP 
GO:0045749 6 54 0.574724 0.232832 0.2 0.71388
9 
2.353655 3.885501 2.84048 4.155438 0.277317 0.746
513 
negative regulation of S 
phase of mitotic cell cycle 
BP 
GO:0045861 7 56 0.068475 0.884025 -0.17857 0.71309
5 
2.594123 3.461883 4.22095 3.205879 0.897912 0.746
513 
negative regulation of 
proteolysis 
BP 
GO:0046856 7 28 0.060771 0.897023 -0.17857 0.71309
5 





GO:0046965 6 68 0.136091 0.797124 0.2 0.71388
9 
2.123397 4.430161 1.397027 4.530316 0.822061 0.746
513 
retinoid X receptor binding MF 
GO:0048844 6 104 0.410202 0.419208 0.2 0.71388
9 
1.891024 4.184359 1.873121 4.363168 0.465122 0.746
513 
artery morphogenesis BP 
GO:0070628 7 39 0.84539 0.01658 0.178571 0.71309
5 
3.722316 4.27441 4.7994 4.802679 0.030309 0.746
513 
proteasome binding MF 
GO:0004857 10 116 0.138793 0.702171 0.139394 0.70720
4 
3.694002 4.469526 4.465802 3.632776 0.737034 0.745
939 
enzyme inhibitor activity MF 
GO:0005086 8 55 -0.01779 0.966656 0.166667 0.70332
3 
2.834204 4.452866 3.694324 4.648291 0.97115 0.742
249 
ARF guanyl-nucleotide 
exchange factor activity 
MF 
GO:0010039 8 61 0.24615 0.556773 0.166667 0.70332
3 
2.685636 4.22205 2.714877 4.076957 0.600956 0.742
249 
response to iron ion BP 




GO:0035176 8 88 -0.10291 0.808409 -0.16667 0.70332
3 
0.730298 2.763651 0.380696 2.011826 0.832815 0.742
249 
social behavior BP 
GO:0048589 11 86 0.129165 0.705057 0.136364 0.69351
1 
2.094279 4.349534 2.037414 4.482276 0.739524 0.733
485 
developmental growth BP 
GO:0005798 9 40 0.177061 0.648585 0.166667 0.67774
5 
4.270202 4.745904 4.11933 4.555844 0.686716 0.717
2 
Golgi-associated vesicle CC 
GO:0010388 9 32 -0.19562 0.613976 -0.16667 0.67774
5 
5.212592 5.454356 5.152003 5.185979 0.654347 0.717
2 
cullin deneddylation BP 
GO:0043015 9 44 0.267954 0.485743 0.166667 0.67774
5 
0.765909 2.905093 0.397828 3.16564 0.531068 0.717
2 
gamma-tubulin binding MF 
GO:0071479 13 82 -0.06873 0.823468 0.131868 0.66926
9 
3.754099 4.544498 4.154754 4.667042 0.845642 0.709
389 
cellular response to ionizing 
radiation 
BP 
GO:0006342 8 45 -0.09394 0.824903 0.190476 0.66458
3 
1.68228 3.320104 1.711693 3.321277 0.846668 0.704
806 
chromatin silencing BP 
GO:0034968 8 40 -0.09873 0.816088 0.190476 0.66458
3 
1.758078 5.185802 2.559593 5.425431 0.839393 0.704
806 
histone lysine methylation BP 
GO:0000028 6 18 0.86197 0.027264 0.257143 0.65833
3 
7.336446 10.69022 7.633733 11.44902 0.045911 0.702
311 
ribosomal small subunit 
assembly 
BP 
GO:0002089 7 42 0.619982 0.137499 0.214286 0.66150
8 
1.564496 2.79103 0.873027 3.265312 0.177817 0.702
311 
lens morphogenesis in 
camera-type eye 
BP 
GO:0004497 7 176 0.324888 0.477094 0.214286 0.66150
8 
3.120909 4.353972 3.347399 4.186589 0.522493 0.702
311 
monooxygenase activity MF 
GO:0004691 6 57 0.56001 0.247798 0.257143 0.65833
3 





GO:0005655 7 27 0.023671 0.959826 0.214286 0.66150
8 
3.927042 3.736024 3.354022 3.411782 0.965285 0.702
311 
nucleolar ribonuclease P 
complex 
CC 
GO:0005675 10 30 0.279228 0.434625 0.163636 0.65672
1 
2.172685 3.92879 2.099752 3.981999 0.481131 0.702
311 
holo TFIIH complex CC 
GO:0006002 6 25 0.337619 0.512814 0.257143 0.65833
3 





GO:0006024 6 34 0.561501 0.246264 0.257143 0.65833
3 





GO:0006613 7 26 0.171048 0.713848 -0.21429 0.66150
8 
5.610698 5.650862 5.775539 5.71471 0.746872 0.702
311 
cotranslational protein 
targeting to membrane 
BP 
GO:0006614 6 26 0.371912 0.467853 0.257143 0.65833
3 




targeting to membrane 
BP 
GO:0006777 6 30 0.418393 0.409031 0.257143 0.65833
3 







GO:0007628 7 80 -0.54028 0.210579 -0.21429 0.66150
8 
3.071974 3.646511 3.541618 3.650579 0.253451 0.702
311 
adult walking behavior BP 
GO:0008053 7 37 0.327517 0.473325 0.214286 0.66150
8 
4.502082 4.585344 4.371054 4.256274 0.519243 0.702
311 
mitochondrial fusion BP 
GO:0008121 6 18 -0.03542 0.946896 -0.25714 0.65833
3 





GO:0008198 7 63 -0.21721 0.639893 -0.21429 0.66150
8 
3.244306 3.849059 2.836501 4.195741 0.678621 0.702
311 
ferrous iron binding MF 
GO:0008312 6 24 0.405308 0.425329 0.257143 0.65833
3 
6.376076 6.212075 6.452568 5.932117 0.471645 0.702
311 
7S RNA binding MF 
GO:0008378 7 73 0.380211 0.400158 0.214286 0.66150
8 





GO:0008535 7 28 -0.09189 0.844654 -0.21429 0.66150
8 
2.624227 3.580697 2.586406 3.741468 0.864204 0.702
311 
respiratory chain complex IV 
assembly 
BP 
GO:0016303 6 24 -0.02094 0.968588 0.257143 0.65833
3 





GO:0030127 7 38 0.209832 0.651568 0.214286 0.66150
8 
4.498504 4.467927 5.09278 4.947864 0.688604 0.702
311 
COPII vesicle coat CC 
GO:0033327 7 74 0.239356 0.605195 0.214286 0.66150
8 
4.698243 5.465353 3.816037 5.664749 0.646406 0.702
311 
Leydig cell differentiation BP 
GO:0045494 6 107 -0.37973 0.45778 -0.25714 0.65833
3 





GO:0046934 6 30 0.246694 0.637466 0.257143 0.65833
3 






GO:0048193 6 20 0.325252 0.529327 0.257143 0.65833
3 
3.883264 4.755331 3.755475 4.632732 0.57452 0.702
311 
Golgi vesicle transport BP 
GO:0048469 6 124 0.284398 0.584904 0.257143 0.65833
3 
2.831301 4.241518 2.286359 3.198199 0.627143 0.702
311 
cell maturation BP 
GO:0048813 7 90 0.444746 0.317376 0.214286 0.66150
8 
2.479469 4.166878 2.249371 4.403025 0.364746 0.702
311 
dendrite morphogenesis BP 
GO:0048839 6 81 0.26652 0.609685 0.257143 0.65833
3 
2.449564 3.753587 2.459437 3.848262 0.650131 0.702
311 
inner ear development BP 
GO:0070330 6 78 0.059672 0.910598 0.257143 0.65833
3 
1.419744 3.911336 1.422053 3.624144 0.922935 0.702
311 
aromatase activity MF 
GO:0071577 6 49 -0.18976 0.718783 0.257143 0.65833
3 
1.452174 4.650851 0.223212 4.561511 0.75042 0.702
311 
zinc ion transmembrane 
transport 
BP 
GO:0008138 15 116 0.253647 0.361668 0.132143 0.63893
3 










GO:0006939 8 59 0.424742 0.294207 0.214286 0.61909
7 
1.502986 3.867751 1.7486 3.566193 0.340818 0.668
226 
smooth muscle contraction BP 
GO:0000080 14 93 0.183091 0.530971 0.147415 0.61502
6 
2.646912 4.406066 2.435286 3.871792 0.575662 0.664
569 
G1 phase of mitotic cell 
cycle 
BP 
GO:0005978 9 55 0.205222 0.596322 0.2 0.61340
4 





GO:0046326 9 108 0.124223 0.750167 0.2 0.61340
4 
2.486307 4.07297 2.629081 4.018281 0.779421 0.663
185 
positive regulation of 
glucose import 
BP 
GO:0090263 12 174 0.198823 0.535598 0.167832 0.60372
8 
1.870801 4.63801 1.375893 4.575197 0.580032 0.653
45 
positive regulation of 
canonical Wnt receptor 
signaling pathway 
BP 


























































































GO:0000083 11 79 0.578206 0.062422 -0.00909 0.98919 0.943491 4.405098 0.690824 3.859411 0.106015 1 regulation of 
transcription 
involved in G1/S 
phase of mitotic 
cell cycle 
BP 








GO:0005484 16 63 0.04252 0.875754 -0.00294 0.991368 4.082291 4.527798 4.394332 4.368086 0.892412 1 SNAP receptor 
activity 
MF 
GO:0005885 6 24 -0.30081 0.562395 -0.02857 1 5.977803 6.504942 6.106591 6.536278 0.612719 1 Arp2/3 protein 
complex 
CC 
GO:0006402 6 42 -0.07763 0.883792 0.028571 1 3.857025 5.245389 4.625575 4.830376 0.899137 1 mRNA catabolic 
process 
BP 





GO:0006836 6 123 0.310487 0.549236 -0.02857 1 1.159222 4.647837 0.969639 5.019907 0.601954 1 neurotransmitter 
transport 
BP 
GO:0008378 9 73 0.3119 0.413885 0 1 1.505785 3.813266 0.780909 3.818202 0.479033 1 galactosyltransfera
se activity 
MF 
GO:0015813 7 39 0.06358 0.892282 0 1 5.923861 4.097933 6.052496 4.273186 0.904829 1 L-glutamate 
transport 
BP 
GO:0017015 6 72 0.045808 0.931336 -0.02857 1 0.847658 4.771944 0.46429 4.715752 0.938846 1 regulation of 
transforming 




GO:0033205 8 24 -0.14781 0.726859 0 1 0.992269 3.63886 0.776114 3.478839 0.763936 1 cell cycle 
cytokinesis 
BP 
GO:0043097 6 34 0.22016 0.675096 -0.02857 1 2.959259 4.683752 2.985357 3.950088 0.71717 1 pyrimidine 
nucleoside salvage 
BP 
GO:0043406 7 161 0.153797 0.741984 0 1 3.516117 5.343588 4.165809 5.619048 0.776784 1 positive regulation 
of MAP kinase 
activity 
BP 
GO:0045600 9 56 0.038286 0.922099 0 1 1.015886 4.173472 1.058894 4.467799 0.931539 1 positive regulation 
of fat cell 
differentiation 
BP 
GO:0048193 6 20 0.007624 0.988565 -0.02857 1 3.94513 5.331832 4.714244 5.026644 0.989621 1 Golgi vesicle 
transport 
BP 
GO:0048255 7 80 0.133501 0.775376 0 1 5.958022 6.59122 6.614494 6.359974 0.806786 1 mRNA stabilization BP 




GO:0048839 6 81 0.074912 0.887842 0.028571 1 1.630889 4.80235 1.160322 4.55511 0.902005 1 inner ear 
development 
BP 
GO:0051457 9 42 0.130211 0.738455 0 1 2.470677 4.417102 2.272297 4.370446 0.773521 1 maintenance of 
protein location in 
nucleus 
BP 
GO:0071479 12 82 0.260734 0.413066 0 1 3.169443 4.710873 3.157797 4.255418 0.478381 1 cellular response to 
ionizing radiation 
BP 
GO:0090200 7 72 0.077148 0.869419 0 1 4.369794 3.527011 3.888969 3.58635 0.887403 1 positive regulation 
of release of 
cytochrome c from 
mitochondria 
BP 
















GO:0045860 10 108 0.196375 0.586616 -0.01818 0.972841 1.774997 4.939309 1.263712 4.85641 0.634794 0.98598
8 
positive regulation 
of protein kinase 
activity 
BP 










GO:0006613 7 26 0.138917 0.766436 0.035714 0.963492 5.735365 6.214166 5.831593 6.338304 0.798471 0.97756
9 
cotranslational 
protein targeting to 
membrane 
BP 











GO:0070403 7 46 0.087757 0.851593 -0.03571 0.963492 3.847249 3.860134 3.910502 3.657623 0.872534 0.97756
9 
NAD+ binding MF 























GO:0043473 9 94 0.292413 0.44513 0.033333 0.948391 0.359067 2.735137 -0.76001 2.880714 0.508112 0.96695
6 
pigmentation BP 
GO:0045022 9 34 0.065087 0.867873 -0.03333 0.948391 0.648975 3.778828 -0.06212 4.268493 0.886308 0.96695
6 









GO:0004812 8 18 0.371342 0.365094 0.047619 0.934871 4.479887 5.742679 5.565166 5.409695 0.431034 0.95421 aminoacyl-tRNA 
ligase activity 
MF 
GO:0006829 8 59 0.282455 0.497891 0.047619 0.934871 2.552103 3.831671 2.91061 4.125763 0.556344 0.95421 zinc ion transport BP 
GO:0007062 8 44 0.016412 0.969233 0.047619 0.934871 3.445465 5.338565 5.112441 5.491767 0.972344 0.95421 sister chromatid 
cohesion 
BP 
GO:0007093 8 57 0.110806 0.793933 0.047619 0.934871 2.567786 4.205014 2.867301 4.076333 0.822899 0.95421 mitotic cell cycle 
checkpoint 
BP 






GO:0021510 8 48 0.245037 0.558616 -0.04762 0.934871 3.034725 5.017556 3.432397 5.04351 0.60931 0.95421 spinal cord 
development 
BP 





GO:0051898 8 64 0.219962 0.600681 -0.04762 0.934871 2.080266 5.208602 1.796763 5.176546 0.648777 0.95421 negative regulation 
of protein kinase B 
signaling cascade 
BP 












GO:0014065 6 52 0.325617 0.528836 0.085714 0.919444 1.174255 4.615857 1.638061 4.913686 0.582932 0.94308
4 
phosphatidylinosit
ol 3-kinase cascade 
BP 















p53 class mediator 
BP 












GO:0043195 6 138 0.428252 0.396892 0.085714 0.919444 1.186655 3.506194 0.670776 4.022345 0.462507 0.94308
4 
terminal button CC 
GO:0045070 6 36 -0.12585 0.812226 0.085714 0.919444 3.864616 4.619701 4.435874 5.360881 0.838614 0.94308
4 
positive regulation 
of viral genome 
replication 
BP 
GO:0046676 6 100 -0.20063 0.703098 0.085714 0.919444 3.295659 4.841598 4.003979 5.289861 0.741874 0.94308
4 
negative regulation 
of insulin secretion 
BP 











GO:0050431 6 53 -0.09596 0.856506 0.085714 0.919444 1.863702 4.532962 1.571686 4.524894 0.87661 0.94308
4 
transforming 
growth factor beta 
binding 
MF 
GO:0055088 6 78 -0.02256 0.966166 0.085714 0.919444 1.789608 4.553299 2.087711 4.304533 0.969787 0.94308
4 
lipid homeostasis BP 
GO:0060135 6 70 0.383073 0.453497 -0.08571 0.919444 2.758274 4.889684 2.411515 4.980563 0.5162 0.94308
4 
maternal process 
involved in female 
pregnancy 
BP 
GO:0060170 6 51 -0.18695 0.722835 0.085714 0.919444 1.162056 2.751843 1.350045 2.636462 0.760559 0.94308
4 
cilium membrane CC 
GO:0071203 6 28 0.570887 0.236699 0.085714 0.919444 3.838014 5.654391 2.70468 5.767017 0.301297 0.94308
4 
WASH complex CC 
GO:0071565 6 56 0.48133 0.333762 -0.08571 0.919444 5.245563 6.062814 5.4654 6.051746 0.400376 0.94308
4 
nBAF complex CC 






GO:0004707 7 74 0.01469 0.975063 -0.07143 0.906349 1.839266 4.376119 2.680382 4.813743 0.977671 0.93941
7 
MAP kinase activity MF 
GO:0043235 7 99 0.277375 0.547017 -0.07143 0.906349 0.485463 3.480122 0.047219 4.303502 0.600502 0.93941
7 
receptor complex CC 
GO:0046326 7 108 -0.33657 0.460433 0.071429 0.906349 1.548996 4.143807 1.058894 4.34284 0.52227 0.93941
7 
positive regulation 
of glucose import 
BP 






GO:0001947 9 112 -0.01805 0.963229 -0.06667 0.880093 0.803134 4.005524 0.406407 3.754132 0.967875 0.91473 heart looping BP 
157 
 




GO:0045766 17 233 0.083013 0.751435 0.04902 0.853696 2.157506 4.099277 1.818579 4.665889 0.785801 0.88828 positive regulation 
of angiogenesis 
BP 











GO:0001938 17 202 0.038874 0.882241 -0.05147 0.846278 1.327589 4.295024 1.553511 4.234063 0.898047 0.88203 positive regulation 
of endothelial cell 
proliferation 
BP 
GO:0035019 9 68 -0.07151 0.854944 0.083333 0.843182 0.839581 4.531917 0.697827 4.770163 0.875489 0.87929
2 
somatic stem cell 
maintenance 
BP 
































GO:0070402 7 28 0.764417 0.045361 0.107143 0.839683 5.358128 2.465531 5.411195 3.045436 0.082494 0.87661
7 
NADPH binding MF 










GO:0005100 12 78 0.202693 0.52752 0.076923 0.817283 0.659569 3.934222 0.703818 4.289986 0.581823 0.85705 Rho GTPase 
activator activity 
MF 










GO:0004177 23 96 0.247571 0.254729 -0.05435 0.805563 3.877978 4.07705 4.240732 4.739203 0.319689 0.84618 aminopeptidase 
activity 
MF 































GO:0034199 6 72 0.142421 0.787813 0.142857 0.802778 1.448272 4.059546 1.21921 4.357716 0.817913 0.84372
7 
activation of 
protein kinase A 
activity 
BP 
GO:0042476 6 110 0.445107 0.376432 0.142857 0.802778 3.016215 4.404291 3.426106 4.292532 0.442514 0.84372
7 
odontogenesis BP 
GO:0042640 6 36 -0.15693 0.766532 -0.14286 0.802778 2.500372 4.934465 3.117595 5.013499 0.798471 0.84372
7 
anagen BP 
GO:0045749 6 54 0.440765 0.381667 0.142857 0.802778 0.672611 4.45561 0.025096 4.427356 0.447546 0.84372
7 
negative regulation 
of S phase of 
mitotic cell cycle 
BP 
GO:0060444 6 54 0.181194 0.731183 0.142857 0.802778 3.603143 4.985588 4.803961 5.02928 0.76762 0.84372
7 
branching involved 










GO:0019894 11 64 0.758699 0.006788 -0.09091 0.796592 2.056325 4.893443 1.350706 4.413659 0.01858 0.84200
9 
kinesin binding MF 





GO:0046965 8 68 0.564747 0.144707 0.119048 0.793006 1.37829 5.350354 0.686975 5.122601 0.201803 0.83957
4 










GO:0004602 7 46 0.204037 0.66078 0.142857 0.78254 6.029682 5.16464 6.107803 5.286291 0.702759 0.82943 glutathione 
peroxidase activity 
MF 




GO:0006476 7 41 0.30824 0.501216 0.142857 0.78254 3.139741 4.304743 2.961283 4.418351 0.55906 0.82943 protein 
deacetylation 
BP 




GO:0042581 7 36 -0.03235 0.945117 -0.14286 0.78254 4.650235 4.587922 4.926256 4.426996 0.951715 0.82943 specific granule CC 





GO:0046329 9 92 -0.08187 0.834137 -0.11667 0.775628 1.597016 5.051806 1.532199 5.420283 0.858401 0.82443
5 
negative regulation 
of JNK cascade 
BP 










GO:0022857 13 127 0.404651 0.170216 0.093407 0.764582 6.726652 6.253938 7.528755 6.669332 0.228785 0.81454 transmembrane 
transporter activity 
MF 




GO:0008206 10 130 0.295908 0.406463 0.115152 0.758833 3.711967 3.706616 3.544795 4.078894 0.4719 0.80933
6 
bile acid metabolic 
process 
BP 










GO:0048661 8 195 0.273265 0.512565 0.142857 0.752034 1.522418 4.689901 1.454915 5.017571 0.568337 0.80299
7 
positive regulation 
of smooth muscle 
cell proliferation 
BP 
GO:0050662 13 67 -0.00087 0.997755 -0.0989 0.75073 3.977718 4.184956 4.224317 4.558348 0.997755 0.80252 coenzyme binding MF 
GO:0006521 41 166 0.242658 0.126347 0.051916 0.746487 6.033826 5.555102 6.346333 5.801958 0.182001 0.79843
9 
regulation of 
cellular amino acid 
metabolic process 
BP 







GO:0032456 9 24 0.182973 0.637493 0.133333 0.743541 2.300023 4.180317 1.895395 3.682134 0.683028 0.79574
1 
endocytic recycling BP 

































GO:0005663 6 28 0.509142 0.302278 0.2 0.713889 5.947455 5.695225 5.939335 5.559639 0.368751 0.76707
3 
DNA replication 
factor C complex 
CC 










GO:0007588 6 149 0.100109 0.850338 0.2 0.713889 2.40698 4.08734 2.655976 4.020161 0.871725 0.76707
3 
excretion BP 






































GO:0050661 14 130 -0.13122 0.65478 -0.11209 0.704285 4.261224 4.216618 4.542605 4.258537 0.697168 0.76199
4 
NADP binding MF 









GO:0007257 15 101 -0.0244 0.931206 -0.11071 0.695276 1.268355 4.48884 1.350706 4.622339 0.938846 0.75311
5 
activation of JUN 
kinase activity 
BP 





GO:0019216 9 66 0.576222 0.104388 0.166667 0.677745 2.097659 3.832253 1.314733 2.720074 0.157338 0.73497
5 
regulation of lipid 
metabolic process 
BP 
GO:0032007 9 40 0.175422 0.65167 0.166667 0.677745 0.71269 4.147382 1.19347 4.263584 0.694251 0.73497
5 
negative regulation 
of TOR signaling 
cascade 
BP 
GO:0030914 13 42 0.213272 0.484179 0.131868 0.669269 2.734504 4.513679 2.500626 4.699925 0.54492 0.72662
4 
STAGA complex CC 
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Table S 13: DAVID GO clustering analysis results in VCaP 
Name ConceptType #Genes Coeff OddsRatio P-Value FDR Direction 
mitochondrial part 
GO Cellular 
Component 459 0.477479055 19.44024111 1.55E-34 5.03E-32 up 
mitochondrial membrane 
GO Cellular 
Component 292 0.483099941 20.13131986 5.13E-27 8.31E-25 up 
mitochondrial envelope 
GO Cellular 
Component 309 0.462403553 17.70163243 7.79E-26 8.41E-24 up 
organelle inner membrane 
GO Cellular 
Component 236 0.494350298 21.58920383 9.29E-25 7.52E-23 up 
177 
 
mitochondrial inner membrane 
GO Cellular 
Component 215 0.505933338 23.20058325 2.01E-24 1.30E-22 up 
organelle envelope 
GO Cellular 
Component 458 0.386747746 11.06166663 5.23E-24 2.82E-22 up 
envelope 
GO Cellular 





0.349829787 0.113715561 3.83E-19 1.55E-17 down 
endoplasmic reticulum part 
GO Cellular 
Component 353 0.350464048 8.828602302 6.27E-17 2.22E-15 up 
subsynaptic reticulum 
GO Cellular 





0.293816416 0.161063936 2.67E-16 7.85E-15 down 
respiratory chain 
GO Cellular 




Component 320 0.345020918 8.534952503 2.26E-15 5.64E-14 up 
mitochondrial lumen 
GO Cellular 
Component 189 0.415265891 13.20657444 2.73E-15 5.78E-14 up 
mitochondrial matrix 
GO Cellular 
Component 189 0.415265891 13.20657444 2.73E-15 5.78E-14 up 
endoplasmic reticulum membrane 
GO Cellular 
Component 313 0.346637401 8.621125111 2.85E-15 5.78E-14 up 








0.403025137 0.081704739 3.26E-14 5.86E-13 down 
Oxidative phosphorylation KEGG Pathway 90 0.602292584 42.22499604 1.05E-14 1.75E-12 up 










0.362892132 0.104849176 2.25E-14 4.64E-12 down 
oxidoreductase activity 
GO Molecular 
Function 366 0.317626291 7.198861712 4.21E-14 5.80E-12 up 
mitochondrial respiratory chain 
GO Cellular 
Component 56 0.563677263 33.21605306 5.01E-13 8.54E-12 up 




0.436687419 0.066281718 1.13E-13 9.36E-12 down 




0.399892894 0.083310756 1.13E-13 9.36E-12 down 
GTP catabolic process 
GO Biological 
Process 59 -0.52379397 0.038574099 2.74E-14 1.59E-11 down 
regulation of GTP catabolic process 
GO Biological 
Process 59 -0.52379397 0.038574099 2.74E-14 1.59E-11 down 
regulation of GTPase activity 
GO Biological 
Process 59 -0.52379397 0.038574099 2.74E-14 1.59E-11 down 
transmembrane transporter activity 
GO Molecular 
Function 227 0.368367218 9.867612143 3.01E-13 1.97E-11 up 




0.273181859 0.183100848 3.34E-13 1.97E-11 down 
179 
 
regulation of small GTPase 




0.429668498 0.0692369 9.09E-14 3.24E-11 down 




0.297871525 0.157055695 1.68E-13 3.24E-11 down 





0.505452116 0.04323146 1.69E-13 3.24E-11 down 





0.505452116 0.04323146 1.69E-13 3.24E-11 down 




0.529230312 0.037292652 1.74E-13 3.24E-11 down 




0.302901267 0.1522224 1.80E-13 3.24E-11 down 




0.298581529 0.15636423 1.98E-13 3.24E-11 down 





0.488350952 0.048079 2.16E-13 3.24E-11 down 











0.495003951 0.046131671 2.42E-13 3.24E-11 down 




0.489600194 0.047707182 5.21E-13 6.24E-11 down 





0.484413545 0.049269978 5.38E-13 6.24E-11 down 
180 
 





0.477711696 0.051365375 9.89E-13 1.08E-10 down 





0.358528029 0.107731723 2.48E-12 1.28E-10 down 
hydrogen ion transmembrane 
transporter activity 
GO Molecular 
Function 51 0.576402535 35.94952463 3.29E-12 1.43E-10 up 




0.377453275 0.095777817 3.45E-12 1.43E-10 down 




0.472818853 0.052951236 1.42E-12 1.45E-10 down 
Parkinson's disease KEGG Pathway 89 0.541592459 28.95621559 2.74E-12 2.29E-10 up 




0.288307935 0.166673107 3.69E-12 3.57E-10 down 





0.451761696 0.060354372 4.38E-12 4.01E-10 down 









0.308028648 0.14744835 5.52E-12 4.81E-10 down 





0.419266346 0.073860579 5.98E-12 4.96E-10 down 
oxidative phosphorylation 
GO Biological 
Process 72 0.511959016 24.08585285 6.96E-12 5.51E-10 up 
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0.357812537 0.108211819 1.69E-11 1.23E-09 down 





0.325062384 0.132637515 3.96E-11 1.36E-09 down 
cellular respiration 
GO Biological 
Process 78 0.489921163 21.00305761 2.19E-11 1.53E-09 up 




0.670649118 0.01548596 5.10E-11 1.62E-09 down 
oxidation reduction 
GO Biological 
Process 348 0.285605888 5.899860264 3.58E-11 2.25E-09 up 




0.440325131 0.0648001 3.65E-11 2.25E-09 down 




0.675894483 0.01498929 3.75E-11 2.25E-09 down 





0.675894483 0.01498929 3.75E-11 2.25E-09 down 




0.510410866 0.041919528 8.12E-11 2.39E-09 down 
generation of precursor metabolites 
and energy 
GO Biological 
Process 204 0.349053446 8.751546 4.51E-11 2.62E-09 up 










0.391007041 0.088040748 5.42E-11 2.89E-09 down 









0.369719088 0.100493801 1.22E-10 3.36E-09 down 
inorganic cation transmembrane 
transporter activity 
GO Molecular 
Function 79 0.469958332 18.55254277 2.12E-10 5.47E-09 up 
Cardiac muscle contraction KEGG Pathway 26 0.714765181 84.94342799 1.29E-10 7.18E-09 up 




0.379607509 0.094504115 3.64E-10 8.84E-09 down 
structural constituent of ribosome 
GO Molecular 
Function 139 0.382435647 10.76917267 4.51E-10 1.03E-08 up 
respiratory electron transport chain 
GO Biological 
Process 52 0.528599666 26.71004638 2.74E-10 1.40E-08 up 
ATP synthesis coupled electron 
transport 
GO Biological 
Process 45 0.550088025 30.52608282 3.04E-10 1.47E-08 up 
mitochondrial ATP synthesis 
coupled electron transport 
GO Biological 
Process 45 0.550088025 30.52608282 3.04E-10 1.47E-08 up 
cation transmembrane transporter 
activity 
GO Molecular 
Function 122 0.396251033 11.7346368 7.39E-10 1.61E-08 up 




0.401009218 0.082734786 4.36E-10 2.05E-08 down 
monovalent inorganic cation 
transmembrane transporter activity 
GO Molecular 
Function 64 0.486460732 20.55620427 1.05E-09 2.07E-08 up 
cytochrome-c oxidase activity 
GO Molecular 
Function 15 0.728307806 92.40190465 1.20E-09 2.07E-08 up 
heme-copper terminal oxidase 
activity 
GO Molecular 
Function 15 0.728307806 92.40190465 1.20E-09 2.07E-08 up 
oxidoreductase activity, acting on 
heme group of donors 
GO Molecular 
Function 15 0.728307806 92.40190465 1.20E-09 2.07E-08 up 
oxidoreductase activity, acting on 
heme group of donors, oxygen as 
acceptor 
GO Molecular 
Function 15 0.728307806 92.40190465 1.20E-09 2.07E-08 up 
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0.363829352 0.104240261 4.98E-10 2.28E-08 down 
nucleobase, nucleoside and 




0.395882137 0.085413396 5.54E-10 2.41E-08 down 
nucleobase, nucleoside, nucleotide 




0.395882137 0.085413396 5.54E-10 2.41E-08 down 
intrinsic to organelle membrane 
GO Cellular 
Component 75 0.448708225 16.25736067 1.77E-09 2.87E-08 up 
ion transmembrane transporter 
activity 
GO Molecular 





0.266571986 0.190778841 1.30E-09 5.53E-08 down 
ribosome 
GO Cellular 










0.300278462 0.154723912 1.72E-09 6.96E-08 down 
Huntington's disease KEGG Pathway 126 0.411594744 12.90868102 2.61E-09 1.09E-07 up 




0.318728933 0.137962219 8.04E-09 1.18E-07 down 
integral to organelle membrane 
GO Cellular 
Component 68 0.44592569 15.97864914 9.98E-09 1.41E-07 up 
Alzheimer's disease KEGG Pathway 106 0.427681417 14.2659046 5.12E-09 1.71E-07 up 




0.289175575 0.165776817 4.65E-09 1.84E-07 down 
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Chemokine signaling pathway KEGG Pathway 56 -0.48185232 0.050060484 7.39E-09 1.95E-07 down 
Glioma KEGG Pathway 25 
-
0.628358948 0.020140862 8.17E-09 1.95E-07 down 
phosphotransferase activity, alcohol 
group as acceptor 
GO Molecular 
Function 285 -0.23531019 0.231688701 1.28E-08 2.04E-07 down 
organelle fission 
GO Biological 




Function 278 0.261541996 5.080354329 3.30E-08 5.05E-07 up 




0.364598728 0.10374304 1.44E-08 5.45E-07 down 





0.357092693 0.108696994 2.45E-08 9.09E-07 down 




0.415907096 0.075418731 1.02E-07 1.38E-06 down 
Chronic myeloid leukemia KEGG Pathway 40 
-
0.509927007 0.042045769 6.87E-08 1.44E-06 down 
RNA processing 
GO Biological 
Process 455 0.212295057 3.740916286 3.96E-08 1.44E-06 up 




0.224680625 0.247510559 5.34E-08 1.90E-06 down 
T cell receptor signaling pathway KEGG Pathway 38 
-







0.210972892 0.269519687 1.52E-07 2.23E-06 down 
Focal adhesion KEGG Pathway 82 
-










0.257183514 0.202241096 7.79E-08 2.71E-06 down 




0.454385848 0.05937809 2.11E-07 3.00E-06 down 
Natural killer cell mediated 
cytotoxicity KEGG Pathway 29 
-
0.549119959 0.032956547 2.34E-07 3.55E-06 down 
ribonucleoprotein complex 
GO Cellular 
Component 428 0.199459193 3.454095793 3.42E-07 4.27E-06 up 
ribosomal subunit 
GO Cellular 
Component 110 0.344368105 8.500396537 3.71E-07 4.45E-06 up 
transmembrane transport 
GO Biological 
Process 282 0.249219641 4.70583111 1.36E-07 4.63E-06 up 
structural molecule activity 
GO Molecular 
Function 264 0.2474829 4.655313402 3.41E-07 4.69E-06 up 
Renal cell carcinoma KEGG Pathway 34 
-
0.513899017 0.041020596 3.73E-07 5.08E-06 down 
Ubiquitin mediated proteolysis KEGG Pathway 88 
-
0.370610161 0.099938837 3.96E-07 5.08E-06 down 
antigen processing and 
presentation of peptide antigen via 
MHC class I 
GO Biological 










0.221787667 0.252000695 8.08E-07 1.04E-05 down 
glycoprotein biosynthetic process 
GO Biological 
Process 67 0.415930914 13.26126826 3.36E-07 1.09E-05 up 
antigen processing and 
presentation of peptide antigen 
GO Biological 
Process 12 0.677755597 67.49040381 3.38E-07 1.09E-05 up 
NADH dehydrogenase (quinone) 
activity 
GO Molecular 
Function 37 0.486434934 20.55290878 1.16E-06 1.37E-05 up 
NADH dehydrogenase (ubiquinone) 
activity 
GO Molecular 
Function 37 0.486434934 20.55290878 1.16E-06 1.37E-05 up 
NADH dehydrogenase activity 
GO Molecular 
Function 37 0.486434934 20.55290878 1.16E-06 1.37E-05 up 
Neurotrophin signaling pathway KEGG Pathway 62 
-
0.404310752 0.081054552 1.18E-06 1.40E-05 down 
mitochondrial respiratory chain 
complex I 
GO Cellular 
Component 39 0.465952811 18.09641975 1.56E-06 1.68E-05 up 
NADH dehydrogenase complex 
GO Cellular 
Component 39 0.465952811 18.09641975 1.56E-06 1.68E-05 up 
respiratory chain complex I 
GO Cellular 
Component 39 0.465952811 18.09641975 1.56E-06 1.68E-05 up 
Pathways in cancer KEGG Pathway 128 
-
0.308548938 0.146972361 1.69E-06 1.88E-05 down 





0.384242314 0.091820895 1.68E-06 1.92E-05 down 
electron carrier activity 
GO Molecular 
Function 70 0.39119475 11.37163462 1.77E-06 1.97E-05 up 
Insulin signaling pathway KEGG Pathway 61 
-
0.398605701 0.083979864 2.12E-06 2.21E-05 down 




oxidoreductase activity, acting on 
NADH or NADPH, quinone or similar 
compound as acceptor 
GO Molecular 
Function 42 0.455624435 16.97136145 2.84E-06 3.09E-05 up 
mitochondrial electron transport, 
NADH to ubiquinone 
GO Biological 
Process 36 0.488526668 20.82182654 1.07E-06 3.32E-05 up 
Non-small cell lung cancer KEGG Pathway 25 
-
0.531450936 0.036781536 3.46E-06 3.40E-05 down 
Regulation of actin cytoskeleton KEGG Pathway 83 -0.34846926 0.114681118 4.26E-06 3.95E-05 down 




0.268804465 0.188150255 1.46E-06 4.45E-05 down 
glycoprotein metabolic process 
GO Biological 
Process 86 0.363685679 9.584660569 1.61E-06 4.85E-05 up 
Vascular smooth muscle 
contraction KEGG Pathway 32 
-
0.476484247 0.051758694 7.27E-06 6.39E-05 down 
Apoptosis KEGG Pathway 42 
-










0.281277446 0.174116774 8.02E-06 8.12E-05 down 




0.296168644 0.1587266 3.00E-06 8.85E-05 down 




0.331873174 0.1271406 8.39E-06 8.89E-05 down 
ErbB signaling pathway KEGG Pathway 37 
-
0.445484903 0.062755184 1.17E-05 9.27E-05 down 
Toll-like receptor signaling pathway KEGG Pathway 31 
-
0.472146465 0.053172962 1.24E-05 9.43E-05 down 
intrinsic to endoplasmic reticulum 
membrane 
GO Cellular 
Component 38 0.442570275 15.64890296 1.03E-05 1.01E-04 up 
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energy derivation by oxidation of 
organic compounds 
GO Biological 
Process 101 0.332166114 7.879640035 3.96E-06 1.15E-04 up 





0.486575198 0.04861252 4.35E-06 1.24E-04 down 




0.556086564 0.031560149 4.42E-06 1.24E-04 down 
centrosome organization 
GO Biological 
Process 23 -0.49298288 0.046714746 4.50E-06 1.24E-04 down 




0.176721333 0.333452841 4.71E-06 1.28E-04 down 
RIG-I-like receptor signaling 
pathway KEGG Pathway 29 
-
0.475282523 0.052146687 1.88E-05 1.37E-04 down 
endoplasmic reticulum lumen 
GO Cellular 
Component 47 0.406296713 12.49058101 1.69E-05 1.61E-04 up 
Fc epsilon RI signaling pathway KEGG Pathway 21 
-
0.523926298 0.03854239 2.54E-05 1.77E-04 down 
oxidoreductase activity, acting on 
NADH or NADPH 
GO Molecular 
Function 60 0.379870293 10.59884465 1.75E-05 1.80E-04 up 





0.260378127 0.198265543 6.80E-06 1.82E-04 down 
B cell receptor signaling pathway KEGG Pathway 28 
-
0.473128364 0.052849482 2.84E-05 1.89E-04 down 




0.220243159 0.254431173 7.32E-06 1.90E-04 down 





0.220243159 0.254431173 7.32E-06 1.90E-04 down 
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0.155962248 0.379369638 2.16E-05 2.17E-04 down 




0.252526087 0.208180317 8.86E-06 2.27E-04 down 




0.467916556 0.054589265 9.35E-06 2.36E-04 down 
integral to endoplasmic reticulum 
membrane 
GO Cellular 
Component 34 0.442417737 15.63407543 2.74E-05 2.54E-04 up 
RNA splicing 
GO Biological 





0.234466879 0.232906134 2.93E-05 2.63E-04 down 
Endocytosis KEGG Pathway 111 
-






0.516058714 0.04047371 1.29E-05 3.08E-04 down 
immune response-activating cell 




0.516058714 0.04047371 1.29E-05 3.08E-04 down 
immune response-regulating cell 




0.516058714 0.04047371 1.29E-05 3.08E-04 down 











0.474059045 0.052544693 1.43E-05 3.31E-04 down 
Shigellosis KEGG Pathway 39 -0.41021859 0.07813261 5.43E-05 3.36E-04 down 
protein modification by small 















Process 251 0.21574066 3.821884593 1.63E-05 3.63E-04 up 
Prostate cancer KEGG Pathway 42 
-
0.397381798 0.084621057 6.14E-05 3.66E-04 down 
antigen processing and 
presentation 
GO Biological 
Process 19 0.53735829 28.20420779 1.82E-05 4.02E-04 up 




0.345418133 0.116876399 4.39E-05 4.32E-04 down 
mTOR signaling pathway KEGG Pathway 24 
-
0.477774822 0.051345228 7.67E-05 4.42E-04 down 




0.202995188 0.283218799 2.06E-05 4.47E-04 down 





0.251983937 0.208882912 2.12E-05 4.57E-04 down 





0.171939241 0.343511392 2.39E-05 5.08E-04 down 










0.257458887 0.201895289 2.49E-05 5.16E-04 down 
glycosylation 
GO Biological 
Process 50 0.396026329 11.71826147 2.60E-05 5.20E-04 up 
macromolecule glycosylation 
GO Biological 
Process 50 0.396026329 11.71826147 2.60E-05 5.20E-04 up 
protein amino acid glycosylation 
GO Biological 
Process 50 0.396026329 11.71826147 2.60E-05 5.20E-04 up 
nucleobase, nucleoside and 




0.191151173 0.304851767 2.64E-05 5.22E-04 down 
Basal transcription factors KEGG Pathway 36 0.423595329 13.90820513 9.39E-05 5.23E-04 up 









0.256644727 0.202919405 2.87E-05 5.62E-04 down 




0.588596264 0.025786734 3.02E-05 5.84E-04 down 
NOD-like receptor signaling 
pathway KEGG Pathway 26 
-
0.456553889 0.058583424 1.13E-04 5.90E-04 down 




0.465531634 0.055404378 3.45E-05 6.60E-04 down 





0.472179768 0.053161958 3.58E-05 6.75E-04 down 
transcription initiation from RNA 
polymerase II promoter 
GO Biological 
Process 54 0.38064986 10.65031748 3.60E-05 6.75E-04 up 
Colorectal cancer KEGG Pathway 30 
-
0.430536986 0.068864213 1.36E-04 6.89E-04 down 
small ribosomal subunit 
GO Cellular 





0.583037222 0.026693162 3.86E-05 7.16E-04 down 
protein amino acid N-linked 
glycosylation 
GO Biological 
Process 26 0.477670924 19.46343535 4.13E-05 7.57E-04 up 
Melanoma KEGG Pathway 21 
-





0.522881225 0.038793526 4.58E-05 8.22E-04 down 























0.322745349 0.134561241 1.06E-04 8.60E-04 down 





0.433621415 0.067556759 4.96E-05 8.65E-04 down 





0.202459318 0.284163553 4.97E-05 8.65E-04 down 





0.202459318 0.284163553 4.97E-05 8.65E-04 down 
organic alcohol transport 
GO Biological 
Process 11 0.599380332 41.46766076 5.23E-05 9.01E-04 up 
transcription initiation 
GO Biological 
Process 66 0.347908657 8.68950486 5.56E-05 9.48E-04 up 
hydrogen ion transporting ATP 
synthase activity, rotational 
mechanism 
GO Molecular 





0.364330347 0.103916215 5.85E-05 9.89E-04 down 
cellular lipid metabolic process 
GO Biological 





0.555928564 0.031591153 6.21E-05 0.00102842 down 
translational elongation 
GO Biological 
Process 90 0.308007338 6.781137762 6.26E-05 0.00102842 up 
integral to peroxisomal membrane 
GO Cellular 
Component 10 0.587162719 38.43567978 1.42E-04 0.001073986 up 
intrinsic to peroxisomal membrane 
GO Cellular 
Component 10 0.587162719 38.43567978 1.42E-04 0.001073986 up 
Golgi membrane 
GO Cellular 
Component 227 0.19750164 3.412329818 1.45E-04 0.001073986 up 
membrane fraction 
GO Cellular 
Component 317 0.170136491 2.878679312 1.46E-04 0.001073986 up 




SH3 domain binding 
GO Molecular 
Function 57 -0.3144631 0.141668575 1.17E-04 0.001097754 down 





0.220906555 0.253384378 6.77E-05 0.001102235 down 




0.553282118 0.032115017 6.97E-05 0.001124189 down 









0.151399344 0.390281272 1.26E-04 0.001156949 down 




0.181944549 0.322802672 7.58E-05 0.001194557 down 
RNA elongation from RNA 
polymerase II promoter 
GO Biological 
Process 41 0.40434698 12.34014805 7.62E-05 0.001194557 up 





0.202229208 0.28457021 7.88E-05 0.001225363 down 




0.584288973 0.026486318 7.97E-05 0.001228372 down 





0.413580938 0.076516916 8.29E-05 0.001258504 down 





0.185018666 0.316694245 8.39E-05 0.001258504 down 




0.185018666 0.316694245 8.39E-05 0.001258504 down 









0.322365766 0.134879041 1.89E-04 0.001361519 down 
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proteoglycan metabolic process 
GO Biological 
Process 14 0.551244629 30.74629 9.24E-05 0.001363458 up 
Hepatitis C KEGG Pathway 59 
-
0.323030956 0.134322615 3.03E-04 0.001407154 down 
regulation of blood pressure 
GO Biological 
Process 20 0.498669574 22.17656223 9.70E-05 0.001418696 up 
mitochondrial ribosome 
GO Cellular 
Component 48 0.360878701 9.418913091 2.13E-04 0.001447391 up 
organellar ribosome 
GO Cellular 
Component 48 0.360878701 9.418913091 2.13E-04 0.001447391 up 
microbody 
GO Cellular 
Component 69 0.315623055 7.109796314 2.19E-04 0.001447391 up 
peroxisome 
GO Cellular 









0.452150039 0.060208888 1.02E-04 0.00147309 down 
Acute myeloid leukemia KEGG Pathway 25 -0.43738848 0.065993568 3.41E-04 0.001504817 down 
N-Glycan biosynthesis KEGG Pathway 34 0.403365275 12.26509109 3.42E-04 0.001504817 up 
DNA integrity checkpoint 
GO Biological 
Process 35 -0.37703747 0.096025633 1.14E-04 0.001644407 down 
holo TFIIH complex 
GO Cellular 





0.491643952 0.047105077 1.20E-04 0.001709661 down 









0.521954797 0.03901752 2.77E-04 0.00172688 down 
neuron projection 
GO Cellular 
Component 133 -0.21628796 0.260762588 2.95E-04 0.001799696 down 
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0.195337121 0.297023609 3.00E-04 0.001799696 down 









0.332662543 0.126518425 2.16E-04 0.001938799 down 




0.310095004 0.145566984 3.37E-04 0.001951241 down 




0.409532701 0.078466363 2.26E-04 0.001954432 down 
UDP-glycosyltransferase activity 
GO Molecular 
Function 37 0.399721935 11.99050606 2.27E-04 0.001954432 up 
Endometrial cancer KEGG Pathway 27 
-
0.418371624 0.074272413 4.65E-04 0.001989047 down 




0.465651006 0.055363292 2.43E-04 0.002046694 down 
Leukocyte transendothelial 
migration KEGG Pathway 41 
-
0.358356585 0.107846567 5.05E-04 0.002107272 down 
transferase activity, transferring 
hexosyl groups 
GO Molecular 
Function 66 0.322802853 7.434216735 2.55E-04 0.002109285 up 
modification-dependent 










0.191984623 0.30327685 1.53E-04 0.00212976 down 
response to retinoic acid 
GO Biological 
Process 16 0.520226531 25.35571148 1.60E-04 0.002214663 up 














0.308556106 0.146965814 3.19E-04 0.002535659 down 




serine hydrolase activity 
GO Molecular 





0.198174934 0.291831251 2.21E-04 0.003006955 down 
RNA elongation 
GO Biological 
Process 45 0.372118008 10.10032483 2.25E-04 0.003030346 up 
fatty acid metabolic process 
GO Biological 





0.290866992 0.164043381 5.51E-04 0.003080693 down 
TGF-beta signaling pathway KEGG Pathway 22 
-
0.436646404 0.066298614 7.57E-04 0.00308307 down 
monocarboxylic acid metabolic 
process 
GO Biological 
Process 160 0.224953078 4.047078335 2.44E-04 0.003224476 up 
lipid metabolic process 
GO Biological 
Process 381 0.152907983 2.586390286 2.44E-04 0.003224476 up 
transferase activity, transferring 
glycosyl groups 
GO Molecular 
Function 97 0.267989742 5.288058781 4.32E-04 0.00330557 up 




0.522227102 0.038951548 2.55E-04 0.003339529 down 
ribosome biogenesis 
GO Biological 
Process 116 0.257003079 4.939052034 2.58E-04 0.003346249 up 
large ribosomal subunit 
GO Cellular 
Component 57 0.318413905 7.234184448 6.34E-04 0.003483706 up 
Peroxisome KEGG Pathway 57 0.320330477 7.320864168 8.77E-04 0.003486558 up 
Pancreatic cancer KEGG Pathway 33 
-





0.262596663 0.195550749 6.63E-04 0.003579866 down 
Ribosome KEGG Pathway 78 0.281863061 5.764212025 0.001045216 0.003967069 up 




negative regulation of microtubule 
depolymerization 
GO Biological 
Process 12 -0.51630267 0.040412394 3.22E-04 0.004093776 down 
regulation of microtubule 
depolymerization 
GO Biological 
Process 12 -0.51630267 0.040412394 3.22E-04 0.004093776 down 
unsaturated fatty acid metabolic 
process 
GO Biological 
Process 17 0.495801905 21.78484483 3.29E-04 0.004151514 up 




0.468466404 0.054403047 3.33E-04 0.004165179 down 
Bladder cancer KEGG Pathway 19 -0.44829168 0.061670036 0.00112336 0.004168915 down 





0.182930403 0.320831003 3.46E-04 0.004274106 down 





0.281620006 0.173746495 3.46E-04 0.004274106 down 




0.319566322 0.137246122 5.90E-04 0.0044297 down 




0.173365994 0.340479041 3.64E-04 0.004442442 down 




0.167453273 0.353222727 3.65E-04 0.004442442 down 
aerobic respiration 
GO Biological 
Process 29 0.419527321 13.56099808 3.74E-04 0.004522376 up 
proteolysis involved in cellular 




0.172576208 0.34215429 4.01E-04 0.004815538 down 
protein processing 
GO Biological 
Process 31 0.408733347 12.68116179 4.08E-04 0.004870251 up 
positive regulation of NF-kappaB 










0.395126664 0.085815352 4.65E-04 0.00545265 down 









0.353184995 0.111368993 4.91E-04 0.005696691 down 
carboxylesterase activity 
GO Molecular 
Function 36 0.376955309 10.40857009 7.78E-04 0.005736629 up 
lipid biosynthetic process 
GO Biological 









Process 171 0.206606597 3.610979367 5.48E-04 0.006233614 up 
ion transport 
GO Biological 





0.324568025 0.133045637 5.56E-04 0.006246603 down 
organelle outer membrane 
GO Cellular 
Component 80 0.266556533 5.241168065 0.001203952 0.006394764 up 
Fructose and mannose metabolism KEGG Pathway 27 
-
0.383721197 0.092118742 0.001767733 0.006417638 down 




0.180407767 0.325900365 5.85E-04 0.006532278 down 
cell surface 
GO Cellular 
Component 95 0.247362741 4.651838389 0.001260348 0.006586336 up 
protein maturation by peptide bond 
cleavage 
GO Biological 
Process 21 0.45274342 16.67020382 5.96E-04 0.00661227 up 





0.263907662 0.193964002 6.27E-04 0.006906491 down 
regulation of microtubule 




0.434909507 0.067018127 6.35E-04 0.006951232 down 
outer membrane 
GO Cellular 
Component 81 0.262095058 5.097845849 0.001403039 0.007130644 up 








0.202064918 0.284860904 0.00143053 0.007130644 down 
mitochondrial outer membrane 
GO Cellular 
Component 69 0.278659624 5.650592218 0.001474548 0.007238688 up 




0.271830542 0.184644987 6.74E-04 0.007334121 down 
negative regulation of microtubule 




0.470050263 0.053870182 7.22E-04 0.007804757 down 
Role of BRCA1, BRCA2 and ATR in 
Cancer Susceptibility Biocarta Pathway 13 
-
0.610444766 0.022512716 8.01E-05 0.00784613 down 










0.289868087 0.165064898 7.50E-04 0.008014594 down 
unsaturated fatty acid biosynthetic 
process 
GO Biological 
Process 11 0.537399543 28.21143959 7.64E-04 0.008096048 up 
coenzyme metabolic process 
GO Biological 
Process 109 0.244917423 4.581680253 7.67E-04 0.008096048 up 
cellular ketone metabolic process 
GO Biological 





0.238478429 0.227171515 8.03E-04 0.008353961 down 
lipid catabolic process 
GO Biological 
Process 78 0.280223946 5.70579317 8.06E-04 0.008353961 up 
mitochondrial nucleoid 
GO Cellular 
Component 27 0.388249952 11.16541771 0.001782086 0.008491117 up 
nucleoid 
GO Cellular 
Component 27 0.388249952 11.16541771 0.001782086 0.008491117 up 
Drug metabolism - other enzymes KEGG Pathway 17 
-
0.441657775 0.064265651 0.002448132 0.008678625 down 






Process 38 0.366128023 9.731248242 8.44E-04 0.008689925 up 
proton-transporting ATP synthase 
complex 
GO Cellular 
Component 13 0.484948921 20.36397665 0.001891073 0.008879822 up 
Fc gamma R-mediated phagocytosis KEGG Pathway 40 
-
0.321931081 0.135243895 0.002622952 0.008939447 down 
proton-transporting ATPase activity, 
rotational mechanism 
GO Molecular 
Function 13 0.504438736 22.98608545 0.001249499 0.009053385 up 
insoluble fraction 
GO Cellular 
Component 332 0.13581346 2.325714789 0.002004879 0.009279724 up 
Rho GTPase binding 
GO Molecular 










0.256964419 0.202516653 9.32E-04 0.009541961 down 
spliceosomal complex 
GO Cellular 
Component 125 0.210636577 3.702557418 0.002093221 0.009552162 up 
regulation of stress-activated 




0.346833219 0.11585307 9.51E-04 0.009679938 down 




0.133954001 0.434972869 9.68E-04 0.009796853 down 





0.461565953 0.056786792 9.89E-04 0.009953848 down 
replication fork 
GO Cellular 





0.449905508 0.061054619 0.002345151 0.010408615 down 




energy coupled proton transport, 
down electrochemical gradient 
GO Biological 





0.458542665 0.05786382 0.001103867 0.010919502 down 





0.398817868 0.083869207 0.001116215 0.010979267 down 
mRNA metabolic process 
GO Biological 
Process 294 0.152696053 2.582986083 0.00112734 0.011026402 up 
transition metal ion transport 
GO Biological 





0.242661597 0.221341897 0.001150814 0.011130926 down 
serine-type peptidase activity 
GO Molecular 
Function 44 0.333611657 7.950745538 0.001641662 0.011300105 up 
rRNA processing 
GO Biological 
Process 86 0.261760256 5.087249995 0.001183127 0.011380243 up 
cellular hormone metabolic process 
GO Biological 
Process 22 0.429053915 14.38810664 0.001213383 0.011607138 up 




0.244419896 0.21893643 0.001286291 0.012226158 down 
rRNA metabolic process 
GO Biological 
Process 87 0.258730818 4.992369453 0.001292138 0.012226158 up 
Thyroid cancer KEGG Pathway 14 
-
0.456608017 0.05856372 0.003839757 0.012573321 down 





0.414335558 0.076158916 0.001868558 0.012651054 down 
Jak-STAT signaling pathway KEGG Pathway 25 
-




Process 38 0.354849912 9.072547856 0.001365291 0.012848495 up 
Phosphatidylinositol signaling 
system KEGG Pathway 35 
-




transmembrane transporter activity 
GO Molecular 
Function 58 0.29547339 6.272978752 0.001992053 0.013059015 up 
primary active transmembrane 
transporter activity 
GO Molecular 
Function 58 0.29547339 6.272978752 0.001992053 0.013059015 up 
DNA-directed RNA polymerase II, 
holoenzyme 
GO Cellular 
Component 65 0.268169087 5.293955945 0.00314129 0.013753756 up 
channel activity 
GO Molecular 
Function 47 0.318506338 7.238341236 0.002175918 0.01382545 up 
passive transmembrane transporter 
activity 
GO Molecular 





0.421233514 0.072963117 0.001491855 0.013914077 down 
fatty acid catabolic process 
GO Biological 
Process 31 0.378597254 10.51532338 0.001494504 0.013914077 up 





0.397298932 0.084664647 0.001542426 0.01424858 down 





0.309094871 0.146474564 0.001546802 0.01424858 down 
Fatty acid metabolism KEGG Pathway 27 0.36431364 9.622138114 0.004609852 0.014256395 up 
regulation of epithelial cell 
differentiation 
GO Biological 
Process 11 0.517993334 25.00624442 0.001559743 0.014292171 up 
Long-term potentiation KEGG Pathway 26 
-
0.359618964 0.107003801 0.004728902 0.014358665 down 
Axon guidance KEGG Pathway 43 -0.29617918 0.158716208 0.004947719 0.014754804 down 
vesicular fraction 
GO Cellular 
Component 109 0.213698137 3.773678184 0.003415668 0.014755687 up 
fat-soluble vitamin metabolic 
process 
GO Biological 






















0.455549796 0.05895013 0.001821114 0.016259279 down 
cytosolic ribosome 
GO Cellular 





0.131950943 0.44042135 0.003891762 0.016375724 down 
active transmembrane transporter 
activity 
GO Molecular 
Function 106 0.223831373 4.018964417 0.002634631 0.016486405 up 
RNA polymerase KEGG Pathway 25 0.36609578 9.729298538 0.005841034 0.017113206 up 





0.495050031 0.046118462 0.001953311 0.017262509 down 





0.495050031 0.046118462 0.001953311 0.017262509 down 





0.256436937 0.203181611 0.001971602 0.017336157 down 





0.336364694 0.123640793 0.002834207 0.017470562 down 
Antigen processing and 
presentation KEGG Pathway 28 0.35139719 8.879949099 0.00608908 0.017532351 up 
small GTPase binding 
GO Molecular 
Function 54 -0.26031903 0.198338373 0.003037775 0.018450014 down 
cofactor catabolic process 
GO Biological 
Process 24 0.402720988 12.21607996 0.002126701 0.018605958 up 




0.212252835 0.267384338 0.002205817 0.019201635 down 
Valine, leucine and isoleucine 





0.319613073 0.137206253 0.00224224 0.01942159 down 
204 
 





0.245777362 0.217097225 0.002283204 0.019628127 down 





0.134809712 0.432665863 0.002288633 0.019628127 down 
positive regulation of stress-





0.489516496 0.047732003 0.00231344 0.019743621 down 
response to oxidative stress 
GO Biological 
Process 96 0.236010616 4.334964774 0.002357593 0.019948728 up 
cellular lipid catabolic process 
GO Biological 
Process 50 0.30781881 6.77319742 0.00236639 0.019948728 up 
cofactor metabolic process 
GO Biological 
Process 142 0.198661235 3.437009363 0.002371848 0.019948728 up 




0.375130163 0.097170613 0.003347502 0.0200365 down 
translation 
GO Biological 
Process 327 0.135576797 2.322296719 0.002401492 0.020100947 up 




0.366296562 0.102654163 0.002437267 0.020302786 down 
Cell cycle KEGG Pathway 76 
-
0.226453002 0.244799282 0.007465867 0.020779997 down 
RNA polymerase II transcription 
factor activity 
GO Molecular 
Function 117 0.208033064 3.643132765 0.003566588 0.021042867 up 
transport vesicle membrane 
GO Cellular 










0.116597091 0.484515806 0.002605804 0.021540581 down 
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0.326939586 0.131099147 0.002610605 0.021540581 down 
RNA splicing, via transesterification 
reactions 
GO Biological 
Process 94 0.235856193 4.330806614 0.00262446 0.021552762 up 
icosanoid metabolic process 
GO Biological 
Process 14 0.469066363 18.44998618 0.002639013 0.021570528 up 
regulation of JNK cascade 
GO Biological 
Process 27 -0.3423452 0.119129845 0.002774551 0.022507001 down 
cation transport 
GO Biological 
Process 143 0.195065396 3.361055261 0.00277944 0.022507001 up 









0.350654191 0.113134447 0.002922587 0.02344804 down 




0.172703732 0.341883237 0.003006405 0.024009868 down 
RNA polymerase II carboxy-terminal 
domain kinase activity 
GO Molecular 
Function 10 0.505089111 23.07917919 0.004196079 0.024069177 up 
Adipocytokine signaling pathway KEGG Pathway 30 -0.32115875 0.13589459 0.008796593 0.024082477 down 




0.147225308 0.400537617 0.004351933 0.024621207 down 
cation-transporting ATPase activity 
GO Molecular 
Function 17 0.429670482 14.44334361 0.004464289 0.024915557 up 




0.239287576 0.226032042 0.003136774 0.024936639 down 
nucleolus 
GO Cellular 




Component 26 0.356634204 9.173710237 0.006396231 0.025592245 up 
Golgi apparatus part 
GO Cellular 
Component 280 0.129608262 2.237735807 0.0064628 0.025592245 up 








0.250263782 0.211127866 0.006556038 0.025592245 down 





0.451843839 0.06032357 0.007072613 0.026423775 down 





0.451843839 0.06032357 0.007072613 0.026423775 down 
external side of plasma membrane 
GO Cellular 
Component 31 0.331423925 7.843379556 0.007140297 0.026423775 up 
mitochondrial small ribosomal 
subunit 
GO Cellular 
Component 18 0.39995633 12.007985 0.007176828 0.026423775 up 
organellar small ribosomal subunit 
GO Cellular 
Component 18 0.39995633 12.007985 0.007176828 0.026423775 up 




0.260696904 0.197873154 0.00341371 0.02701486 down 
positive regulation of kinase activity 
GO Biological 
Process 83 -0.21745818 0.258873082 0.003469348 0.027289124 down 
nuclear mRNA splicing, via 
spliceosome 
GO Biological 
Process 85 0.239736569 4.436513525 0.00349539 0.027289124 up 
RNA splicing, via transesterification 
reactions with bulged adenosine as 
nucleophile 
GO Biological 
Process 85 0.239736569 4.436513525 0.00349539 0.027289124 up 
response to tumor necrosis factor 
GO Biological 
Process 10 -0.47516848 0.052183659 0.003531451 0.02737711 down 
ncRNA processing 
GO Biological 
Process 153 0.184708215 3.151533535 0.00353811 0.02737711 up 
nucleoplasm part 
GO Cellular 





0.115616078 0.487478732 0.007774671 0.027988817 down 
Arachidonic acid metabolism KEGG Pathway 14 0.416236386 13.28646723 0.01043069 0.028095568 up 
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Integrin Signaling Pathway Biocarta Pathway 26 
-
0.402630857 0.081905185 0.001089562 0.028665447 down 
Growth Hormone Signaling Pathway Biocarta Pathway 13 
-
0.503574009 0.043739001 0.001420145 0.028665447 down 
PTEN dependent cell cycle arrest 
and apoptosis Biocarta Pathway 15 -0.47758933 0.051404451 0.001459957 0.028665447 down 
CXCR4 Signaling Pathway Biocarta Pathway 15 -0.47752301 0.051425642 0.001462523 0.028665447 down 
Citrate cycle (TCA cycle) KEGG Pathway 26 0.339765932 8.260722967 0.011188265 0.029657782 up 
microbody part 
GO Cellular 
Component 40 0.295792381 6.285426653 0.008489582 0.029898093 up 
peroxisomal part 
GO Cellular 
Component 40 0.295792381 6.285426653 0.008489582 0.029898093 up 
cofactor binding 
GO Molecular 
Function 154 0.175498018 2.976212155 0.005431735 0.029910754 up 
cytosolic small ribosomal subunit 
GO Cellular 
Component 32 0.321498657 7.374205447 0.008645429 0.030119559 up 
Glycosaminoglycan biosynthesis - 
chondroitin sulfate KEGG Pathway 11 0.439445571 15.34795142 0.012386826 0.031171105 up 
Chagas disease (American 
trypanosomiasis) KEGG Pathway 35 
-
0.291231739 0.163671956 0.012466934 0.031171105 down 
Toxoplasmosis KEGG Pathway 48 
-
0.256969647 0.202510073 0.01249133 0.031171105 down 
Tryptophan metabolism KEGG Pathway 18 0.378952841 10.53858615 0.012505773 0.031171105 up 
lysosomal membrane 
GO Cellular 
Component 44 0.282905222 5.801665812 0.009066186 0.031249407 up 




0.216088865 0.261085429 0.005758851 0.031294808 down 








Function 11 0.479188288 19.64784009 0.006051723 0.032043098 up 
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protein transmembrane transporter 
activity 
GO Molecular 
Function 11 0.479188288 19.64784009 0.006051723 0.032043098 up 
mitochondrial proton-transporting 
ATP synthase complex 
GO Cellular 





0.122686222 0.466523544 0.009605474 0.032418474 down 




0.136507831 0.428123887 0.004232109 0.032458602 down 















0.224148743 0.248330044 0.009951436 0.033239847 down 









0.302602039 0.152505734 0.004406419 0.033354675 down 




0.163102499 0.362903576 0.004436979 0.03344061 down 




0.161941842 0.365530673 0.006558939 0.033501766 down 




0.265414207 0.192156472 0.006570564 0.033501766 down 




0.181114569 0.32447199 0.010255117 0.033904671 down 
copper ion transport 
GO Biological 
Process 11 0.48535155 20.41499487 0.004527686 0.033977159 up 
ion transmembrane transport 
GO Biological 
Process 38 0.323069046 7.446525235 0.00459049 0.034300612 up 
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organic acid metabolic process 
GO Biological 
Process 316 0.128494483 2.222300354 0.004620277 0.034373715 up 




0.169503861 0.348749957 0.00463976 0.034373715 down 
nuclear membrane 
GO Cellular 
Component 83 0.212576059 3.74745484 0.010659411 0.034885346 up 
microbody membrane 
GO Cellular 
Component 33 0.310085251 6.869273231 0.010942802 0.035103644 up 
peroxisomal membrane 
GO Cellular 
Component 33 0.310085251 6.869273231 0.010942802 0.035103644 up 
lipoprotein binding 
GO Molecular 
Function 13 0.451142423 16.50516486 0.006971909 0.035114616 up 
Cell Cycle: G1/S Check Point Biocarta Pathway 15 
-
0.462385899 0.056498163 0.002171196 0.035462874 down 
aminoglycan metabolic process 
GO Biological 
Process 20 0.40266071 12.21150461 0.004831434 0.035642062 up 
rRNA binding 
GO Molecular 
Function 21 0.385679996 10.98850832 0.007213898 0.035895661 up 
Long-term depression KEGG Pathway 23 
-
0.335806092 0.124070756 0.014625504 0.035918518 down 





0.241769711 0.22257214 0.004906243 0.03604122 down 
substrate-specific channel activity 
GO Molecular 
Function 41 0.301195927 6.500081067 0.007368167 0.036226821 up 
acetyl-CoA metabolic process 
GO Biological 
Process 32 0.341556632 8.353165837 0.00500899 0.036641396 up 





0.120738193 0.472205715 0.00507753 0.036987363 down 
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0.093559123 0.55909645 0.005182427 0.037594189 down 





0.123544418 0.464042034 0.005232892 0.037802759 down 




0.375936845 0.096684695 0.005312857 0.037908539 down 




0.375936845 0.096684695 0.005312857 0.037908539 down 




0.375936845 0.096684695 0.005312857 0.037908539 down 




0.197061386 0.293857806 0.005413883 0.038471713 down 
oxidoreductase activity, acting on 
peroxide as acceptor 
GO Molecular 
Function 17 0.409594724 12.74922761 0.008094494 0.038872397 up 
peroxidase activity 
GO Molecular 
Function 17 0.409594724 12.74922761 0.008094494 0.038872397 up 
nuclear envelope 
GO Cellular 
Component 153 0.158103788 2.6712675 0.012283717 0.039018866 up 
carboxylic acid metabolic process 
GO Biological 
Process 313 0.126388399 2.193403329 0.005539605 0.039036971 up 
oxoacid metabolic process 
GO Biological 
Process 313 0.126388399 2.193403329 0.005539605 0.039036971 up 




0.303264841 0.151878847 0.005560694 0.039036971 down 




0.269170229 0.187723061 0.008359777 0.03968492 down 




0.407963926 0.079235098 0.005736832 0.040066687 down 





0.241303916 0.223217361 0.005776415 0.040066687 down 
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0.241303916 0.223217361 0.005776415 0.040066687 down 
oligosaccharide metabolic process 
GO Biological 
Process 17 0.418081618 13.43970529 0.005816909 0.040187457 up 
negative regulation of translational 
initiation 
GO Biological 
Process 12 -0.4289135 0.069562524 0.005949484 0.040940919 down 




0.379469005 0.094585494 0.006034577 0.041200777 down 









0.405640664 0.080387406 0.006137286 0.041738342 down 





0.111451733 0.500259238 0.009014588 0.042307102 down 
hydrogen transport 
GO Biological 
Process 29 0.346772131 8.62834654 0.006297979 0.042499153 up 
proton transport 
GO Biological 
Process 29 0.346772131 8.62834654 0.006297979 0.042499153 up 




0.168762053 0.350361422 0.006324978 0.042516554 down 
viral genome expression 
GO Biological 
Process 10 0.486698853 20.58664637 0.006391588 0.042598867 up 
viral transcription 
GO Biological 
Process 10 0.486698853 20.58664637 0.006391588 0.042598867 up 




0.439026987 0.065324987 0.006420649 0.042598867 down 
mitochondrial ATP synthesis 
coupled proton transport 
GO Biological 
Process 10 0.48645779 20.55582841 0.006435096 0.042598867 up 
positive regulation of epithelial cell 
proliferation 
GO Biological 
Process 11 0.473024323 18.90943092 0.006492884 0.042818601 up 












0.189573926 0.307854609 0.014132105 0.043607637 down 




0.363164326 0.104671965 0.009521572 0.043899691 down 
ATPase activity, coupled to 
transmembrane movement of 
substances 
GO Molecular 
Function 51 0.267752332 5.280262498 0.009672813 0.043899691 up 
hydrolase activity, acting on acid 
anhydrides, catalyzing 
transmembrane movement of 
substances 
GO Molecular 
Function 51 0.267752332 5.280262498 0.009672813 0.043899691 up 
pore complex 
GO Cellular 
Component 64 0.229041291 4.151218325 0.014438723 0.044133456 up 
metal cluster binding 
GO Molecular 
Function 41 0.291823389 6.132288415 0.009919243 0.044528774 up 




0.246244772 0.216467522 0.006813838 0.044765633 down 





0.383357566 0.09232715 0.006862175 0.044913713 down 
glutathione transferase activity 
GO Molecular 






0.434315739 0.067265883 0.01029979 0.045253335 down 
mammary gland morphogenesis 
GO Biological 
Process 12 0.458784574 17.30795685 0.006942186 0.045267215 up 
Bacterial invasion of epithelial cells KEGG Pathway 40 
-
0.262493442 0.195676231 0.018787613 0.045471469 down 












0.293097196 0.161785449 0.007056155 0.045668274 down 
coenzyme binding 
GO Molecular 
Function 124 0.179005414 3.041797111 0.010517375 0.045722902 up 
p53 signaling pathway KEGG Pathway 34 -0.27923113 0.176345165 0.019189143 0.045779813 down 





0.320281826 0.136637201 0.0071456 0.046075888 down 
Links between Pyk2 and Map 
Kinases Biocarta Pathway 18 
-
0.417519256 0.074666888 0.003319565 0.046473911 down 





0.288851834 0.166110683 0.00728896 0.046654704 down 





0.288851834 0.166110683 0.00728896 0.046654704 down 
ATPase activity, coupled to 
movement of substances 
GO Molecular 
Function 52 0.261750067 5.086927854 0.010961311 0.047156475 up 
Inositol phosphate metabolism KEGG Pathway 31 
-
0.287628928 0.167377914 0.020190085 0.047489356 down 
mitochondrial large ribosomal 
subunit 
GO Cellular 
Component 17 0.378101774 10.48299425 0.015911035 0.047733104 up 
organellar large ribosomal subunit 
GO Cellular 
Component 17 0.378101774 10.48299425 0.015911035 0.047733104 up 
ATM Signaling Pathway Biocarta Pathway 12 
-
0.467581848 0.054702934 0.004670063 0.047753208 down 
Signaling of Hepatocyte Growth 
Factor Receptor Biocarta Pathway 24 
-
0.364264299 0.103958878 0.004698167 0.047753208 down 
PKC-catalyzed phosphorylation of 
inhibitory phosphoprotein of 
myosin phosphatase Biocarta Pathway 15 
-
0.427820448 0.070036663 0.005115393 0.047753208 down 
Fc Epsilon Receptor I Signaling in 
Mast Cells Biocarta Pathway 12 
-
0.461399003 0.056845741 0.005360054 0.047753208 down 
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oxidoreductase activity, acting on 
paired donors, with incorporation 
or reduction of molecular oxygen 
GO Molecular 
Function 53 0.258591261 4.988041498 0.011348081 0.047927597 up 




0.235698966 0.231129597 0.01137265 0.047927597 down 





0.323343119 0.134062286 0.007536747 0.048026735 down 









Component 18 0.37018306 9.97959633 0.016163327 0.04804512 up 




0.274560032 0.181539322 0.007882094 0.04990082 down 
 
Table S 14: Discordance-based LRPath Gene Ontology and pathway analysis results with FDR <= 0.05 
Name ConceptType #Genes Coeff OddsRatio P-Value FDR Direction 
ectoderm development GO Biological Process 70 -0.29244408 0.162443448 1.63E-15 1.61E-12 down 
epidermis development GO Biological Process 65 
-





0.294481258 0.160399835 6.26E-14 2.03E-11 down 
cell adhesion GO Biological Process 220 
-
0.211939819 0.26790498 5.75E-13 3.34E-10 down 
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biological adhesion GO Biological Process 221 
-
0.210783743 0.269836689 7.72E-13 3.36E-10 down 





0.247915139 0.214232066 9.28E-12 1.50E-09 down 
tissue development GO Biological Process 243 
-
0.195736299 0.296287684 1.91E-11 5.54E-09 down 
serine-type endopeptidase inhibitor 
activity 
GO Molecular 
Function 15 -0.37131091 0.099504562 2.35E-11 6.16E-09 down 




0.278352324 0.177310897 2.98E-11 6.16E-09 down 
response to wounding GO Biological Process 135 
-
0.223254447 0.24971403 2.99E-11 7.43E-09 down 




0.391509148 0.087766454 1.59E-10 1.72E-08 down 




0.320368741 0.136563418 2.41E-10 1.95E-08 down 




0.375101077 0.097188179 6.24E-10 3.52E-08 down 
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0.205784902 0.27835096 6.53E-10 3.52E-08 down 
keratinocyte differentiation GO Biological Process 25 
-
0.315359679 0.140881409 3.64E-10 7.91E-08 down 
DNA damage response, signal 
transduction by p53 class mediator GO Biological Process 25 
-
0.312278924 0.143604666 7.13E-10 1.33E-07 down 
epidermal cell differentiation GO Biological Process 29 
-
0.301697976 0.153364983 7.62E-10 1.33E-07 down 
blood vessel morphogenesis GO Biological Process 81 
-
0.237879632 0.22801846 9.41E-10 1.49E-07 down 
ECM-receptor interaction KEGG Pathway 26 
-





0.318250885 0.138372697 1.07E-08 4.94E-07 down 
blood vessel development GO Biological Process 97 
-
0.221791577 0.251994572 4.35E-09 6.31E-07 down 
vasculature development GO Biological Process 99 
-
0.215963913 0.261288248 1.33E-08 1.79E-06 down 
regulation of epithelial cell 
differentiation GO Biological Process 11 
-
0.358507654 0.107745365 1.96E-08 2.44E-06 down 
cell-substrate junction assembly GO Biological Process 24 
-
0.295608502 0.1592801 3.72E-08 4.15E-06 down 
cell junction assembly GO Biological Process 37 
-
0.267516448 0.189662352 3.82E-08 4.15E-06 down 
angiogenesis GO Biological Process 67 
-
0.232053253 0.236425998 4.26E-08 4.36E-06 down 
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Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) KEGG Pathway 23 
-
0.328449091 0.129875058 7.59E-08 6.34E-06 down 




0.249836113 0.211689748 1.59E-07 6.43E-06 down 
negative regulation of cell adhesion GO Biological Process 24 
-
0.291911263 0.162982231 7.43E-08 6.60E-06 down 
chemotaxis GO Biological Process 33 
-
0.271174514 0.185399313 7.58E-08 6.60E-06 down 
taxis GO Biological Process 33 
-





0.286440078 0.168619121 2.18E-07 7.85E-06 down 
cell junction organization GO Biological Process 45 
-





0.285495831 0.169611508 4.11E-07 1.33E-05 down 
Dilated cardiomyopathy KEGG Pathway 19 
-
0.332625915 0.126547227 2.67E-07 1.49E-05 down 




0.195700138 0.296354276 8.43E-07 2.48E-05 down 
cell-substrate adhesion GO Biological Process 56 -0.22824575 0.242087056 6.79E-07 5.20E-05 down 
regulation of chemotaxis GO Biological Process 11 -0.33468572 0.124937635 6.87E-07 5.20E-05 down 
positive regulation of multicellular 
organismal process GO Biological Process 60 
-
0.223701605 0.24902106 7.71E-07 5.59E-05 down 
tissue regeneration GO Biological Process 12 
-
0.323258922 0.134132453 1.33E-06 9.27E-05 down 
regeneration GO Biological Process 29 -0.26273504 0.195382656 1.45E-06 9.70E-05 down 
regulation of behavior GO Biological Process 12 
-
0.321363379 0.135721884 1.73E-06 1.12E-04 down 
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response to biotic stimulus GO Biological Process 152 
-
0.170901273 0.345734398 1.94E-06 1.21E-04 down 
response to other organism GO Biological Process 102 
-
0.187192077 0.312445447 3.56E-06 2.13E-04 down 
Cytokine-cytokine receptor 
interaction KEGG Pathway 11 
-
0.347073593 0.115680134 6.07E-06 2.54E-04 down 
endothelial cell proliferation GO Biological Process 18 -0.28620369 0.168867014 4.37E-06 2.54E-04 down 
Vascular smooth muscle 
contraction KEGG Pathway 32 0.322811683 7.434624688 8.95E-06 2.99E-04 up 
regulation of blood coagulation GO Biological Process 12 
-
0.312526508 0.14338388 5.69E-06 3.09E-04 down 
regulation of wound healing GO Biological Process 12 
-
0.312526508 0.14338388 5.69E-06 3.09E-04 down 
lipid catabolic process GO Biological Process 78 0.209742252 3.682036133 8.74E-06 4.61E-04 up 
insulin-like growth factor receptor 
signaling pathway GO Biological Process 11 0.308974893 6.822035414 1.12E-05 5.75E-04 up 
ossification GO Biological Process 41 
-
0.227791574 0.242771317 1.38E-05 5.91E-04 down 
regulation of apoptosis GO Biological Process 370 
-
0.122280002 0.46770277 1.39E-05 5.91E-04 down 
regulation of programmed cell 
death GO Biological Process 371 
-
0.122096346 0.468236889 1.41E-05 5.91E-04 down 
regulation of cell death GO Biological Process 375 
-
0.121630342 0.469594882 1.42E-05 5.91E-04 down 
cytokine-mediated signaling 
pathway GO Biological Process 28 
-
0.249952931 0.211536121 1.43E-05 5.91E-04 down 
initiation of signal transduction GO Biological Process 28 
-
0.249952931 0.211536121 1.43E-05 5.91E-04 down 
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signal initiation by diffusible 
mediator GO Biological Process 28 
-
0.249952931 0.211536121 1.43E-05 5.91E-04 down 
signal initiation by protein/peptide 
mediator GO Biological Process 28 
-
0.249952931 0.211536121 1.43E-05 5.91E-04 down 
response to external stimulus GO Biological Process 171 
-
0.154074793 0.383845766 1.53E-05 6.21E-04 down 
Hypertrophic cardiomyopathy 
(HCM) KEGG Pathway 20 
-
0.291193426 0.16371093 2.37E-05 6.61E-04 down 





0.281705811 0.17365387 7.28E-06 6.82E-04 down 





0.287002779 0.168030496 9.69E-06 6.82E-04 down 





0.267218941 0.19001334 9.90E-06 6.82E-04 down 





0.267218941 0.19001334 9.90E-06 6.82E-04 down 
regulation of response to external 
stimulus GO Biological Process 39 
-
0.229046077 0.240885972 1.75E-05 6.94E-04 down 
regulation of steroid hormone 





0.107006742 0.514270976 2.84E-05 7.66E-04 down 
regulation of coagulation GO Biological Process 15 
-
0.286795228 0.168247369 2.09E-05 7.90E-04 down 
epithelium development GO Biological Process 120 
-
0.167490521 0.353140973 2.57E-05 9.52E-04 down 
synaptic vesicle 
GO Cellular 
Component 21 0.283182191 5.811660546 4.04E-05 0.001005769 up 
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small molecule catabolic process GO Biological Process 202 0.155892047 2.634801838 2.82E-05 0.001023778 up 
epithelial cell differentiation GO Biological Process 62 
-
0.199703165 0.289072746 3.06E-05 0.001087322 down 
digestive tract development GO Biological Process 13 
-
0.292960953 0.161922491 3.22E-05 0.001121726 down 
positive regulation of response to 
external stimulus GO Biological Process 15 
-
0.283062869 0.172195504 3.32E-05 0.001121726 down 
DNA damage response, signal 
transduction resulting in induction 
of apoptosis GO Biological Process 20 -0.26436069 0.193418685 3.35E-05 0.001121726 down 
cellular component movement GO Biological Process 207 
-
0.140701293 0.417110795 3.53E-05 0.001143973 down 
response to insulin stimulus GO Biological Process 58 0.213854624 3.777349886 3.61E-05 0.001143973 up 
DNA damage response, signal 
transduction GO Biological Process 62 
-
0.198563134 0.291128054 3.61E-05 0.001143973 down 
odontogenesis GO Biological Process 19 
-
0.266709467 0.190615911 3.75E-05 0.00116622 down 
regulation of leukocyte migration GO Biological Process 10 
-
0.309724692 0.14590237 3.94E-05 0.00120277 down 
integrin-mediated signaling 
pathway GO Biological Process 22 
-
0.256809824 0.202711314 4.11E-05 0.001227622 down 
response to abiotic stimulus GO Biological Process 150 
-
0.153998574 0.384027625 4.16E-05 0.001227622 down 




0.228793316 0.241264654 2.53E-05 0.001307481 down 




0.228793316 0.241264654 2.53E-05 0.001307481 down 
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0.151123984 0.390949714 2.86E-05 0.001311718 down 
endopeptidase regulator activity 
GO Molecular 
Function 42 -0.22223254 0.251304949 3.51E-05 0.001449737 down 
muscle tissue development GO Biological Process 54 
-
0.203123103 0.282993747 5.37E-05 0.001559506 down 
myeloid leukocyte differentiation GO Biological Process 23 -0.25145429 0.209571592 5.72E-05 0.001632447 down 
ligase activity, forming carbon-
sulfur bonds 
GO Molecular 
Function 15 0.277862369 5.622664874 4.62E-05 0.001654697 up 
GTPase regulator activity 
GO Molecular 
Function 169 0.15729416 2.657860718 4.81E-05 0.001654697 up 




0.238433926 0.227234352 5.42E-05 0.001721341 down 
positive regulation of immune 
system process GO Biological Process 65 
-
0.192335809 0.302615676 6.16E-05 0.001728755 down 
serine-type endopeptidase activity 
GO Molecular 
Function 30 0.239390463 4.426981223 6.17E-05 0.001820832 up 
locomotion GO Biological Process 174 -0.14375074 0.409280511 7.27E-05 0.002010322 down 
response to glucocorticoid stimulus GO Biological Process 30 
-
0.232485534 0.235791701 8.48E-05 0.002306027 down 
cell-cell adhesion GO Biological Process 69 
-





0.197707637 0.292679981 1.03E-04 0.002379765 down 
response to mechanical stimulus GO Biological Process 26 
-
0.239653314 0.225518874 9.85E-05 0.002566604 down 
222 
 
defense response GO Biological Process 138 
-
0.152128305 0.388517217 9.88E-05 0.002566604 down 
cell-matrix adhesion GO Biological Process 47 
-
0.205802014 0.27832136 1.02E-04 0.002615411 down 
blood coagulation GO Biological Process 30 
-
0.230855721 0.238192089 1.04E-04 0.002615411 down 
negative regulation of 
developmental process GO Biological Process 73 
-
0.182385385 0.321919524 1.06E-04 0.002641753 down 
RNA processing GO Biological Process 455 
-
0.103244797 0.526435769 1.13E-04 0.002772715 down 
regulation of immune system 
process GO Biological Process 113 
-
0.160335848 0.369197163 1.16E-04 0.002774582 down 
inflammatory response GO Biological Process 65 
-
0.187648003 0.311561416 1.16E-04 0.002774582 down 
response to corticosteroid stimulus GO Biological Process 32 
-
0.225994567 0.245497709 1.19E-04 0.002804658 down 
skin development GO Biological Process 14 
-
0.276225418 0.17967013 1.23E-04 0.002825307 down 
regulation of cell adhesion GO Biological Process 60 
-
0.191335208 0.304503307 1.24E-04 0.002825307 down 
digestive system development GO Biological Process 15 
-




Function 174 0.15041931 2.546696583 1.04E-04 0.002873394 up 
negative regulation of cell 
differentiation GO Biological Process 62 
-
0.189245266 0.308484043 1.30E-04 0.00290213 down 
coagulation GO Biological Process 32 
-
0.224010223 0.248543911 1.51E-04 0.003335753 down 
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regulation of cell proliferation GO Biological Process 268 
-
0.120567254 0.472707615 1.61E-04 0.003467759 down 
cell fate specification GO Biological Process 10 0.290446389 6.080035175 1.61E-04 0.003467759 up 
regulation of small GTPase 
mediated signal transduction GO Biological Process 102 0.173443575 2.938454747 1.86E-04 0.00392772 up 
regulation of cellular catabolic 
process GO Biological Process 109 0.170243293 2.880590618 1.87E-04 0.00392772 up 
anchoring junction 
GO Cellular 
Component 92 -0.16850933 0.350912124 1.85E-04 0.003993539 down 
gland morphogenesis GO Biological Process 30 
-
0.225274655 0.246598519 2.01E-04 0.004164271 down 
locomotory behavior GO Biological Process 59 
-
0.188210772 0.310473668 2.06E-04 0.004188142 down 
multi-organism process GO Biological Process 332 
-
0.110778619 0.502356274 2.07E-04 0.004188142 down 
Focal adhesion KEGG Pathway 82 
-
0.190324191 0.306422547 1.93E-04 0.004262825 down 





0.155485338 0.380495686 2.22E-04 0.004486302 down 
GTP metabolic process GO Biological Process 64 0.194051775 3.339949648 2.25E-04 0.00449432 up 
protein maturation by peptide 
bond cleavage GO Biological Process 21 
-
0.244764412 0.218468181 2.36E-04 0.004561255 down 
purine ribonucleotide metabolic 
process GO Biological Process 132 0.159348988 2.692019117 2.37E-04 0.004561255 up 
response to drug GO Biological Process 93 
-
0.164217179 0.360398321 2.40E-04 0.004561255 down 
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leukocyte differentiation GO Biological Process 58 
-
0.187826432 0.311216126 2.40E-04 0.004561255 down 
hemostasis GO Biological Process 32 
-
0.220011486 0.254797756 2.41E-04 0.004561255 down 
melanosome 
GO Cellular 
Component 72 -0.1783283 0.330139332 2.54E-04 0.004578307 down 
pigment granule 
GO Cellular 
Component 72 -0.1783283 0.330139332 2.54E-04 0.004578307 down 
negative regulation of cell death GO Biological Process 179 -0.13400212 0.434842813 2.54E-04 0.004755984 down 
regulation of ion homeostasis GO Biological Process 11 
-
0.284610128 0.170547674 2.68E-04 0.004891163 down 
GTP catabolic process GO Biological Process 59 0.196263537 3.386175012 2.73E-04 0.004891163 up 
regulation of GTP catabolic process GO Biological Process 59 0.196263537 3.386175012 2.73E-04 0.004891163 up 
regulation of GTPase activity GO Biological Process 59 0.196263537 3.386175012 2.73E-04 0.004891163 up 
Insulin signaling pathway KEGG Pathway 61 0.23908232 4.41851171 2.80E-04 0.005190971 up 
Notch signaling pathway GO Biological Process 22 
-
0.239761341 0.225367524 2.99E-04 0.005320454 down 
purine ribonucleoside triphosphate 
catabolic process GO Biological Process 64 0.191144351 3.280143701 3.12E-04 0.005426972 up 
ribonucleoside triphosphate 
catabolic process GO Biological Process 64 0.191144351 3.280143701 3.12E-04 0.005426972 up 
positive regulation of cytokine 
production GO Biological Process 28 
-
0.225183969 0.246737535 3.16E-04 0.005443982 down 
purine ribonucleotide catabolic 
process GO Biological Process 67 0.188589806 3.228480961 3.24E-04 0.005536562 up 
negative regulation of apoptosis GO Biological Process 175 
-
0.133106628 0.437269518 3.28E-04 0.005545708 down 
negative regulation of programmed 
cell death GO Biological Process 176 -0.13266593 0.438468738 3.37E-04 0.005642173 down 
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nucleoside triphosphate catabolic 
process GO Biological Process 67 0.188038907 3.217446762 3.45E-04 0.005716934 up 
Amoebiasis KEGG Pathway 33 
-
0.233609039 0.234151105 3.47E-04 0.005800083 down 
regulation of nucleotide catabolic 
process GO Biological Process 61 0.192187594 3.3014791 3.58E-04 0.005830017 up 
regulation of purine nucleotide 
catabolic process GO Biological Process 61 0.192187594 3.3014791 3.58E-04 0.005830017 up 
purine ribonucleoside triphosphate 
metabolic process GO Biological Process 117 0.161163599 2.722549085 3.69E-04 0.005941629 up 
ribonucleoside triphosphate 





0.264810595 0.192878645 3.59E-04 0.0061145 down 
striated muscle tissue development GO Biological Process 50 
-
0.191102022 0.3049449 4.06E-04 0.006387462 down 
purine nucleoside triphosphate 
catabolic process GO Biological Process 66 0.187239846 3.20150901 4.07E-04 0.006387462 up 
response to organic cyclic 
substance GO Biological Process 53 
-
0.187846717 0.311176896 4.16E-04 0.006465618 down 
ribonucleotide catabolic process GO Biological Process 68 0.185490701 3.166896265 4.22E-04 0.006498914 up 
ribonucleotide metabolic process GO Biological Process 139 0.151798327 2.568615696 4.35E-04 0.006648819 up 
COPI-coated vesicle 
GO Cellular 
Component 14 0.285507605 5.89625776 4.28E-04 0.006926958 up 
coated vesicle 
GO Cellular 
Component 94 0.176494276 2.994696106 4.59E-04 0.007079173 up 
small GTPase regulator activity 
GO Molecular 
Function 123 0.15871416 2.681419465 2.75E-04 0.007092422 up 
response to bacterium GO Biological Process 43 
-
0.197664387 0.292758659 4.76E-04 0.007208594 down 
regulation of developmental 





Function 10 0.282350899 5.781714038 3.14E-04 0.007267494 up 
GTPase activator activity 
GO Molecular 
Function 95 0.16952289 2.867722972 3.17E-04 0.007267494 up 
muscle organ development GO Biological Process 69 
-
0.172533253 0.34224564 5.16E-04 0.007618296 down 
tissue remodeling GO Biological Process 18 
-
0.246465886 0.216170271 5.16E-04 0.007618296 down 
muscle structure development GO Biological Process 85 
-
0.162089478 0.365195452 5.30E-04 0.007756459 down 
positive regulation of protein 
transport GO Biological Process 23 -0.23115602 0.237747981 5.55E-04 0.008052488 down 
response to steroid hormone 
stimulus GO Biological Process 70 
-
0.170902867 0.345730972 5.73E-04 0.00818727 down 
behavior GO Biological Process 99 
-
0.154182708 0.383588426 5.74E-04 0.00818727 down 
purine nucleoside triphosphate 
metabolic process GO Biological Process 122 0.155208975 2.623640759 5.79E-04 0.008197591 up 
leukocyte chemotaxis GO Biological Process 10 -0.28236786 0.172940861 5.94E-04 0.008336561 down 
response to inorganic substance GO Biological Process 113 
-
0.147521786 0.399800309 6.12E-04 0.008364431 down 
purine nucleotide catabolic process GO Biological Process 72 0.179262513 3.046661086 6.14E-04 0.008364431 up 
estrogen receptor signaling 
pathway GO Biological Process 12 0.267488972 5.271627465 6.14E-04 0.008364431 up 
nucleoside triphosphate metabolic 
process GO Biological Process 127 0.152828879 2.585119126 6.15E-04 0.008364431 up 
lipid transporter activity 
GO Molecular 
Function 26 0.23074997 4.195534028 3.87E-04 0.008409404 up 
anatomical structure formation 
involved in morphogenesis GO Biological Process 143 
-
0.136763949 0.427442994 6.31E-04 0.008514637 down 




regulation of Ras protein signal 
transduction GO Biological Process 91 0.167454938 2.831104212 6.67E-04 0.008866121 up 
induction of apoptosis by 
intracellular signals GO Biological Process 34 
-
0.207138359 0.276019511 6.72E-04 0.008866121 down 
protein processing GO Biological Process 31 
-
0.211916542 0.267943737 6.95E-04 0.009096946 down 
regulation of peptidase activity GO Biological Process 51 
-
0.184989955 0.316750756 7.10E-04 0.009226172 down 
di-, tri-valent inorganic cation 
transport GO Biological Process 55 -0.1806911 0.325327025 7.42E-04 0.009573316 down 
negative regulation of 
transmembrane receptor protein 
serine/threonine kinase signaling 
pathway GO Biological Process 14 
-
0.257784735 0.201486861 7.63E-04 0.009765055 down 
phosphoric ester hydrolase activity 
GO Molecular 
Function 142 0.14749272 2.500796935 4.82E-04 0.009951015 up 
heterocycle catabolic process GO Biological Process 88 0.167451178 2.831038048 7.87E-04 0.010000106 up 
carboxylic acid catabolic process GO Biological Process 65 0.181232724 3.084193989 8.26E-04 0.010350354 up 
organic acid catabolic process GO Biological Process 65 0.181232724 3.084193989 8.26E-04 0.010350354 up 
female sex differentiation GO Biological Process 26 
-
0.219894603 0.254982904 8.39E-04 0.010383843 down 
cell migration GO Biological Process 148 -0.13291975 0.437777646 8.41E-04 0.010383843 down 
phospholipase activity 
GO Molecular 
Function 25 0.22953199 4.163896782 5.40E-04 0.010579832 up 




0.279372493 0.17619031 5.64E-04 0.010579832 down 
negative regulation of cell growth GO Biological Process 32 
-
0.207894907 0.27472481 8.71E-04 0.01067961 down 
regulation of catabolic process GO Biological Process 126 0.149540341 2.532823318 9.11E-04 0.011091051 up 




generation of a signal involved in 
cell-cell signaling GO Biological Process 40 0.203099588 3.533130635 9.49E-04 0.011312938 up 
signal release GO Biological Process 40 0.203099588 3.533130635 9.49E-04 0.011312938 up 
hormone secretion GO Biological Process 24 0.227770765 4.118570102 9.74E-04 0.011530315 up 
ion transport GO Biological Process 191 
-
0.120788702 0.472057517 0.001008941 0.011868685 down 
response to lipopolysaccharide GO Biological Process 32 
-
0.205452504 0.27892655 0.001104318 0.012854296 down 
growth GO Biological Process 188 
-
0.120632341 0.472516447 0.001112017 0.012854296 down 
hair cycle process GO Biological Process 13 
-
0.257936278 0.201297194 0.001129642 0.012854296 down 
hair follicle development GO Biological Process 13 
-
0.257936278 0.201297194 0.001129642 0.012854296 down 
molting cycle process GO Biological Process 13 
-
0.257936278 0.201297194 0.001129642 0.012854296 down 
alcohol metabolic process GO Biological Process 208 0.125067508 2.175471777 0.001190351 0.013431032 up 
regulation of endothelial cell 
proliferation GO Biological Process 15 -0.24841073 0.213573267 0.001195755 0.013431032 down 
regulation of nitric oxide 
biosynthetic process GO Biological Process 10 
-
0.273398843 0.182854109 0.001261061 0.01407376 down 
skeletal system development GO Biological Process 58 
-
0.172735782 0.341815148 0.001283446 0.014232348 down 
hormone transport GO Biological Process 25 0.222625204 3.988951428 0.001304397 0.014373135 up 
regulation of cell activation GO Biological Process 48 
-
0.181878497 0.322935205 0.001344249 0.014553961 down 
hair cycle GO Biological Process 14 
-
0.251257539 0.209827998 0.001345886 0.014553961 down 
molting cycle GO Biological Process 14 
-
0.251257539 0.209827998 0.001345886 0.014553961 down 
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renal system development GO Biological Process 29 
-
0.208409785 0.273847161 0.001390925 0.0148361 down 
cell motility GO Biological Process 152 
-
0.127455467 0.452899162 0.001397542 0.0148361 down 
localization of cell GO Biological Process 152 
-
0.127455467 0.452899162 0.001397542 0.0148361 down 
response to molecule of bacterial 
origin GO Biological Process 34 
-
0.199526379 0.289390512 0.001415648 0.01493723 down 
microtubule 
GO Cellular 
Component 129 0.152174671 2.574630275 0.00106478 0.015681301 up 
negative regulation of epithelial cell 
proliferation GO Biological Process 10 0.267032585 5.256696922 0.001497269 0.015703281 up 
response to radiation GO Biological Process 85 
-
0.152452939 0.387734182 0.001534944 0.016002026 down 
acid-thiol ligase activity 
GO Molecular 
Function 10 0.271317325 5.398552411 9.07E-04 0.01629198 up 
Salivary secretion KEGG Pathway 23 0.284590194 5.862736799 0.001073633 0.016299695 up 
purine nucleotide metabolic 
process GO Biological Process 154 0.135076234 2.315083735 0.001615919 0.016745923 up 
positive regulation of intracellular 
protein transport GO Biological Process 15 
-
0.244756346 0.218479134 0.00162774 0.016768617 down 
regulation of cytokine-mediated 
signaling pathway GO Biological Process 10 
-
0.269967521 0.18679522 0.001653697 0.016935806 down 
regulation of cytokine production GO Biological Process 46 
-
0.181722141 0.323249151 0.001684987 0.017155331 down 




0.197357559 0.293317427 0.001054561 0.018147243 down 
positive regulation of lymphocyte 
activation GO Biological Process 28 
-
0.207041807 0.276185182 0.001871676 0.018945283 down 
cholesterol transport GO Biological Process 14 
-
0.247048603 0.215388856 0.001901266 0.01902359 down 




receptor metabolic process GO Biological Process 27 
-





0.087280621 0.581342697 0.001373952 0.019354801 down 
regulation of fatty acid oxidation GO Biological Process 15 0.243297235 4.535779569 0.001963146 0.019419533 up 
fructose metabolic process GO Biological Process 13 0.250414741 4.740911784 0.001974654 0.019423012 up 
positive regulation of cell 
communication GO Biological Process 134 
-
0.129526735 0.447106751 0.002005435 0.019614952 down 
mesenchymal cell development GO Biological Process 13 
-
0.250632568 0.210644544 0.002051702 0.019844517 down 
mesenchymal cell differentiation GO Biological Process 13 
-
0.250632568 0.210644544 0.002051702 0.019844517 down 
nitric oxide biosynthetic process GO Biological Process 14 
-
0.245884106 0.216953257 0.002086134 0.019955822 down 
nitric oxide metabolic process GO Biological Process 14 
-
0.245884106 0.216953257 0.002086134 0.019955822 down 
Arachidonic acid metabolism KEGG Pathway 14 0.314441683 7.057789017 0.001441625 0.020062617 up 
regulation of Ras GTPase activity GO Biological Process 53 0.180864552 3.077145275 0.002153499 0.020487662 up 
actin filament bundle assembly GO Biological Process 19 0.230340501 4.184871277 0.002176892 0.020597657 up 
long-chain fatty acid transport GO Biological Process 12 0.252983484 4.817201736 0.002233125 0.021015514 up 
homophilic cell adhesion GO Biological Process 18 
-
0.229582545 0.24008421 0.002317868 0.021695741 down 
positive regulation of intracellular 
transport GO Biological Process 17 
-
0.232827874 0.235290586 0.002337932 0.021766522 down 
Chemokine signaling pathway KEGG Pathway 56 0.219585713 3.914310323 0.001715845 0.022042015 up 
cholesterol homeostasis GO Biological Process 13 
-
0.248538785 0.213403371 0.002413839 0.022207997 down 
sterol homeostasis GO Biological Process 13 
-
0.248538785 0.213403371 0.002413839 0.022207997 down 
anti-apoptosis GO Biological Process 107 
-
0.137486204 0.425528702 0.002423618 0.022207997 down 
231 
 
regulation of hormone levels GO Biological Process 57 0.175819119 2.982157163 0.002485668 0.022620983 up 
response to organic substance GO Biological Process 337 
-
0.092488427 0.562829056 0.002494675 0.022620983 down 
regulation of nucleotide metabolic 
process GO Biological Process 74 0.163481589 2.762052347 0.002519233 0.022725309 up 
ligase activity 
GO Molecular 
Function 240 0.115915133 2.055187584 0.001378775 0.022777363 up 
cytokine production GO Biological Process 56 
-
0.167246651 0.353676583 0.00257132 0.02307561 down 
response to calcium ion GO Biological Process 30 
-
0.199466925 0.289497457 0.002597399 0.023190115 down 
leukocyte migration GO Biological Process 21 
-
0.218966367 0.256458055 0.002664192 0.02366509 down 
response to oxidative stress GO Biological Process 96 
-
0.141286551 0.415596457 0.002689527 0.023768867 down 
lipase activity 
GO Molecular 
Function 31 0.208376195 3.650909782 0.001510264 0.023989965 up 
elevation of cytosolic calcium ion 
concentration GO Biological Process 14 
-
0.242254678 0.221902345 0.002764687 0.024309701 down 
regulation of cell-cell adhesion GO Biological Process 14 
-
0.241906454 0.222383078 0.00283871 0.024835149 down 
endothelial cell migration GO Biological Process 19 
-





0.085068372 0.589390342 0.001907457 0.025750675 down 
cytosolic calcium ion homeostasis GO Biological Process 16 
-
0.233127709 0.234852564 0.003019634 0.026155142 down 
ligase activity, forming carbon-
nitrogen bonds 
GO Molecular 
Function 147 0.134451104 2.306107229 0.001715634 0.026242844 up 
232 
 
Malaria KEGG Pathway 10 
-
0.284673177 0.170480862 0.002213367 0.026402305 down 
di-, tri-valent inorganic cation 
homeostasis GO Biological Process 62 
-
0.160316073 0.369242539 0.003069952 0.026459342 down 
iron ion transport GO Biological Process 16 
-
0.232727693 0.235437121 0.003113109 0.026699126 down 
peptide hormone secretion GO Biological Process 21 0.220958091 3.947837422 0.003155455 0.026836121 up 
skeletal muscle tissue development GO Biological Process 32 
-
0.193650676 0.300152962 0.003159911 0.026836121 down 
double-stranded DNA binding 
GO Molecular 
Function 55 -0.17312878 0.340981342 0.001921888 0.027372498 down 





0.237201127 0.228981963 0.002012815 0.027372498 down 
acid-amino acid ligase activity 
GO Molecular 
Function 125 0.139734002 2.383075935 0.002059718 0.027372498 up 
serine-type peptidase activity 
GO Molecular 
Function 44 0.188009308 3.216854989 0.002061547 0.027372498 up 




0.145442514 0.404999995 0.002160473 0.027372498 down 




0.149955367 0.39379932 0.002187149 0.027372498 down 
Gap junction KEGG Pathway 27 0.260466941 5.046525375 0.002485372 0.027670475 up 
cell chemotaxis GO Biological Process 12 -0.24918138 0.212552849 0.00331875 0.028048268 down 
fat cell differentiation GO Biological Process 30 
-
0.196297256 0.295256587 0.003377264 0.028404911 down 
regulation of metal ion transport GO Biological Process 20 -0.2184978 0.257205939 0.003440627 0.028798711 down 
response to gamma radiation GO Biological Process 10 
-
0.259482419 0.199372261 0.003577765 0.029803295 down 
serine hydrolase activity 
GO Molecular 
Function 45 0.184940349 3.156083285 0.002466671 0.029962792 up 
positive regulation of cellular 
component movement GO Biological Process 46 
-
0.173055333 0.341137017 0.003659367 0.030337892 down 
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positive regulation of anti-
apoptosis GO Biological Process 16 
-
0.230271993 0.239057733 0.003742316 0.030740412 down 
positive regulation of cell migration GO Biological Process 41 
-
0.178635464 0.329509728 0.003743232 0.030740412 down 
response to DNA damage stimulus GO Biological Process 239 
-
0.100717813 0.534768287 0.003837123 0.031363529 down 
myoblast differentiation GO Biological Process 10 
-
0.257718861 0.201569363 0.004040665 0.03287289 down 
regulation of homeostatic process GO Biological Process 29 
-
0.195714911 0.296327069 0.004091968 0.032880685 down 
positive regulation of cell activation GO Biological Process 31 
-
0.192127763 0.303007189 0.004098282 0.032880685 down 
positive regulation of leukocyte 
activation GO Biological Process 31 
-





0.251064316 0.210080113 0.00256098 0.033190298 down 
regulation of canonical Wnt 
receptor signaling pathway GO Biological Process 12 
-
0.245973845 0.216832297 0.00416906 0.033295106 down 
peptide secretion GO Biological Process 22 0.215110076 3.806936582 0.004196337 0.033338881 up 
regulation of cellular component 
movement GO Biological Process 80 
-
0.144773426 0.406687538 0.00421284 0.033338881 down 
extracellular matrix organization GO Biological Process 30 
-
0.193452547 0.300522767 0.004237396 0.033381475 down 
small molecule biosynthetic process GO Biological Process 232 0.107946409 1.955888621 0.004366662 0.034224402 up 
monocarboxylic acid metabolic 
process GO Biological Process 160 0.123028707 2.148081669 0.004383711 0.034224402 up 
response to peptide hormone 
stimulus GO Biological Process 82 0.152223879 2.57541774 0.004441274 0.034519007 up 
microtubule cytoskeleton 
GO Cellular 
Component 292 0.105542594 1.92688722 0.00278381 0.034690558 up 




negative regulation of cell size GO Biological Process 36 
-
0.182986511 0.320719153 0.004533912 0.034927169 down 
vesicle localization GO Biological Process 25 0.207840872 3.638784023 0.004558708 0.034963481 up 
appendage morphogenesis GO Biological Process 29 
-
0.194082482 0.299348579 0.0046449 0.035313411 down 
limb morphogenesis GO Biological Process 29 
-
0.194082482 0.299348579 0.0046449 0.035313411 down 
regulation of T cell proliferation GO Biological Process 19 
-
0.217313977 0.25910518 0.004678078 0.035411013 down 
cellular membrane fusion GO Biological Process 33 
-
0.186606389 0.313584763 0.004874391 0.036737295 down 
metal ion transport GO Biological Process 104 -0.13127505 0.442275191 0.004948066 0.037131825 down 
nucleobase, nucleoside and 
nucleotide metabolic process GO Biological Process 248 0.103944965 1.907850516 0.005000387 0.037363405 up 
regulation of blood pressure GO Biological Process 20 0.217027807 3.852578896 0.005172007 0.038480613 up 
gliogenesis GO Biological Process 26 
-





0.165586493 0.357344434 0.003301974 0.03856594 down 
synapse part 
GO Cellular 
Component 63 0.17617752 2.988806797 0.003332859 0.03856594 up 
response to oxygen levels GO Biological Process 59 
-
0.156428734 0.378271428 0.00527663 0.038926329 down 
regulation of anti-apoptosis GO Biological Process 22 -0.20722594 0.275869319 0.005355827 0.03934386 down 
regulation of leukocyte 
proliferation GO Biological Process 23 
-
0.204440563 0.280686194 0.005485694 0.039572681 down 
regulation of lymphocyte 
proliferation GO Biological Process 23 
-
0.204440563 0.280686194 0.005485694 0.039572681 down 
regulation of mononuclear cell 
proliferation GO Biological Process 23 
-
0.204440563 0.280686194 0.005485694 0.039572681 down 
235 
 
regulation of ARF protein signal 
transduction GO Biological Process 21 0.213860958 3.777498591 0.0054882 0.039572681 up 
ncRNA metabolic process GO Biological Process 188 
-
0.106124374 0.517098762 0.005500625 0.039572681 down 
mesenchyme development GO Biological Process 15 
-
0.228278809 0.242037323 0.005641974 0.040422539 down 
cellular response to stress GO Biological Process 361 
-
0.083273175 0.596002659 0.00576057 0.041103082 down 
protein maturation GO Biological Process 38 -0.17693479 0.333010792 0.005845726 0.041540443 down 
nucleoside phosphate metabolic 
process GO Biological Process 232 0.104697547 1.916794425 0.005932026 0.041812375 up 
nucleotide metabolic process GO Biological Process 232 0.104697547 1.916794425 0.005932026 0.041812375 up 
ureteric bud development GO Biological Process 13 
-
0.235588165 0.231288803 0.006088609 0.042743014 down 
Adipocytokine signaling pathway KEGG Pathway 30 0.245044885 4.585310975 0.004096861 0.042760989 up 
response to vitamin GO Biological Process 33 -0.18357227 0.319553774 0.006137749 0.042914944 down 




0.214320436 0.263970608 0.00389503 0.043297889 down 




0.155863809 0.379601793 0.004110883 0.043297889 down 
coated vesicle membrane 
GO Cellular 
Component 55 0.180577211 3.071655288 0.004142699 0.043297889 up 
fatty acid metabolic process GO Biological Process 111 0.134514823 2.307020596 0.006284535 0.043661646 up 
negative regulation of growth GO Biological Process 38 
-
0.175955513 0.335043616 0.006297196 0.043661646 down 
amine catabolic process GO Biological Process 36 0.186074829 3.1784134 0.006319779 0.043661646 up 
activation of caspase activity GO Biological Process 25 
-
0.197727526 0.292643807 0.006409542 0.044106768 down 
regulation of ossification GO Biological Process 20 
-
0.209894139 0.271332624 0.006456167 0.044219874 down 
nucleotide catabolic process GO Biological Process 83 0.147031129 2.493633404 0.006476777 0.044219874 up 
236 
 
nucleobase, nucleoside and 
nucleotide catabolic process GO Biological Process 85 0.145681413 2.472804391 0.006621545 0.044856456 up 
nucleobase, nucleoside, nucleotide 
and nucleic acid catabolic process GO Biological Process 85 0.145681413 2.472804391 0.006621545 0.044856456 up 
hormone binding 
GO Molecular 
Function 10 0.253621001 4.836324963 0.00399207 0.045170486 up 




0.135214414 0.431579048 0.004055189 0.045170486 down 
kinase activity 
GO Molecular 
Function 314 0.095596095 1.811385945 0.004142546 0.045170486 up 
microtubule motor activity 
GO Molecular 
Function 27 0.203409882 3.539950336 0.004156122 0.045170486 up 
response to estrogen stimulus GO Biological Process 37 
-
0.176226852 0.33447912 0.006832184 0.046104 down 
regulation of lymphocyte activation GO Biological Process 41 -0.17092953 0.34567369 0.00688017 0.046248554 down 
regulation of ion transport GO Biological Process 24 
-
0.198461931 0.291311213 0.007114239 0.047474742 down 
cellular response to insulin stimulus GO Biological Process 45 0.173954952 2.947808031 0.007117121 0.047474742 up 
regulation of T cell activation GO Biological Process 37 
-
0.175603679 0.335776995 0.007153968 0.047538389 down 
peptidyl-serine phosphorylation GO Biological Process 21 
-
0.205599799 0.278671343 0.007200673 0.047564109 down 
development of primary female 
sexual characteristics GO Biological Process 22 
-
0.202972895 0.28325804 0.007232602 0.047564109 down 
peptide transport GO Biological Process 25 0.20156463 3.499587773 0.0072834 0.047564109 up 
mRNA processing GO Biological Process 251 
-
0.092907929 0.561363647 0.007303132 0.047564109 down 
appendage development GO Biological Process 30 
-
0.186139204 0.314496539 0.007321758 0.047564109 down 
limb development GO Biological Process 30 
-
0.186139204 0.314496539 0.007321758 0.047564109 down 
237 
 
positive regulation of signaling 
pathway GO Biological Process 125 -0.11900698 0.477313514 0.007402823 0.047911953 down 
heterocycle metabolic process GO Biological Process 238 0.101201214 1.875594895 0.007465836 0.048140816 up 
regulation of protein kinase B 
signaling cascade GO Biological Process 17 
-
0.216558714 0.26032419 0.007639796 0.049080757 down 
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